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General introduction
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The kidneys play a central role in the treatment of cancer, as many chemotherapeutic and 
supportive care drugs are eliminated by the kidneys. Unfortunately, they are also the target 
of toxicity. The toxic effects on the kidneys may be acute and reversible, but also have the 
potential to cause chronic and irreversible damage. Toxicity monitoring during treatment 
and precise drug dosing, especially of potentially nephrotoxic drugs and drugs cleared by 
the kidneys such as carboplatin, are therefore crucial. The aim of this thesis is to gain insight 
into renal function in childhood cancer, both for toxicity monitoring during treatment and 
carboplatin dosing.
Childhood CanCer
epidemiology
In Western countries the age-standardized incidence rate of childhood cancer ranges be-
tween 121 and 160 cases per million person years.1 In The Netherlands about 650 children 
are diagnosed with cancer each year. Leukemia (23%), lymphoma (10%) and tumors of the 
central nervous system (26%) are the most common types.2 Survival rates for most pediatric 
cancers have improved at a remarkable pace over the past four decades (Figure 1.1).2 In the 
1960s only 30% of childhood cancer patients survived for more than five years, whereas five-
year survival reaches 80% in Europe these days.3,4 The increased survival rates resulted in the 
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figure 1.1. Overall survival of childhood cancer in The Netherlands.
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emerge of a new group of ‘patients’: childhood cancer survivors (CCS). It is estimated that 
nowadays approximately one in every 750 individuals has a history of pediatric cancer.5
renal (late) effects
The success in curing cancer has not come without a price. Despite the dramatic improve-
ments in survival, toxicity remains an important complication of many anti-cancer drugs and 
sometimes limits life-saving therapy. Nephrotoxicity is the development of kidney damage 
after exposure to certain types of chemotherapy, radiation or kidney surgery and can present 
at the glomerular or tubular level. It may be acute and transient, but may also cause irrevers-
ible damage. Acute nephrotoxicity can be a dose-limiting factor for several treatment mo-
dalities and even an exclusion criterion for trials, precluding optimal anti-cancer treatment.6 
Commonly used chemotherapy known for their nephrotoxic potential are ifosfamide,7-14 
cyclophosphamide,9,15 high-dose methotrexate,7,16,17 and the platinum compounds cispla-
tin7,12,18,19 and carboplatin.7,12,19,20
The growing population of CCS represent a highly vulnerable group of individuals at 
risk for adverse health- or quality of life-related outcomes during their lifetime, either as a 
result of their disease or its treatment. Up to 98% of long-term survivors will experience one 
or more chronic health conditions, of which 68% is severe, disabling or life-threatening.21 
Impaired renal function is an important late-effect after treatment for childhood cancer. The 
overall prevalence of renal dysfunction among CCS is around 5%; two-third of this number 
is attributable to the exposure to nephrotoxic treatment modalities.21 Among long-term 
survivors exposed to modalities with nephrotoxic potential the prevalence of renal adverse 
effects even ranges up to 84%, depending on type of malignancy, prescribed treatment 
and outcome measure.22 Although some of the reported conditions may not immediately 
influence the patient’s health status, their presence may reflect early disease outcomes that 
may be remediated and should therefore be monitored closely to assess future decline in 
function.
renal funCtion in Childhood
exogenous markers
For the assessment of renal function the mechanisms responsible for the formation of urine, 
namely glomerular filtration, tubular reabsorption and tubular secretion, must be taken 
into consideration. It is widely accepted that renal function is best measured as glomerular 
filtration rate (GFR), both in health and disease.23-25 GFR represents the volume of plasma 
ultrafiltrate presented to the nephrons per unit time in the process of urine formation. The 
classic inulin clearance is regarded as the gold standard for measuring GFR.26 It requires an 
intravenous priming dose of inulin, followed by constant infusion to establish a steady state 
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plasma concentration. After equilibration, timed urine samples are collected over a period of 
several hours. Continuous infusion clearances might obviate the need for urine collection, 
as once a steady state is achieved the infusion rate is essentially equal to the excretion rate. 
Although highly accurate, this method is cumbersome and invasive, especially in young chil-
dren who often need bladder catheterization for accurate urine collection. Although plasma 
clearances after single-injection of inulin27,28 or other exogenous markers such as 51Cr-EDTA, 
99Tc-DTPA, 125I-iothalamate or iohexol29-33 have shown to correlate well with the renal clearance 
of inulin and do not require urine collection, they are still too costly and time-consuming for 
daily clinical practice and involve undesirable effects such as radiation exposure or the need 
for multiple blood samples. The use of these exogenous markers is therefore often limited to 
situations where conventional endogenous GFR markers are unreliable.
endogenous renal function markers
It has become preferred practice to use an endogenous renal function marker that is: (i) pro-
duced at a constant rate; (ii) freely filtered by the glomerulus; (iii) not synthesized, secreted 
or reabsorpted by the tubules and (iv) not extra-renally eliminated. Endogenous markers 
accumulate with decreasing GFR.
Creatinine
Serum creatinine is the most widely used endogenous GFR marker. Measurement of serum 
creatinine is easy, accurate and reproducible across clinical laboratories nowadays.34 Although 
the serum creatinine concentration can provide a rough index of the level of GFR, numerous 
factors can lead to errors in estimating GFR from the serum concentration alone. Creatinine 
is a metabolite of muscle creatine, so its concentration is strongly related to muscle mass35,36 
and as such varies across age, gender, race, nutritional status, body composition and diet.37,38 
Muscle mass increases with growth in children, as a result creatinine levels vary with age.39,40 
While creatinine is a useful marker of GFR for children with (near) normal body composition 
and renal function, it has multiple limitations for individuals. The major drawback is its depen-
dency on muscle mass, leading to overestimation of GFR. This severely hampers the use of 
creatinine as a GFR marker in children with cancer, who often have diminished muscle mass. 
In addition, there is considerable (10-20%) secretion of creatinine by the proximal tubules.41 
The finding that 65% of cancer patients with normal serum creatinine levels had a decreased 
GFR, underscores that serum creatinine is not appropriate for evaluating renal function in 
these patients.42 To overcome the problem of muscle mass dependency, creatinine clearance 
from timed urine collection is sometimes used. However, the problem of tubular secretion, 
leading to overestimation of GFR, remains. Furthermore, this test is complicated and burden-
some. It requires precisely timed urine collection, which might be difficult to obtain, and 
therefore is prone to errors making estimation of GFR imprecise and unreliable in adults,43 let 
alone in children who have not been toilet trained.
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Cystatin C
Low-molecular weight proteins have long been proposed as alternative markers of GFR.44,45 
Cystatin C was first suggested as a GFR marker in 197946,47 and since the first automated 
procedure for analysis of cystatin C was introduced 1994 its use has been extensively inves-
tigated. Cystatin C is produced at a constant rate by all nucleated cells and freely filtered by 
the glomerulus.48 The serum cystatin C concentration is independent of nutritional status, 
diet, and gender49 and the influence of muscle mass on its concentration is insignificant 
compared to the influence on creatinine concentration.36,50 Its utility as a GFR marker derives 
from the fact that after filtration, it is completely reabsorbed and degraded in the tubules 
and thus does not reenter circulation again. In addition, there is no active tubular secretion 
of cystatin C, making it a potentially excellent marker of GFR. Since cystatin C levels are not 
influenced by muscle mass, it is a more accurate GFR marker across a range of body types 
and ages, including patients with wasting, infants and toddlers. Non-GFR determinants of 
cystatin C also exist, though they are quantifiably smaller than those of creatinine.51 Cystatin 
C concentrations may be altered in patients with derangements in thyroid function51,52 and 
high-dose glucocorticoid therapy.53,54
estimated glomerular filtration rate
International guidelines rule against the use of serum markers alone for the assessment of 
renal function and recommend to use serum marker-based prediction equations.55,56 Estimat-
ing GFR has become the clinical standard to assess GFR, predominantly because it partially 
compensates for the limitations of endogenous markers, including demographic and an-
thropometric factors. Moreover, it is easier for the healthcare provider to recognize clinically 
important changes in renal function when dealing with a physiologically relevant parameter 
such as GFR, rather than serum concentrations that are inversely related to GFR. Several 
pediatric GFR estimating equations exists, both for creatinine and cystatin C.25,29,57-61 Because 
cystatin C is independent of body composition, it is suggested that cystatin C-based GFR es-
timating equations with simple formulations might replace more complex creatinine-based 
equations with anthropometric variables.25 Furthermore, several studies have suggested that 
the addition of a cystatin C measurement to a creatinine measurement to calculate eGFR sig-
nificantly improves its prediction, both in adults57 and children.60 The recent introduction of a 
certified cystatin C calibrator (ERM-DA471/IFCC)62 by the working group of the International 
Federation of Clinical Chemistry (IFCC) allows different diagnostic companies to produce 
cystatin C assays with reduced inter-assay variability, which is an essential step in producing 
an assay-independent GFR estimating equation. This will enable clinicians to use one single 
equation for both children and adults and will further improve GFR estimation.
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CarBoPlatin
The platinum-compound carboplatin, frequently used for the treatment of pediatric solid 
tumors, is almost exclusively (up to 80%) cleared by glomerular filtration. Thus, carboplatin 
is one of the drugs for which elimination is most dependent on GFR. Its pharmacokinetics is 
therefore mainly determined by the patient’s renal function.63,64 Indeed, renal function-based 
carboplatin dosing results in more reproducible drug exposure than flat dosing65,66 and real-
time monitoring with adaptive dosing has been associated with more consistent platinum 
exposure in children.67 Furthermore, carboplatin exposure is related to clinical efficacy68 
and toxicity69,70 and renal function-based dosing allows for correcting for the physiological 
changes in renal function during early childhood.24 Unfortunately, the kidneys are also a 
target of carboplatin-induced toxicity;12,18,20,22 thus carboplatin-induced renal dysfunction 
leads to delayed elimination of and the resulting sustained, elevated plasma concentrations 
may lead to a marked enhancement of other toxicities. Therefore, careful dosing to optimize 
exposure and prevent adverse effects is important. To this end several dosing equations for 
children are available (Table 1.1).71-73 Although the concept of renal function-based dosing is 
widely accepted and supported by solid evidence, it is not always practiced. This most likely 
reflects the fact that the majority of pediatric dosing equations were developed using a gold 
standard GFR measurement, which is often too complex and costly for routine measurement 
of GFR in children.72,73 In clinical practice the gold standard technique is often substituted 
by estimated GFR, leading to variable degree of bias and imprecision.74,75 However, formal 
external validation studies of pediatric dosing equations using estimated GFR are sparse. 
The main limitation of most used eGFR equations is that they rely on creatinine, which is 
a suboptimal renal function marker in children, particularly in those with cancer, because 
of its dependency on muscle mass. As cystatin C does not share this shortcoming, cystatin 
C-based GFR might be more appropriate for renal function-based carboplatin dosing. This 
has, however, not been studied in children.
table 1.1. Formulae for carboplatin drug dosing
Carboplatin Clearance
Chatelut Cl = 2.85 × weight [kg] × (1 − 0.00357 × creatinine [mg/dL]) × (1 − 0.372 × Np) + 8.7
Dose formula
Newell Dose = TargetAUC × (GFR [mL/minute] + 0.36 × weight [kg])
Marina Dose = TargetAUC × (0.93 × GFR [mL/minute/m²] + 15)
Chatelut Dose = TargetAUC × carboplatin clearance
AUC, area under the time-concentration curve; Cl, carboplatin clearance; GFR, glomerular filtration rate; 
Np, nephrectomy
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PoPulation PharmaCoKinetiCs
An alternative to the approach of using estimated GFR in gold standard-based dosing for-
mulae is pharmacometric research, the quantitative science behind the time-course of drug 
effects. Pharmacometrics requires population pharmacokinetic and/or pharmacokinetic-
pharmacodynamic models to be fitted to individual data.76,77 Population pharmacokinetic 
analysis has several advantages. First, it relies on pooling of samples in a group of patients, 
with relatively few data points from each subject. Because it utilizes data from all subjects 
simultaneously to characterize the concentration time-course of a drug for both the study 
population and individual patients, as few as 2-4 samples per subject are needed. This is 
particularly advantageous in children, in which blood collection is often difficult. Second, it 
allows for identifying subject-specific factors that may influence drug clearance and associ-
ated drug effects. Finally, it can be used to develop and optimize dosing strategies. These 
strategies allow for dose individualization and therapeutic drug monitoring, producing the 
best possible therapeutic response and minimal toxicity for individual patients and specific 
subgroups of patients, such as those with renal impairment. Nonlinear mixed-effects model-
ing (NONMEM) is a widely accepted and validated method for pharmacokinetic analysis and 
the preferable approach in pediatric patients according to the U.S. Food and Drug Adminis-
tration.78 This approach is therefore particularly useful to study the value of cystatin C as a 
predictor of carboplatin pharmacokinetics in children.
outline of this thesis
The field of pediatric oncology is rapidly changing and improves the outcomes for many 
types of cancer. The development of kidney damage after certain treatment modalities 
may limit lifesaving therapy and cause chronic renal impairment. It is therefore essential to 
carefully monitor renal function to remediate future decline in function and to gain more 
insight into how renal (late) effects can be prevented. Furthermore, individualized dosing of 
the potentially nephrotoxic drugs carboplatin might lead to better efficacy with less renal 
toxicity. The overall aim of this thesis is to study how renal function should be assessed in 
children with cancer and how renal function could be used to individualize carboplatin dos-
ing in these patients.
The first part of this thesis, chapters 2 to 6, focuses on assessment of renal function in chil-
dren, including those with cancer. The review in Chapter 2 gives an overview of the relevant 
literature on assessing glomerular filtration rate in children and focuses on the limitations of 
the different markers. In Chapter 3 a creatinine-based GFR estimating equation that does not 
require height information is externally validated in a cohort comprising children with cancer. 
The results of an international effort to produce an assay-independent GFR estimating equa-
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tion based on cystatin C that can be used in both children and adults are reported in Chapter 
4. The cross-sectional study in Chapter 5 is conducted to compare the diagnostic accuracy 
of a creatinine-based eGFR equation with a cystatin C-based equation in childhood cancer 
patients and controls. The survey in Chapter 6 gives an overview of the recommendations 
for renal toxicity monitoring and dose modifications in childhood cancer treatment protocols 
containing potentially nephrotoxic drugs.
The second part of this thesis, chapters 7 to 9, focuses on the pharmacokinetics and 
pharmacodynamics of the renally cleared and potentially nephrotoxic drug carboplatin. In 
Chapters 7 and 8 methods to optimize dosing of carboplatin are evaluated. In the former we 
externally validate an existing pediatric dosing equation using different endogenous renal 
function markers; in the latter we study covariates that influence carboplatin clearance in 
children and developed a simple model that can be used for dosing. In Chapter 9 we report 
on the variability in carboplatin exposure seen after flat dosing. In Chapter 10 the results of 
this thesis are discussed and directions for future research are given. Finally, in Chapter 11 an 
overall summary in English and Dutch is provided.

Part I
Renal function in children (with cancer)

Chapter 2
Nierfunctie bij kinderen: meten, schatten, 
nieuwe markers of toch creatinine?
Hester N. Blufpand, Gertjan J.L. Kaspers and Arend Bökenkamp
Tijdschrift voor Kindergeneeskunde 2014;82(4):126-133
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nederlandse samenvatting
De glomerulaire filtratie snelheid (GFR) is de belangrijkste klinische maat voor de nierfunctie. 
De ideale GFR marker heeft een stabiele concentratie in het lichaam en wordt alleen door 
de glomerulus uitgescheiden. Inuline bezit deze eigenschappen, de renale klaring ervan 
wordt beschouwd als de gouden standaard voor het meten van de GFR. Klaringsonderzoe-
ken zijn echter complex en invasief. In de klinische praktijk wordt daarom gebruik gemaakt 
van serumconcentraties van endogene nierfunctiemarkers. De creatinineconcentratie 
blijft wereldwijd de meest gebruikte marker, ondanks dat het ook niet-glomerulair wordt 
uitgescheiden. De niet-lineaire relatie tussen markerconcentraties en de GFR maakt het lastig 
om een verslechtering van de nierfunctie te herkennen. Richtlijnen adviseren daarom om 
de GFR te schatten aan de hand van markerconcentraties. De meest gebruikte formule voor 
kinderen is de Schwartz formule die corrigeert voor de leeftijdsgebonden toename in crea-
tinine door de lichaamslengte te betrekken in de berekening. Cystatine C is de laatste jaren 
in opkomst als een alternatieve nierfunctiemarker. Het is een laagmoleculair eiwit dat alle 
kenmerken van de ideale marker bezit. Ondanks dat het belangrijke voordelen heeft boven 
creatinine, waarvan de belangrijkste stabiele concentratie vanaf de leeftijd van twee jaar en 
onafhankelijkheid van lichaamssamenstelling zijn, is de klinische toepassing ervan nog niet 
wijdverspreid. Ook voor cystatine C bestaan diverse formules waarmee de GFR geschat kan 
worden. Deze review geeft een overzicht van de diverse mogelijkheden die de kinderarts 
heeft om de GFR bij kinderen te bepalen.
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 2
aBstraCt
It is widely accepted that renal function is best measured as glomerular filtration rate (GFR). 
It is the single most important renal function parameter in clinical practice. The ideal GFR 
marker has a stable plasma concentration and is exclusively eliminated by the glomerulus. 
Inulin shares these features of the ideal marker; its clearance is therefore regarded as the 
gold standard for measuring GFR. Because clearance studies are invasive and cumbersome, 
it has become preferred practice to use an endogenous renal function marker. Creatinine 
remains the most widely used marker, despite its well-known limitations of which muscle 
dependency and non-glomerular elimination are the most important. The inverse relation-
ship between marker concentrations and GFR complicates rapid detection of impaired renal 
function. International guidelines therefore advise to estimate GFR using concentrations of 
an endogenous marker. The most widely used pediatric equation is by Schwartz et al. and 
corrects for the age-dependent increase in muscle mass by including height in the equation. 
In the last decades, cystatin C has emerged as an alternative GFR marker. It is a low-molecular 
weight protein that shares the properties of the ideal renal function marker. Despite its 
advantages over creatinine, of which the stable reference range above the age of two years 
and independency of body composition are the most important, widespread clinical use 
remains limited. Similar to the Schwartz equation for creatinine, several equations have been 
developed to estimate GFR from cystatin C. This review summarizes the different methods 
available to the pediatrician to determine the GFR in children.
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inleiding
De nieren hebben diverse functies, in de praktijk wordt het begrip nierfunctie echter meestal 
gebruikt om de glomerulaire filtratiesnelheid (GFR) aan te duiden. De GFR is de belang-
rijkste klinische parameter om het beloop en de prognose van nierziekten bij kinderen te 
beoordelen. Daarnaast is het van belang voor het correct doseren van geneesmiddelen. De 
GFR is leeftijdsafhankelijk en wordt uitgedrukt in mL per minuut, gestandaardiseerd naar 
1.73 m² lichaamsoppervlak (mL/minuut/1.73 m²). Dit getal vertegenwoordigt het lichaams-
oppervlak van de gemiddelde volwassene. Met deze standaardisatie wordt er gecorrigeerd 
voor het kleinere lichaam en de daarbij behorende kleinere nieren, wat vergelijking van 
individuen van verschillende formaten en het vervolgen van de nierfunctie over de jaren 
mogelijk maakt. In het eerste levensjaar zijn kinderen fysiologisch nierinsufficiënt, dit is het 
meest uitgesproken in de eerste vier levensmaanden.24 Vanaf de leeftijd van ongeveer 1,5 
jaar hebben kinderen een GFR van 90 tot 150 mL/minuut/1.73 m², vergelijkbaar met de nier-
functie van een volwassene. De GFR van een individu wordt bepaald door de som van de GFR 
van alle functionerende nefronen (‘single nephron GFR’). Daar het in vivo bepalen van de GFR 
van de afzonderlijke nefronen niet mogelijk is, zijn wij in de klinische praktijk aangewezen op 
andere methoden. Hiervoor hebben wij de beschikking over verschillende markers, zowel 
endogene als exogene. De ideale marker heeft (I) een stabiele concentratie, (II) wordt uitslui-
tend en vrij gefiltreerd door de glomerulus, (III) kent geen tubulaire secretie, reabsorptie of 
synthese en (IV) wordt niet extra-renaal geëlimineerd. Idealiter wordt het ook nog door het 
lichaam geproduceerd (Tabel 2.1). Indien een stof bovenstaande eigen-schappen bezit zal 
de hoeveelheid gefiltreerd door de glomerulus gelijk zijn aan de hoeveelheid uitgescheiden 
door de nieren.
tabel 2.1. Kenmerken van ideale en beschikbare nierfunctiemarkers
Kenmerken ideale marker inuline Creatinine ureum Cystatine c
Endogeen geproduceerd ja nee ja ja ja
Vrij gefiltreerd ja ja ja ja ja
Tubulaire reabsorptie nee nee nee ja nee*
Tubulaire secretie nee nee ja** nee nee
Bepaling eenvoudig complex eenvoudig eenvoudig eenvoudig
* Na tubulaire reabsorptie volledig gemetaboliseerd in de tubulus.
**Tevens enige mate van secretie in de darm
exogene filtratie marKers
Inuline, een exogeen polysacharide (fructose polymeer afkomstig van de Jeruzalem artisjok) 
beschikt over alle eigenschappen waar de ideale marker aan moet voldoen.79,80 De renale 
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klaring van inuline na continue infusie, ook wel ‘klassieke inulineklaring’ genoemd, wordt dan 
ook gezien als de gouden standaard voor het bepalen van de GFR. Deze methode, ontwikkeld 
door Homer Smith in 1935,26 start met een intraveneuze bolus injectie inuline gevolgd door 
continue infusie gedurende enkele uren totdat een stabiele plasma-concentratie is bereikt. 
Tijdens infusie moeten er meerdere, nauwkeurig getimede, urine-porties worden afgenomen 
waarmee het verschijnen van inuline in de urine wordt gevolgd. Om volledige blaaslediging 
te garanderen is blaaskatheterisatie soms vereist, zeker bij jonge en niet-zindelijke kinderen. 
De GFR kan ook worden berekend uit de infusiesnelheid en de plasmaconcentratie indien 
deze laatste absoluut constant is. Meestal vereist dit echter zeer langdurige infusie. Hierdoor 
is de klassieke inulineklaring veelal te invasief en complex om in de dagelijkse praktijk toe 
te passen. Vanwege bovengenoemde bezwaren wordt er daarom meestal gebruik gemaakt 
van zogenoemde ‘single-injection plasmaklaringen’ waarbij na een éénmalige intraveneuze 
injectie van een exogene marker op verschillende tijdstippen bloedmonsters worden af-
genomen om de plasmaverdwijningscurve te construeren. De meest gebruikte markers 
hiervoor zijn naast inuline,27,28 99Tc-DTPA (met de radio-isotoop technetium-99 gelabeld 
diethyleentriamine pentaazijnzuur),33,81,82 51Cr-EDTA (met de radio-isotoop chroom-51 gela-
beld ethyleendiamine tetraazijnzuur),31,82,83 iohexol (röntgen-contrastmiddel)32,84,85 en iotha-
lamaat (röntgencontrastmiddel, eventueel gelabeld met een radio-isotoop).30,86,87 Zie voor 
een overzicht van de toepassing van de verschillende markers bij kinderen referenties29 en.88
Nucleaire technieken om de GFR te bepalen worden toegepast sinds de jaren 70. Het grote 
voordeel van het gebruik van radioactief gelabelde markers is ze makkelijker kwantificeer-
baar zijn dan inuline doordat de radioactiviteit direct gemeten kan worden. In Nederland is 
het gebruik van radio-isotopen als GFR marker voor kinderen beperkt vanwege de blootstel-
ling aan straling.
endogene filtratie marKers
Ondanks dat bovengenoemde single-injection technieken zeer betrouwbaar zijn en minder 
belastend dan de klassieke inulineklaring, is toepassing ervan beperkt vanwege de com-
plexiteit, de kosten ermee gemoeid en de beperkte beschikbaarheid van de markers. Voor 
de dagelijkse klinische praktijk zijn we daarom veelal afhankelijk van endogene nierfunctie-
markers. De ideale endogene marker wordt met een constante snelheid geproduceerd, bezit 
de eigenschappen van de ideale marker en maakt daarmee injectie van een exogene marker 
overbodig.
Sinds de introductie ervan in 1937 is de creatinineconcentratie in serum wereldwijd 
de meeste gebruikte GFR marker.89 Het voordeel van creatinine is dat het gemakkelijk en 
snel te bepalen is en niet duur (€ 1,96 per bepaling; opgesteld door het College Tarieven 
Gezondheidzorg). Creatinine is een afbraakproduct van creatine, een metaboliet van spier-
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weefsel, en daarmee afhankelijk van spiermassa en dieet (vlees en vis).35,36 Personen met een 
bovengemiddeld grote spiermassa (of vleesrijk dieet) hebben een hogere creatininecon-
centratie waardoor de GFR wordt onderschat. Personen met een lage creatinineproductie 
(bijvoorbeeld bij een neuromusculaire aandoening, cachexie of amputatie), hebben lagere 
creatinineconcentraties waardoor de GFR wordt overschat. Aangezien de spiermassa van 
kinderen toeneemt met de groei, laat de creatinineconcentratie een parallelle stijging 
zien.39,40 Een ander nadeel van creatinine is dat de concentratie niet alleen afhankelijk is van 
de GFR, maar ook van niet-glomerulaire factoren (Tabel 2.1). Creatinine wordt niet alleen 
vrij gefiltreerd door de glomerulus, maar gedeeltelijk ook actief uitgescheiden door de 
proximale tubulus en in geringe mate door de darm. Hierdoor is de creatinineklaring een 
overschatting van de werkelijke glomerulaire filtratiesnelheid, waardoor milde nierfunctie-
stoornissen kunnen worden gemist. Dit wordt het ‘blind bereik’ van creatinine genoemd en is 
het meest uitgesproken bij individuen met lage creatinineconcentratie (Figuur 2.1). De crea-
tinineconcentratie is ook afhankelijk van geslacht, ras en hoeveelheid lichaamsbeweging.37,38 
Door deze afhankelijkheid van niet-renale factoren is de serum creatinineconcentratie een 
suboptimale maat voor de GFR bij kinderen. Om te corrigeren voor verschillen in creatini-
neproductie en variabiliteit gedurende de dag, wordt vaak de creatinineklaring bepaald uit 
verzamelurine en een gelijktijdig afgenomen serumconcentratie. Deze methode is echter 
niet betrouwbaarder dan het schatten van de GFR, wat veelal te wijten is aan onnauwkeurige 
urineverzameling.56 Nauwgezet noteren van de starttijd (tijdstip van de laatste mictie vóór 
het begin van de urineverzameling) en eindtijd (tijdstip van de laatste mictie die wordt opge-
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figuur 2.1. Relatie tussen glomerulaire filtratie snelheid en de creatinineconcentratie.
(A) Patiënt met een normale spiermassa. (B) Patiënt met een verminderde spiermassa. De creatininecon-
centratie stijgt pas als de GFR vrijwel gehalveerd is (‘blind bereik’, aangeduid in het grijs). Dit is het meest 
uitgesproken bij patiënten met een verminderde spiermassa (B).
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vangen) en volledige blaaslediging zijn cruciaal voor een nauwkeurige urineverzameling. Dit 
wordt belangrijker naarmate de verzameltijd korter is. Ureum, een eveneens veel gebruikte 
endogene marker, is ook niet heel geschikt als maat voor de nierfunctie omdat de productie 
ervan wordt beïnvloed door eiwitintake en -metabolisme. Daarnaast is het afhankelijk van de 
hydratietoestand doordat de renale resorptie bij een lage urineproductie toeneemt.
Sinds de jaren tachtig wordt er gesuggereerd dat laag-moleculair eiwitten goede endo-
gene nierfunctiemarkers zijn omdat ze vrij gefiltreerd worden in gezonde nieren.46 Diverse 
eiwitten zijn onderzocht waaronder β-trace protein, β2-microglobuline en cystatine C. Vooral 
de laatste is een zeer veelbelovende nierfunctiemarker. Cystatine C wordt met een vrijwel 
constante snelheid door alle kernhoudende cellen in het menselijk lichaam geproduceerd48 
en is daarmee, in tegenstelling tot creatinine, onafhankelijk van spiermassa, voedingstoe-
stand, dieet en geslacht.36,49 Dit is terug te zien in de referentiewaarden die vanaf de leeftijd 
van één jaar constant zijn.90,91 Na filtratie door de glomerulus wordt cystatine C gereabsor-
beerd en in de tubuli afgebroken, er komt dus geen cystatine C meer terug in de circulatie. Bij 
normaal functionerende proximale tubuli komt er ook geen cystatine C in de urine terecht. 
Een belangrijk voordeel van cystatine C is dat het eerder stijgt dan creatinine92,93 wat vroege 
interventie mogelijk maakt. Een ander voordeel is dat het, in tegenstelling tot creatinine en 
ureum, de placenta niet passeert. Concentraties in (navelstreng) bloed geven dus daadwer-
kelijk de nierfunctie van de foetus of pasgeborene weer en niet tevens die van de moeder.94,95 
Cystatine C kent ook niet-renale beïnvloeding, echter minder dan de conventionele nier-
functie markers.51 Alleen van zeer hoge doses glucocorticoïden is onomstreden aangetoond 
dat het een (dosisafhankelijke) stijging van de cystatine C concentratie tot gevolg heeft.53,54 
Normale tot lage doses laten dit effect echter niet zien.60,96 De schildklierfunctie lijkt ook 
van invloed op de concentratie, de resultaten hierover zijn echter verre van eenduidig.29,51,52 
Door bovengenoemde eigenschappen wordt cystatine C meer en meer beschouwd als een 
uitstekend alternatief voor creatinine, zowel bij volwassenen als kinderen. Diverse studies 
bij kinderen hebben aangetoond dat cystatine C beter met een gouden standaard klaring 
correleert dan creatinine.97,98 Twee grote meta-analyses van in totaal 70 studies bevestigen 
de superieure diagnostische nauwkeurigheid van cystatine C die in diverse kleinere studies 
wordt gevonden.99,100 Het grote voordeel van cystatine C boven creatinine is de onafhan-
kelijkheid van spiermassa waardoor het toepasbaar is over de volle breedte van lichaams-
samenstellingen, waaronder jonge kinderen en ouderen. Vooral voor patiënten met een 
verminderde spiermassa (spina bifida,101 reumatoïde artritis,102 kanker,103 levercirrose104),bij 
wie de creatinineproductie verlaagd is, is cystatine C een betere maat voor de GFR dan creati-
nine. De introductie van commerciële assays op moderne auto-analyzers heeft grootschalige 
klinische toepassing en snelle rapportage van cystatine C als marker voor de GFR mogelijk 
gemaakt. De bepaling is in Nederland momenteel echter wel vier tot vijf keer duurder dan 
een creatinine bepaling. Het grootste obstakel in de implantatie van cystatine C in de kliniek 
was het ontbreken van gecertificeerd referentiemateriaal. Dit is inmiddels geproduceerd en 
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de meeste laboratorium bepalingen van cystatine C zijn gestandaardiseerd. Hiermee zijn de 
referentiewaarden voor alle laboratoria gelijk.
sChatten van de gfr
Er bestaat een omgekeerd evenredige (inverse) relatie tussen serumconcentraties van endo-
gene nierfunctiemarkers en de GFR. Deze niet-lineaire relatie maakt dat een absolute stijging 
van een markerconcentratie bij een normale nierfunctie een veel grotere daling van de GFR 
weergeeft dan als er sprake is van een verminderde nierfunctie (Figuur 2.2). Hierdoor is het 
lastig voor het ongeoefende oog om de mate van verslechtering van de GFR in te schatten. 
Vanwege dit en bovenstaande beperkingen van serumconcentraties van endogene markers 
adviseren internationale richtlijnen dan ook om de GFR te schatten (estimated GFR; eGFR) 
aan de hand van concentraties van endogene markers.55,56,105
In de kindergeneeskunde zijn hiervoor diverse formules beschikbaar.29 De meest gebruikte 
is de bedside-Schwartz formule.25 Deze formule corrigeert voor de belangrijkste niet-renale 
confounder van creatinine – de leeftijdsgebonden toename van de spiermassa – met een 
constante (‘k-waarde’) en door de lengte mee te nemen in de berekening. De originele 
Schwartz formule uit 1976106 kan als gevolg van twee belangrijke wijzigingen in laborato-
rium technieken niet meer gebruikt worden: (I) de specificiteit van de creatinine bepaling 
is verbeterd (alkaline picraat Jaffé reactie vs enzymatische methode) en (II) vergelijking van 
A
B
25% 50% 75% 100%
Glomerulaire filtratie snelheid (% van normaal)
M
ar
ke
r c
on
ce
nt
ra
tie
figuur 2.2. Relatie tussen glomerulaire filtratie snelheid en de serumconcentratie van een marker. Exact 
dezelfde verandering weerspiegelt een kleinere verandering in de GFR bij een verminderde nierfunctie (A) 
dan bij een normale nierfunctie (B).
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creatinine waarden van verschillende laboratoria is mogelijk door gebruik te maken van een 
methode gekalibreerd op een internationale isotope dilution mass spectometry (IDMS) re-
ferentie standaard. Formules gebaseerd op met Jaffé gemeten creatinine, zoals de originele 
Schwartz, kunnen niet gebruikt worden met enzymatische IDMS creatinine waarden die alle 
Nederlandse laboratoria tegenwoordig rapporteren. Door de verbeterde creatinine bepa-
ling is de nauwkeurigheid van GFR formules sterk verbeterd,25,34 maar de originele Schwartz 
formule dus onbruikbaar geworden. In 2009 heeft Schwartz zijn formule aangepast aan de 
nieuwe creatinine standaard (bedside Schwartz):25
GFR (mL/minuut/1.73 m²) = 36.5 ×
lengte [cm]
creatinine [µmol/L]
De originele Schwartz formule differentieerde met de k-waarde naar puberteitsstadium en 
geslacht, waarmee de invloed van spiermassa op de creatinineconcentratie gecorrigeerd 
werd. De nieuwe Schwartz-formule kent een vaste k-waarde. Recent is echter gesuggereerd 
dat het gebruik van een aparte coëfficiënt voor kinderen onder de 13 jaar de diagnostische 
accuratesse wellicht verder kan verbeteren.107 Een groot nadeel van de Schwartz formule is 
dat de lengte van de patiënt bekend moet zijn om de GFR te kunnen schatten. Hierdoor 
kan de GFR niet bepaald worden in situaties waarin geen lengte bekend is en kan het labo-
ratorium, dat vaak niet op de hoogte is van de lengte van de patiënt, niet automatisch een 
geschatte GFR rapporteren naast de creatinineconcentratie. Bij volwassenen is dit standaard 
zorg omdat de veelgebruikte eGFR formules voor volwassenen (veelal MDRD of CKD-EPI) 
geen gebruik maken van antropometrische patiëntgegevens. Recent hebben wij een for-
mule waarmee de GFR geschat kan worden zonder lengte (Pottel et al.108) vergeleken met 
de nieuwe Schwartz formule. Onze resultaten laten zien dat de lengte-onafhankelijke Pottel 
formule de gouden standaard even goed benadert als de Schwartz formule.109
Naast de veelgebruikte Schwartz formule zijn er diverse formules voor kinderen ontwikkeld, 
gebaseerd op één of meerdere endogene nierfunctie markers en één of meerdere niet-renale 
factoren (bijvoorbeeld antropometrische factoren als lengte, geslacht, leeftijd en ziekte; zie 
voor een overzicht van veel gebruikte formules referentie29). Over het algemeen geldt dat hoe 
meer factoren er in een formule worden opgenomen, des te nauwkeuriger het de GFR kan 
schatten. Dit gaat echter vaak ten koste van de klinische toepasbaarheid omdat een formule 
te complex is om even snel een GFR uit te rekenen. Formules geven de ware GFR het beste 
weer indien de populatie waarin ze toegepast worden de populatie waarin ze ontwikkeld zijn 
zoveel mogelijk benadert.110 Veel formules zijn ontwikkeld in een kleine populatie kinderen, 
vaak met een vergelijkbare aandoening en daarmee als het ware op maat gemaakt voor deze 
populatie. Klinisch worden ze echter veelal breder toegepast. Een formule ontwikkeld in een 
groep kinderen met een mild verlaagde nierfunctie en aangeboren afwijkingen van de nie-
ren en urinewegen is dus niet per definitie geschikt voor kinderen met een ernstig verlaagde 
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nierfunctie of gezonde kinderen. De generaliseerbaarheid van de verschillende formules is 
daarmee beperkt. De bedside Schwartz formule is ontwikkeld in een groep kinderen met 
matig-ernstig chronische nierziekten (mediane GFR van 41 mL/minuut/1.73 m²) en daardoor 
minder geschikt voor kinderen met een normale nierfunctie of kinderen met een acute ver-
slechtering van de nierfunctie. Behalve dat de populatie waarin de formule wordt toegepast 
zo veel mogelijk moet overeenkomen met de populatie waarin het ontwikkeld is, moeten 
ook gebruikte technieken – zoals merk apparatuur en assay – overeenkomen.111,112 Dit laatste 
is vooral van belang voor formules gebaseerd op cystatine C aangezien deze bepaling (in 
tegenstelling tot creatinine) nog niet overal gestandaardiseerd is. Hiermee zullen, analoog 
aan de eerdere ontwikkelingen rondom creatinine, op cystatine C gebaseerd formules in de 
toekomst verder verbeteren. Het recentelijk ontwikkelde gestandaardiseerde referentiema-
teriaal voor cystatine C maakt het mogelijk universele (assay onafhankelijke) eGFR formules 
te ontwikkelen.62 De eerste pogingen hiertoe zijn gaande.
ConClusies en aanBevelingen
Gouden standaard GFR bepalingen zijn complex en invasief. In de dagelijkse praktijk wordt 
er daarom veelal gebruik gemaakt van serumconcentraties van endogene markers. Deze zijn 
echter een slechte maat voor de GFR. Formules waarmee de GFR geschat kan worden op 
basis van endogene markers zijn veel nauwkeuriger en zeker beter dan de (24-uurs) creatini-
neklaring die door verzamelfouten notoir onnauwkeurig is. De endogene marker creatinine 
wordt veel gebruikt maar heeft als nadeel dat afhankelijk is van de spiermassa. Hierdoor is 
het niet geschikt voor jonge kinderen en die met een afwijkende spiermassa. De Schwartz 
formule corrigeert gedeeltelijk voor de nadelen van creatinine en is een goede maat voor de 
GFR bij kinderen met een normale lichaamssamenstelling. Cystatine C is niet afhankelijk is 
van spiermassa, formules gebaseerd op deze marker zijn daarmee geschikter voor patiënten 
met een afwijkende lichaamssamenstelling. Doordat de cystatine C concentratie eerder stijgt 
dan de creatinineconcentratie is het geschikter voor het opsporen van milde nierfunctie-
stoornissen. Met het gecertificeerde referentiemateriaal voor cystatine C zijn universele, 
assay-onafhankelijke, schattingsformules binnen handbereik. Dit zal de accuratesse van op 
cystatine C gebaseerde formules in de toekomst verder verbeteren. Voor alle formules geldt 
echter dat het slechts een schatting betreft met een variatie van circa 30%, daarom blijven 
we voor een zeer nauwkeurige bepaling van de GFR afhankelijk van gouden standaard 
technieken.
Chapter 3
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aBstraCt
objective: To compare the diagnostic performance of two height-independent equations 
used to calculate estimated glomerular filtration rate (eGFR), those of Pottel (eGFR-Pottel) 
and the British Columbia Children’s Hospital (BCCH; eGFR-BCCH), with the commonly used 
Schwartz equation (eGFR-Schwartz).
study design: We externally validated eGFR-Pottel and eGFR-BCCH in a well-characterized 
pediatric patient population (n = 152) and compared their diagnostic performance with that 
of eGFR-Schwartz using Bland-Altman analysis. All patients underwent glomerular filtration 
rate measurement using the gold standard single-injection inulin clearance method (GFR-
inulin).
results: Median GFR-inulin was 92.0 [IQR 76.1-107.4] mL/minute/1.73 m². Compared with 
GFR-inulin, the mean bias for eGFR-Schwartz was −10.1 mL/minute/1.73 m² (95% limits of 
agreement [LOA], −77.5 to 57.2 mL/minute/1.73 m²), compared with −12.3 mL/minute/1.73 
m² (95% LOA, −72.6 to 47.9 mL/minute/1.73 m²) for eGFR-Pottel and −22.1 mL/minute/1.73 
m² (95% LOA, −105.0 to 60.8 mL/minute/1.73 m²) for eGFR-BCCH. eGFR-Pottel showed com-
parable accuracy to eGFR-Schwartz with 77% and 76% of estimates within 30% of GFR-inulin, 
respectively. eGFR-BCCH was less accurate than eGFR-Schwartz (66% of estimates within 30% 
of GFR-inulin; P < 0.01).
Conclusion: Performance of eGFR-Pottel is superior to that of eGFR-BCCH and comparable 
with that of eGFR-Schwartz. eGFR-Pottel is a valid alternative to eGFR-Schwartz in children 
and could be reported by the laboratory if height data are not available.
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introduCtion
Glomerular filtration rate (GFR) is the best indicator of renal function in children.113 Gold 
standard GFR measurement techniques114 are cumbersome, costly and often unavailable. 
As an alternative, current guidelines recommend the use of estimated GFR (eGFR) based 
on serum creatinine concentration in both adults and children.115 The most commonly used 
equation for calculating eGFR in children is the Schwartz equation (eGFR-Schwartz),25 which 
is calculated from serum creatinine concentration, height and an empirical constant, k, that 
adjusts for muscle mass and the creatinine measurement method. A major disadvantage of 
eGFR-Schwartz is the need for height information, which hampers its use in settings in which 
height data are not available. This precludes automatic reporting of eGFR in children by most 
clinical laboratories, which has become common practice in adult patients, because most 
equations for adults do not require anthropometric data.116,117 To overcome this problem, 
Zappitelli et al.118 and Pottel et al.108 have recently developed eGFR equations (termed the 
modified British Columbia Children’s Hospital equation (BCCH; [eGFR-BCCH] and eGFR-
Pottel, respectively) using different approaches to estimate GFR in children independent 
of height. In their hands both equations performed similarly to eGFR-Schwartz. Because a 
height-independent eGFR can be easily calculated by laboratory reporting software, use of 
these alternative equations may significantly improve pediatric care and facilitate screening 
for chronic kidney disease (CKD) in children. eGFR-BCCH and eGFR-Pottel have not yet been 
validated using inulin clearance, however.
In the present study we aimed to externally validate both the eGFR-BCCH and eGFR-Pottel 
equations using measurement of GFR by the single-injection inulin clearance method (GFR-
inulin) as the gold standard in a well-defined pediatric cohort with varying degrees of CKD. 
We also compared the diagnostic performance of the height-independent eGFR equations 
and eGFR-Schwartz. We hypothesized that both equations would perform as well as eGFR-
Schwartz.
methods
Data from all patients who consecutively underwent a gold standard GFR measurement at 
the Pediatric Renal Center of the VU University Medical Center between March 2008 and 
September 2012 were analyzed retrospectively. GFR measurements were performed based 
on clinical indication. Anthropometric data were obtained by chart review. All patient data 
were recorded in an anonymous manner such that subjects could not be identified directly 
or through identifiers linked to the subjects. The study was therefore exempted from institu-
tional review. Anthropometric data values are expressed as SDS (z-scores) away from the mean 
using the growth data of the Fourth Dutch Growth Study.119 The reference standard and the 
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index test were performed at the same time. Because muscle mass influences serum creati-
nine levels and thus the performance of creatinine-based equations, malnourished patients 
(ie, children with a body mass index SDS < −3) and patients with spina bifida were excluded 
from this study. GFR was measured by single-injection inulin clearance, a validated method 
for accurately determining GFR in children.28 The GFR-inulin studies were performed at the 
pediatric outpatient clinic after an overnight fast. Clinical hydration status of all patients was 
assessed before measurement. Before and during GFR measurement, patients had free access 
to water or tea without sugar. GFR measurements were performed exclusively in patients 
with normal hydration status as assessed by the supervising physician. All patients received a 
single intravenous dose (5000 mg per 1.73m² of body surface area, with a maximum dose of 
5000 mg) of inulin (Inutest®; Fresenius, Bad Homburg, Germany), administered over one min-
ute. Dedicated nurses assessed for extravasation of inulin during administration. Serial blood 
samples were obtained at 10, 30, 90, and 240 minutes after injection. After sampling, blood 
was centrifuged for five minutes at 1800 g and then stored at −20°C until measurements. 
Inulin was measured within 14 days using an enzymatic method based on the determination 
of fructose concentration after acid hydrolysis of inulin as described by Jung et al.120 with 
minor modifications.121 GFR-inulin was calculated using a two-compartmental model with 
MW/Pharm 3.5 software (Mediware, Groningen, The Netherlands), a pharmacokinetic pro-
gram using Bayesian estimates from patient and population data.28 Immediately before the 
GFR-inulin clearance study, blood was drawn for measurement of serum creatinine, using an 
enzymatic method (Modular analytics <P>; Roche diagnostics, Mannheim, Germany), which 
is traceable to an isotope dilution mass spectrometry (IDMS) standard.122
egfr equations
All three equations are based on IDMS-traceable standards for creatinine measurement. 
eGFR-Schwartz is calculated as:
eGFR-Schwartz [mL/minute/1.73 m²] = 41.3 ×
height [m]
serum creatinine [mg/dL]
eGFR-BCCH, by Zappitelli et al., estimates GFR based on serum creatinine concentration and 
age:
inverse ln(eGFR-BCCH [mL/minute/1.73 m²]) = 8.067
+

 1.034 × ln



0.011 


 + (0.305 × ln(age [years]))
serum creatinine [mg/dL]
  + 0.064 if male
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eGFR-Pottel uses median serum creatinine reference values:
eGFR-Pottel [mL/minute/1.73 m²] = 107.3 / 
serum creatinine [mg/dL] 
Q
Q is the median serum creatinine concentration for children based on age and sex (Table 
3.1).123 Renal function was classified according to the National Kidney Foundation’s Kidney 
Disease Outcome Quality Initiative (K/DOQI) guidelines for CKD.115 Underclassification was 
considered if the CKD stage based on GFR-inulin was higher than that based on eGFR, and 
overclassification was considered if the CKD stage based on GFR-inulin was lower than the 
CKD stage based on eGFR.
table 3.1. Median serum creatinine concentrations for different age categories123
age all patients males females
Newborns 0.54 - -
1 month to <1 year 0.25 - -
1 to <2 years 0.27 - -
2 to <3 years 0.30 - -
3 to <4 years 0.33 - -
4 to <5 years 0.36 - -
5 to <6 years 0.38 - -
6 to <7 years 0.43 - -
7 to <8 years 0.45 - -
8 to <9 years 0.47 - -
9 to <10 years 0.50 - -
10 to <11 years 0.52 - -
11 to <12 years 0.54 - -
12 to <13 years 0.57 - -
13 to <14.5 years 0.61 - -
14.5 to <15.5 years - 0.68 0.62
15.5 to <16.5 years - 0.78 0.68
16.5 to <17.5 years - 0.82 0.70
17.5 to <18.5 years - 0.85 0.71
18.5 to <19.5 years - 0.86 0.71
19.5 to <20.5 years - 0.88 0.70
Median serum creatinine concentrations for children and adolescents. (median serum creatinine = 0.0270 x 
age + 0.2329). To express serum creatinine in µmol/L, multiply by 88.4.
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statistical analyses
All analyses were performed using SPSS 20.0 (IBM, Armonk, New York). Continuous variables 
are presented as mean (SD) for variables with a Gaussian distribution and median [IQR] 
for variables with a non-Gaussian distribution. Differences between continuous variables 
between patients aged ≤ 14 years and patients aged > 14 years were analyzed using Student 
t test. Nonnormally distributed variables were naturally log-transformed before analysis. Dif-
ferences in bias between the tested equations were analyzed using the paired samples t test. 
Qualitative variables are shown as counts (proportion) and were compared using the χ² test 
or McNemar test. The analytical performance of the different eGFR equations was assessed 
in compliance with the Standard for the Reporting of Diagnostic accuracy studies (STARD) 
criteria.124 Using Bland-Altman analysis,125 we calculated bias (ie, mean difference between 
GFR-inulin and eGFR) and the limits of agreement (LOA; mean bias ± 1.96 × SD). Accuracy 
was determined as proportions of patients with an eGFR value within 30%, 20% and 10% of 
that measured by GFR-inulin. Differences were considered statistically significant at a P value 
< 0.05 and a trend at P values of 0.05–0.10 in all analyses.
results
A total of 152 participants were included in the analyses, their characteristics are summarized 
in Table 3.2. Because eGFR-Pottel was calibrated in a cohort of children aged 2-14 years, chil-
dren aged > 14 years are displayed separately. Ninety-five children (63%) had a congenital 
anomaly of the kidney or urinary tract, 26 (18%) had glomerular disease and 29 (19%) had 
a malignancy. Two children (1%) were healthy siblings. The median age at testing was 14.5 
[9.3-17.5] years. The median GFR-inulin value was 92.0 mL/minute/1.73 m² (IQR, 76.1-107.4 
mL/minute/1.73 m²; range, 19.4-173.8 mL/minute/1.73 m²). The GFR-inulin value was < 90 
mL/minute/1.73 m² (indicating CKD stage 2 or worse) in 49% of measurements. The rate of a 
GFR-inulin <90 ml/minute/1.73 m² tended to be higher in children aged > 14 years compared 
with those aged ≤ 14 years (55% vs 42%; P = 0.10). Differences in median GFR between age 
groups were not identified by GFR-inulin or eGFR-Pottel, whereas children aged > 14 years 
had lower median eGFR-Schwartz and eGFR-BCCH values than those aged ≤ 14 years (P < 
0.001 for both equations).
Figure 3.1 shows Bland-Altman plots for all tested equations. The mean difference between 
GFR-inulin and eGFR-Schwartz was −10.1 mL/minute/1.73 m² (SD, 34.3 mL/minute/1.73 m²; 
95% LOA, −77.5 to 57.2 mL/minute/1.73 m²), and the mean difference between GFR-inulin 
and eGFR-Pottel was −12.3 mL/minute/1.73 m² (SD, 30.7 mL/minute/1.73 m²; 95% LOA, −72.6 
to 47.9 mL/minute/1.73 m²) (P = 0.01, eGFR-Pottel vs eGFR-Schwartz). eGFR-BCCH showed 
the highest bias, at −22.1 mL/minute/1.73 m² (SD, 42.3 mL/minute/1.73 m²; 95% LOA, 
−105.0 to 60.8 mL/minute/1.73 m²) (P < 0.001, eGFR-BCCH vs eGFR-Schwartz) (Table 3.3). For 
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table 3.2. Clinical characteristics of participants at renal function measurement
total
n=152
≤ 14 years
n=74
> 14 years
n=78
Patient characteristics
Age, years, median [IQR] 14.5 [9.3-17.5] 9.2 [6.0-11.4] 17.4 [16.4-18.0]
Male sex, % 60 60 60
Height SDS, mean (SD) −0.5 (1.2) −0.6 (1.3) −0.4 (1.1)
Weight for height SDS, mean (SD) 0.2 (1.3) 0.3 (1.2) 0.0 (1.5)
Body mass index SDS, mean (SD) 0.2 (1.3) 0.3 (1.2) 0.1 (1.3)
Malignancy, % 19 35 4
Renal function parameters
Creatinine, mg/dL, median [IQR] 0.71 [0.50-0.93] 0.52 [0.38-0.65] 0.89 [0.76-0.98]
GFR-inulin, mL/minute/1.73 m², median [IQR] 92.0 [76.1-107.4] 95.1 [76.8-113.1] 90.0 [76.1-99.8]
eGFR-Schwartz, mL/minute/1.73 m², median [IQR] 91.0 [76.6-114.5] 101.9 [88.3-131.0] 81.0 [71.7-92.7]
eGFR-Pottel, mL/minute/1.73 m², median [IQR] 96.3 [80.4-112.0] 98.5 [83.4-123.3] 94.9 [77.6-107.0]
eGFR-BCCH, mL/minute/1.73 m², median [IQR] 98.7 [82.7-129.4] 123.6 [98.0-151.1] 88.7 [76.0-99.0]
CKD-stage 1*, % 51 58 45
CKD-stage 2*, % 38 28 46
CKD-stages 3-5*, % 11 14 9
Data for patients aged ≤ 14 years are displayed separately.
*CKD stage based on GFR-inulin: stage 1 > 90 mL/minute/1.73 m², stage 2 60-89 mL/minute/1.73 m², stage 
3-5 < 60 mL/minute/1.73 m².
table 3.3. Diagnostic performance of eGFR equations
mean bias
(ml/minute/1.73 m²)
accuracy ± 30%
(%)
accuracy ± 20%
(%)
accuracy ± 10%
(%)
eGFR-Schwartz −10.1 76 61 28
≤ 14 years −22.2 68 58 31
> 14 years 1.3 85 63 24
eGFR-Pottel −12.3* 77 63 34
≤ 14 years −14.8 77 62 37
> 14 years −10.0 77 63 32
eGFR-BCCH −22.1† 66 47 28
≤ 14 years −39.7 50 28 18
> 14 years −5.3 81 64 39
Shown are mean differences between GFR-inulin and the three eGFR estimates (mL/minute/1.73 m²) and 
proportion of eGFR estimates within the 30% limits of GFR-inulin. Subanalyses based on age ≤ 14 years and
> 14 years are also presented.
*P = 0.01 compared with eGFR-Schwartz. †P < 0.001 compared with eGFR-Schwartz.
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eGFR-Schwartz and eGFR-BCCH, but not for eGFR-Pottel, overestimation of GFR-inulin was 
significantly higher in children aged ≤ 14 years compared to those aged > 14 years (P < 0.001 
for both tested equations).The accuracy of the tested equations, measured as the percentage 
of estimates within 10%, 20%, and 30% of GFR-inulin values, is shown in Table 3.3. Accuracy 
was comparable in eGFR-Pottel and eGFR-Schwartz; however eGFR-BCCH demonstrated sig-
nificantly lower proportions of estimates within 20% and 30% of GFR-inulin values compared 
with eGFR-Schwartz (P = 0.001 and 0.002, respectively). A sub-analysis of children aged > 14 
years showed higher accuracy within 30% of GFR-inulin values for all estimating equations, 
table 3.4. CKD stage based on Kidney Disease Outcome Quality Initiative guidelines for eGFR equations
CKd stage 1*
(%)
CKd stage 2*
(%)
CKd stage 3-5*
(%)
underclassification
of CKd stage* (%)
overclassification
of CKd stage* (%)
eGFR-Schwartz 51 38 11 40 20
eGFR-Pottel 61 31 9 25 12
eGFR-BCCH 64 26 10 28 30
*Based on GFR-inulin.
CKD stages: stage 1, >90 mL/minute/1.73 m²; stage 2, 60-89 mL/minute/1.73 m²; stage 3-5, < 60 L/min-
ute/1.73 m².
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figure 3.1. Bland-Altman plots for A, eGFR-Schwartz, B, eGFR-Pottel, and C, eGFR-BCCH showing bias (solid 
line) and the 95% LOA (ie, mean bias ± 1.96 x SD [gray area]).
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which was most marked in eGFR-Schwartz and eGFR-BCCH (Table 3.3). CKD stages according 
to K/DOQI guidelines are displayed in Table 3.4. The misclassification rate was lower for eGFR-
Pottel (37%) compared with eGFR-BCCH and eGFR-Schwartz (both 40%). Underestimation of 
CKD stage was least frequent with eGFR-Schwartz (20%) compared with eGFR-Pottel (25%; P 
= 0.06) and eGFR-BCCH (28%; P = 0.001). The proportion of patients with a GFR-inulin value < 
75 mL/minute/1.73 m² (ie, cutoff value for progressed CKD) but an eGFR > 75 mL/minute/1.73 
m² was 9% for eGFR-Schwartz, 10% for eGFR-Pottel, and 11% for eGFR-BCCH. When an eGFR 
cutoff value of < 60 mL/minute/1.73 m² for eGFR was used, the proportion of patients with a 
GFR-inulin > 60 mL/minute/1.73 m² was 3% for eGFR-Schwartz, 1% for eGFR-Pottel and 1% 
for eGFR-BCCH.
disCussion
In our hands the height-independent eGFR equation of Pottel et al. demonstrated similar 
diagnostic performance as the widely used eGFR-Schwartz equation. eGFR-BCCH, however, 
was less precise and had lower accuracy than eGFR-Schwartz and eGFR-Pottel. Based on 
these findings, we recommend the use of eGFR-Pottel over eGFR-BCCH in children when 
height data are unavailable.
Height-independent equations are important because they can be used for the automatic 
reporting of eGFR by laboratories, which often do not have access to anthropometric data. 
From a broader perspective, height-independent eGFR can facilitate screening for pediatric 
CKD.126 Bearing in mind the well-documented imprecision of estimating equations, a finding 
of impaired GFR should be confirmed using a gold standard GFR measurement.100
Originating from muscle metabolism, creatinine production is closely related to muscle 
mass. In children, muscle mass increases with linear growth, along with a parallel increase in 
serum creatinine reference values. This prompted Schwartz et al.,106 and Counahan-Barrett 
et al.127 to develop equations combining height and serum creatinine to estimate GFR. The 
use of different k values allows correction for differences in muscle mass and the specificity 
of the creatinine assay used.128 Until recently, large interlaboratory differences in creatinine 
measurement precluded the widespread use of differentiated pediatric reference values. This 
has changed since the implementation of IDMS-traceable creatinine measurements in clini-
cal chemistry. Instead of using height as a surrogate for age-specific creatinine production, 
Pottel et al.108 used age-specific IDMS-traceable creatinine concentrations in healthy children. 
Our results show that this method has similar performance as eGFR-Schwartz.
The maximum accuracy within 20% of GFR-inulin values for our tested eGFR measures was 
63%, for eGFR-Pottel, which might not be ideal for clinical practice. Nevertheless, the accura-
cies within 30% of GFR-inulin for eGFR-Schwartz (76%) and eGFR-Pottel (77%) were compa-
rable with the accuracy originally reported by Schwartz et al. (79%). Thus, we believe that the 
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use of eGFR-Pottel instead of eGFR-Schwartz in clinical practice is justified. Still, equations 
based on serum cystatin C level alone or cystatin C in combination with serum creatinine 
levels have been shown to be superior in children,60 particularly in children with abnormal 
muscle mass, such as those with spina bifida or malnourishment, who were excluded from 
our study. In contrast to serum creatinine, cystatin C is produced at a constant rate in children 
and adults and is independent of muscle mass; thus many serum cystatin C-based equa-
tions do not require height information.59 However, given the lack of a certified calibrator 
for cystatin C until recently,62 the nonuniformity in cystatin C measurement techniques has 
hindered the universal use of cystatin C as a marker for renal function.
We decided to test eGFR-BCCH by Zappitelli et al.,118 a modification of the equation originally 
published by Mattman et al.,129 because it was established using an IDMS-traceable creatinine 
assay. eGFR-BCCH overestimated GFR compared with eGFR-Pottel and eGFR-Schwartz. This 
overestimation might be explained by differences in the gold standard technique used for 
calibration. Zappitelli et al.118 used the continuous iothalamate plasma infusion technique, 
while Pottel et al.108 used single-injection 51Cr-EDTA clearance and Schwartz et al.25 single-
injection iohexol clearance. It has been shown that the continuous iothalamate plasma 
infusion technique may overestimate GFR when the duration of sampling is too short,130 
which might explain why eGFR-BCCH overestimated GFR compared with eGFR-Pottel and 
eGFR-Schwartz in the present study.
Along with differences in the gold standard measurement technique used, GFR values 
also depend on the population tested.131 Differences in diet or obesity rates, both of which 
can affect renal function, might have further influenced the performance of eGFR-BCCH in 
this study. Furthermore, the fact that mean GFR in our cohort (88 mL/minute/1.73 m²) more 
closely resembles the mean GFR in the original calibration population of Pottel et al. (84 mL/
minute/1.73 m²) than that of Zappitelli et al. (77 mL/minute/1.73 m²) may have favored eGFR-
Pottel over eGFR-BCCH. The superior performance of eGFR-Schwartz in our subjects aged > 
14 years is in line with previous findings132 and likely reflects the lower GFR in the subgroup 
of patients aged > 14 years. In line with our findings in the younger age-group, De Souza et 
al.107 have recently suggested that a lower k value of 36.8 rather than 41.3 (for creatinine in 
mg/dL and height in m) might be more suitable for children aged < 13 years. Recalibration of 
the Schwartz equation was beyond the scope of the present study, however.
Our study has several limitations. First, although we used the inulin single-injection 
method, which has been shown accurately determine true GFR in children and adults,28,133 we 
measured inulin by an enzymatic method, which has a lower sensitivity than mass spectrom-
etry measurement and can be biased by cross-reactions with other serum metabolites such 
as glucose. To reduce this risk, all GFR measurements were performed after an overnight fast. 
Single-injection GFR measurements are hampered by the need for complete equilibration 
of the tracer in the extracellular space after injection, which must be separated from the 
decline in concentration reflecting glomerular filtration. This problem is seen primarily at 
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low GFR, where late sampling is essential. Nonetheless, our results for both eGFR-Pottel and 
eGFR-Schwartz are comparable with the original reports. Second, the original studies differed 
in the age spectrum of the respective calibration populations. eGFR-BCCH was calibrated in 
a cohort aged 2-18 years, eGFR-Schwartz was calibrated in a cohort aged 1-16 years, and 
eGFR-Pottel was calibrated in children aged ≤ 14 years. In line with this difference in age 
among the calibration populations, GFR-Schwartz and eGFR-BCCH performed significantly 
better in adolescents, but eGFR-Pottel did not. Finally, we did not recalibrate the eGFR equa-
tions to our local creatinine assay because the assay was IDMS-traceable, as was the case in 
the original reports. Recalibration might have corrected for differences in patient population 
and the gold standard GFR measurement and thus possibly improved the performance of 
the equations. However, our study aimed to evaluate diagnostic performance of the original 
equations in clinical practice, rather establish yet another equation for estimating GFR.
In summary, our findings from the present study show that the performance of the height-
independent eGFR-Pottel was comparable with eGFR-Schwartz and superior to that of 
eGFR-BCCH in a large pediatric cohort. Our study supports use of the eGFR-Pottel by pediatri-
cians and clinical laboratories to automatically report eGFR when anthropometric data are 
unavailable.
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Generation of a new cystatin c-based estimating 
equation for glomerular filtration rate 
by use of seven assays standardized to the 
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aBstraCt
Background: Many different cystatin C-based equations exist for estimating glomerular 
filtration rate (GFR). Major reasons for this are the previous lack of an international cystatin C 
calibrator and the non-equivalence of results from different cystatin C assays.
methods: Use of the recently introduced certified reference material, ERM-DA471/IFCC, and 
further work to achieve high agreement and equivalence of seven commercially available 
cystatin C assays allowed a substantial decrease of the CV of the assays, as defined by their 
performance in an external quality assessment for clinical laboratory investigations. By 
use of two of these assays and a population of 4690 subjects, with large subpopulations 
of children and Asian and Caucasian adults, with their GFR determined by either renal or 
plasma inulin clearance or plasma iohexol clearance, we attempted to produce a virtually 
assay-independent simple cystatin C-based equation for estimation of GFR.
results: We developed a simple cystatin C-based equation for estimation of GFR comprising 
only two variables, cystatin C concentration and age. No terms for race and sex are required 
for optimal diagnostic performance. The equation,
eGFR = 130 × cystatin C −1.069 × age−0.117 − 7
is also biologically oriented with one term for the theoretical renal clearance of small mol-
ecules and one constant for extra-renal clearance of cystatin C.
Conclusions: A virtually assay-independent simple cystatin C-based and biologically ori-
ented equation for estimation of GFR, without terms for sex and race, was produced.
Assay-independent eGFR 45
 4
introduCtion
Knowledge of glomerular filtration rate (GFR) is essential for the detection and monitoring of 
impairment of renal function, for safety in the use of potentially nephrotoxic pharmaceuticals 
and radiographic contrast media, and for administration of correct dosage of medicines 
cleared by the kidneys. Measurement of GFR in humans requires invasive techniques, and the 
plasma/serum concentration of endogenous substances, particularly creatinine, has there-
fore been used as a marker for GFR for almost a century.134 It has become evident, however, 
that the circulating creatinine concentration alone is far from ideal as a GFR marker because 
it is considerably influenced not only by GFR, but also by other factors including muscle mass, 
amount of ingested meat, and tubular secretion.38,41,135-139 Creatinine-based GFR-estimating 
equations (eGFRcreatinine-eq) that include demographic and anthropometric factors,116,117,140 
can partially compensate for the influence of muscle mass. Cystatin C was suggested as an 
alternative marker for GFR in 197946,47,141 and since the introduction of the first automated 
procedure for analysis of cystatin C in 1994,142 its use as marker for GFR has been exten-
sively investigated. Circulating cystatin C concentrations are not influenced by ingestion of 
meat49,143 or tubular secretion, and the influence of muscle mass on the cystatin C level is sub-
stantionally smaller than its influence on creatinine concentrations.50,144-148 Cystatin C-based 
GFR-estimating equations (eGFRcystatin C-eq), with simple formulations, therefore can often 
replace more complex eGFRcreatinine equations, with vague and ill-defined anthropometric 
variables such as race.135 Several eGFRcystatin C equations have been suggested. The main 
reason for these multiple equations has been the use of differing calibrators. To improve this 
situation, IFCC and the standardization authority, JRC-IRMM, of the European Commission 
have established and supported a working group for the production of an international 
cystatin C calibrator (WG-SCC). This group recently produced such a calibrator (ERM-DA471/
IFCC), which now is available to diagnostic companies and research groups.62,112,149 Although 
the availability of a certified reference material allows different diagnostic companies to 
produce cystatin C assays with reduced inter-assay variability, further optimization of the 
individual assays is required to produce the best possible inter-assay agreement. The pres-
ent work was undertaken in an effort to use the certified reference material coupled with 
further adjustments in the cystatin C-assays of seven international diagnostic companies 
to achieve sufficiently good agreement between the assays that all can be used to develop 
virtually identical eGFRcystatin C equations from a cohort of persons with known GFR. An 
eGFRcystatin C equation that was virtually assay-independent was then developed by use of 
samples from Caucasian, Asian, pediatric, and adult (CAPA) cohorts, totaling 4960 individuals, 
with varying GFRs as determined by renal or plasma clearance of inulin or plasma clearance 
of iohexol. The equation was tentatively called the CAPA equation.
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materials and methods
study cohort used to produce an international cystatin C-based estimating 
equation for gfr in adults and children
We used plasma samples from 3495 Swedish (Lund Cystatin C Standardization Cohort; LCS) 
and 763 Japanese adults and from a mixed cohort of 262 Dutch and 440 Swedish children 
(LCS) to develop and validate internally an international eGFRcystatin C-eq (Table 4.1). All 
procedures involving patients and data were in accordance with the Helsinki Declaration of 
1975, revised in 2000, concerning ethical principles for medical research involving human 
subjects.
determination of gfr
We used plasma clearance of iohexol85,150 to measure GFR in the adult and pediatric Swedish 
population (see Supplemental Data Method). We used renal inulin clearance was used to 
measure GFR in the Japanese adult population, and single-injection plasma-disappearance 
of inulin in the Dutch pediatric population.103,151 These three methods produce comparable 
GFR values according to a recent meta-analysis.152 We used the DuBois–DuBois formula for 
calculation of body surface area.153
efforts to optimize agreement between six commercially available cystatin c 
assays
The WG-SCC cooperated with six diagnostic companies (Abbott, Dako, Gentian, Roche, Sen-
tinel, Siemens), offering assays for cystatin C, to optimize assay agreement. The Abbott and 
Sentinel assays are identical. Five of these assays are particle-based immunoturbidimetric 
assays,142 and one, Siemens, is a particle-based immunonephelometric assay154 (see Supple-
mental Data Method for technical specifications).
To optimize assay agreement, we used plasma samples, anticoagulated with Li-heparinate 
and by use of the Vacutainer system of Becton Dickinson, from 3495 adult (age ≥ 18 years) 
patients, consecutively referred to the University Hospital of Lund for determination of GFR 
by iohexol clearance measurements. Common causes for referral of patients were manifest 
or suspected diabetic nephropathy, interstitial nephritis, glomerulonephritis, nephrotic 
syndrome, hematuria, proteinuria, reflux nephropathy, myeloma, vasculitis, consideration of 
initiation of hemodialysis, control after kidney transplantation, and determination of GFR in 
patients before start of treatment with drugs cleared by the kidneys. In the Japanese cohort 
of adults, 21% had diabetes, 1.4% had received kidney transplants and 1.4% kidney donors. 
The Dutch cohort of children comprised 49% oncology patients and 51% patients with glo-
merulonephritis/glomerulopathy. The corresponding numbers for the Swedish cohorts were 
not available.
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Efforts have been made to optimize several cystatin C assays produced by Japanese manu-
facturers to maximal agreement by use of the certified reference material. One of these as-
says, a sol particle homogeneous immunoassay for measuring serum cystatin C155 produced 
by Alfresa, was used to determine serum cystatin C in the Japanese cohort. We therefore 
investigated the agreement between this assay and the assays used for the Swedish and 
Dutch cohorts.
development and internal validation of new cystatin c-based gfr-estimating 
equations
All statistical analyses were conducted by use of SPSS Statistics release 20.0.0 (IBM Corp.) and 
Microsoft Excel. From the complete data set, comprising 4960 GFR and cystatin C determina-
tions for adults and children, we established a development set with 2295 randomly chosen 
Swedish adults, 413 Japanese adults, and 456 Swedish and Dutch children. The remaining 
1796 patients formed three internal validation sets with 1200 Swedish adults, 350 Japanese 
adults, collected April to July 2007, and 246 Swedish and Dutch children.
There were no important differences with respect to general characteristics between the 
development and the corresponding internal validation sets (Table 4.1). All regression analy-
ses in the development set were conducted by use of statistical weights (see Supplemental 
Method). The purpose was to re-weight all regression analyses to give equal importance 
to the Swedish and Japanese adult populations, despite their unequal sample sizes (2295 
and 413 individuals, respectively), when estimating the regression coefficients. Firstly, the 
extra-renal elimination, E, was estimated as the intercept in a linear regression model with 
measured GFR (mGFR) as the dependent variable and 1/Cystatin C as the independent vari-
able.156 We then estimated the regression coefficients (a, b and c) of the following equation:
ln(mGFR + E) = ln(a) + b x ln(CysC) + c x ln(Age)
where ln denotes the natural logarithm, CysC denotes the cystatin C concentration in mg/L, 
and age is in years. Linear regression with 1/mGFR as regression weights was used to increase 
the importance of patients with low GFR.140 The regression equation above corresponds to an 
eGFR equation of the following form:
eGFR = a × CysCb × Agec − E.
We also assessed the effect of adding sex (0=Male, 1=Female) as an additional covariate to the 
regression equation. The equations, with coefficients established on the basis of the develop-
ment set, were validated in the three internal validation sets separately in comparison with 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation.57 The 
validation of the equations focused on bias and accuracy.157 Bias was defined as the median 
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of the individual differences between eGFR and mGFR (eGFR − mGFR), expressed in mL/min-
ute/1.73 m². Accuracy was expressed as the median of the absolute percentage differences 
between eGFR and mGFR relative to mGFR. The accuracy was further reflected by P30, i.e., the 
percentage of estimates within 30% of mGFR. At least 75% of eGFR should be within 30% of 
mGFR to be considered “sufficient for good clinical decision-making”.56 Non-parametric and 
asymptotic 95% confidence intervals (95% CI) were calculated as measures of the statistical 
uncertainty in medians and proportions (P30), respectively, for overall results. To facilitate 
comparisons, validation results among children were presented also for the CKD-EPI cystatin 
C equation, although this equation is intended for GFR estimation only among adults.
For the Swedish adults and children and for the Dutch children mean values of two avail-
able cystatin C measurements from two different assays were used to increase statistical 
precision in the estimated regression coefficients. However, the validation of the equations 
was based on a single cystatin C measurement to mimic the expected accuracy in clinical 
practice. The coefficients of the final equation presented were obtained by use of the total 
data set (n=4960), with the same weighting scheme (equal weights for the Swedish and Japa-
nese adult populations) as for the development set, to increase statistical precision further.
results
optimization of agreement between six commercially available cystatin C 
assays
In a joint effort, the WG-SCC and the six diagnostic companies Dako, Siemens, Gentian, Roche, 
Abbott and Sentinel worked to improve the agreement between the cystatin C assays pro-
vided by the companies. Several of the factors known to influence the performance of assays 
of cystatin C (see Supplemental Table 4.1) were varied to increase the agreement between 
assays, but only two were systematically studied for all assays. These concerned use of the 
same total volume and consistent volume of antiserum in all standards and samples158 and 
selection of positions of the calibrator-points used to construct the dose-response curves, 
including most important assay interval (see Supplemental Data Results).
Linear equations and correlation coefficients for the six assays adjusted for maximal agree-
ment are given in Table 4.2 with the values produced by the Dako assay as the independent 
variable. Table 4.2 also shows the same data for the Alfresa assay by use of quintuple tests of 
ten plasma pools with varying concentrations of cystatin C.
The equations of Table 4.2 were then used to assess the achievable increase in agreement 
between the assays with results from the Swedish provider of external quality assessment 
for clinical laboratory investigations, EQUALIS (www.equalis.se/en/start.aspx). EQUALIS has 
monitored the quality of cystatin C assays for 10 years by distributing plasma samples with 
cystatin C concentrations unknown to the laboratories running cystatin C. During the last 
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three years, 35 laboratories have participated in the quality assessments. The CVs for the 
determined cystatin C concentrations during the 17 different test periods during 2010-2012, 
by use of the mean cystatin C values for each type of assay to calculate CV, varied from 6 to 
14%, with a mean CV of 9.7% shown in Supplemental Figure 4.3A. If the equations of Table 4.2 
are applied to these results, the corresponding CV is decreased to between 1 and 5%, with a 
mean CV of 2.8% as shown in Supplemental Figure 4.3B. If the cystatin C results are used to 
estimate GFR according to the cystatin C-based GFR estimation equation developed in this 
work (see below), a corresponding increase in agreement is seen (see Supplemental Figure 
4.4). The CV for eGFR varies between 9 and 19%, with a mean CV of 13.9%, and is reduced 
to between 2.0 and 7.1%, with a mean CV of 3.7% after applying the equations of Table 4.2. 
Supplemental Figure 4.5 demonstrates the practical consequences of this for the full GFR 
spectrum.
Ten plasma pools with varying concentrations of cystatin C were analyzed by the Alfresa 
assay and two of the adjusted assays described above using quintuple tests. The agreement 
between the two adjusted cystatin C assays (Dako and Gentian) on one hand, and the Alfresa 
assay on the other hand, was excellent. Table 4.2 shows the results.
evaluation of equations in the development set
The eGFR equation without a sex factor produced similar negative bias among both females 
and males (−2.6 and −4.0 mL/minute/1.73 m² in median) when evaluated in the development 
set (n=3164) with statistical weights. The overall accuracy was also similar (P30 = 79% for 
both sexes). Among children, most of them with a GFR within reference intervals, there was 
a sex difference in bias (median bias −8.5 and +0.8 mL/minute/1.73 m² for boys and girls, 
respectively). However, adding sex as a covariate in the eGFR equation yielded a correction 
table 4.2. Regression analysis
reagent samples (n) slope (95% Ci) intercept (95% Ci) r² value
Siemens 979 0.984 (0.974–0.994) −0.0124 (−0.0242 to −0.000547) 0.993
Gentian 988 1.058 (1.050–1.066) −0.0697 (−0.0799 to −0.0594) 0.998
Roche 992 1.012 (1.007–1.018) −0.0250 (−0.0320 to −0.0180) 0.998
Sentinel/Abbott 806 0.932 (0.928–0.935) 0.0388 (0.0325 to 0.0450) 0.998
Quintuple tests of ten plasma pools
 Alfrese vs. Dako 10 1.048 −0.1105 0.999
 Alfresa vs. Gentian 10 1.049 −0.0343 1.000
Deming regression analysis, allows for errors in both the independent and dependent variable, between 
each of five cystatin C assays (Siemens, Gentian, Roche and Sentinel/Abbott) adjusted for maximal agree-
ment and expressed as linear equations (y = slope*x + intercept) in relation to the Dako cystatin C assay (x; 
mg/L). For comparison, regression analysis of quintuple tests of ten plasma pools with varying concentra-
tions of cystatin C are presented for the Alfresa assay vs. the Dako and Gentian cystatin C assays. A delta-
value of 1 was used in the analysis.
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factor of 0.99 for females, implying that the eGFR equations with and without a sex factor 
would yield similar estimates. Internal validation results below are therefore presented for 
the eGFR equation from the development set without sex only (labeled “CAPA” in the tables).
internal validation
Overall accuracy of the CAPA equation was satisfactory in the three validation cohorts (P30 
= 83%, 78%, 80% among Swedish adults, Japanese adults and children, respectively) and 
comparable with the CKD-EPI cystatin C equation (Table 4.3). Both the CAPA and the CKD-EPI 
equation exhibited some negative bias among Swedish adults (−5 and −6 mL/minute/1.73 
m² in median), and among children (−9 and −11 mL/minute/1.73 m² in median).
Bias and accuracy of the two equations were generally similar among males and females in 
the three validation cohorts. Among Swedish adults, P30 for males and females was 81% and 
84% respectively, for the CAPA equation and 81% and 78% for the CKD-EPI equation (not in 
tables). The corresponding figures among Japanese adults were 77% and 78% for CAPA and 
77% and 81% for CKD-EPI. The CKD-EPI equation was less accurate among girls (P30 = 74%) 
than among boys (P30 = 86%), whereas the CAPA equation had similar performance for both 
sexes (P30 = 81% and 79% for boys and girls, respectively).
table 4.3. Overall bias, precision and accuracy of the CAPA and CKD-EPI† cystatin C equations57
swedish adults Japanese adults swedish and dutch children†
Bias, mL/minute/1.73 m², median difference (95% CI)
CAPA −5.2 (−5.9 to −4.8)- 0.5 (−0.5 to 1.7) −8.8 (−11.2 to −6.2)
CKD-EPI −5.7 (−6.2 to −5.2) 1.0 (−0.6 to 1.9) 10.6 (−13.5 to −7.4)
Precision, mL/minute/1.73 m²,IQR of differences (95% CI)
CAPA 12.0 (11.2 to 12.8) 14.8 (13.0 to 18.1) 27.9 (22.8 to 32.1)
CKD-EPI 12.5 (11.5 to 13.2) 14.8 (12.3 to 17.8) 25.1 (20.7 to 29.5)
Accuracy, mL/minute/1.73 m², median absolute percentage difference (95% CI)
CAPA 15.5 (13.5 to 17.5) 16.1 (12.2 to 20.0) 16.4 (11.8 to 21.0)
CKD-EPI 16.4 (14.3 to 18.5) 16.6 (12.7 to 20.5) 14.9 (10.5 to 19.3)
Accuracy P30*, % (95% CI)
CAPA 82.8 (80.7 to 84.9) 77.7 (73.3 to 82.1) 80.1 (75.1 to 85.1)
CKD-EPI 80.0 (77.7 to 82.3) 78.9 (74.6 to 83.2) 80.9 (76.0 to 85.8)
†The CKD-EPI equation is not intended for use among children. Results presented only for comparison.
*P30 refers to percentage of GFR estimates within 30% of measured GFR.
Refers to the validation sets of Swedish adults (N=1200), Japanese adults (N=350) and the mixed cohort of 
Dutch and Swedish children (N=246).
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stratification for glomerular filtration rate in adults
In the Swedish cohort, both the CAPA and CKD-EPI equation demonstrated an increasing 
negative bias with increasing mGFR measurements, reaching about −15 and −9 mL/min-
ute/1.73 m², respectively, at mGFR ≥ 90 mL/minute/1.73 m² (Table 4.4). At the same time, 
accuracy in terms of P30 increased with increasing mGFR (Table 4.4). In the Japanese cohort, 
no marked bias was noted except for the negative bias (11 mL/minute/1.73 m² in median) for 
the CAPA equation at mGFR ≥ 90 mL/minute/1.73 m². Substandard P30 values were noted for 
both equations at mGFR < 30 mL/minute/1.73 m² in the adult Japanese population.
table 4.4. Comparison of the CAPA and CKD-EPI cystatin C equations.
measured gfr intervals, ml/minute/1.73 m² <30 30-59 60-89 ≥90
Number in the Swedish/Japanese cohorts 335/87 362/108 334/76 169/79
Median mGFR in the Swedish/Japanese cohorts, mL/
minute/1.73 m²
18/19 44/43 73/76 102/101
Bias, mL/minute/1.73 m²
Swedish adults CAPA −1.1 −5.7 −10.2 −15.0
CKD-EPI −1.6 −7.4 −9.8 −9.8
Japanese adults CAPA 2.3 1.0 −2.8 −11.1
CKD-EPI 2.0 −0.8 −1.5 −3.5
Accuracy P30*, %
Swedish adults CAPA 75.8 84.0 86.5 86.4
CKD-EPI 77.6 76.2 81.7 89.3
Japanese adults CAPA 60.9 81.5 85.5 83.5
CKD-EPI 65.5 79.6 84.2 87.3
age intervals, years 18-39 40-59 60-79 ≥80
Number in the Swedish/Japanese cohorts 161/90 351/118 570/131 118/11
Median mGFR in the Swedish/Japanese cohorts, mL/
minute/1.73 m²
82/88 61/53 45/44 24/29
Bias, mL/minute/1.73 m²
Swedish adults CAPA −5.9 −5.8 −4.9 −4.6
CKD-EPI −3.5 −5.7 −6.1 −5.9
Japanese adults CAPA −2.8 0.7 1.6 0.3
CKD-EPI 0.6 1.4 0.6 1.0
Accuracy P30*, %
Swedish adults CAPA 85.7 85.2 83.3 68.6
CKD-EPI 85.7 84.9 79.1 61.9
Japanese adults CAPA 81.1 79.7 74.0 72.7
CKD-EPI 83.3 80.5 74.0 81.8
Bmi intervals, kg/m² <20 20-24 25-29 ≥30
Number in the Swedish/Japanese cohorts 69/59 348/181 492/90 291/20
Median mGFR in the Swedish/Japanese cohorts, mL/
minute/1.73 m²
57/75 60/52 52/53 42/45
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stratification for age in adults
In the Swedish cohort both the CAPA and CKD-EPI equation demonstrated a negative bias 
(4-6 mL/minute/1.73 m²) at all age intervals, whereas both equations were virtually unbiased 
in the Japanese cohort irrespective of age (Table 4.4). Substandard P30 among the elderly 
above 80 years old was noted for both equations in the Swedish cohort, but only for the CAPA 
equation in the Japanese cohort. The pattern with substandard P30 among those above 80 
years old was similar among males and females (not in tables).
stratification for body mass index in adults
In the Swedish cohort, both the CAPA and CKD-EPI equation demonstrated a negative bias 
(3-7 mL/minute/1.73 m²) at all body mass index (BMI) intervals, whereas both equations were 
generally unbiased in the Japanese cohort at all BMI intervals except for the CKD-EPI equa-
tion at BMI < 20 kg/m² (+4 mL/minute/1.73 m², Table 4.4). The equations demonstrated P30 
above 75% at all BMI intervals in both cohorts.
stratification for glomerular filtration rate in children
Both the CAPA and CKD-EPI equation demonstrated a negative bias (2-6 mL/minute/1.73 m²) 
at mGFR measurements below < 120 mL/minute/1.73 m², whereas the negative bias above 
this level was marked, exceeding 25 mL/minute/1.73 m² for both equations (Table 4.5). Still, 
P30 ranged between 77% and 83% at all GFR measurements for both equations.
stratification for age in children
Both the CAPA and CKD-EPI equation demonstrated an increased negative bias with increas-
ing age reaching between −12 and −13 mL/minute/1.73 m² at age above 12 years (Table 4.5). 
Still, P30 ranged between 76% and 86% at all levels for both equations at all age intervals.
Bias, mL/minute/1.73 m²
Swedish adults CAPA −2.4 −5.0 −5.1 −6.1
CKD-EPI −3.3 −5.2 −5.6 −7.1
Japanese adults CAPA 0.4 −0.1 1.4 0.0
CKD-EPI 4.3 0.6 1.3 1.4
Accuracy P30*, %
Swedish adults CAPA 82.6 86.5 83.3 77.3
CKD-EPI 76.8 82.2 81.1 76.3
Japanese adults CAPA 72.9 75.7 82.2 90.0
CKD-EPI 76.3 76.8 82.2 90.0
*P30 refers to percentage of GFR estimates within 30% of measured GFR.
Bias and accuracy stratified by mGFR, age and body mass index (BMI) intervals in the validation sets of 
Swedish adults (N=1200) and Japanese adults (N=350). Median mGFR are given for the various GFR and 
age intervals
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final equation
The final CAPA equation, with coefficients estimated from the complete data set, is
eGFR = 130 × cystatin C −1.069 × age−0.117 − 7
P30 of the final CAPA equation in the complete data set was 81% among Swedish adults, 78% 
among Japanese adults and 82% among children. The difference between eGFR and mGFR at 
different levels of mGFR by use of this final CAPA equation and the CKD-EPI equation on the 
entire data set of Swedish and Japanese adult cohorts as well as among children is presented 
together with limits for P30 accuracy in Figure 4.1.
table 4.5. Bias and accuracy of the CAPA and CKD-EPI† cystatin C equations in children stratified by mea-
sured GFR and age.
measured gfr intervals, ml/minute/1.73 m² <60 60-119 ≥120
Number 34 138 74
Median mGFR, mL/minute/1.73 m² 41 92 143
Bias, mL/minute/1.73 m²
CAPA −2.5 −6.3 −27.9
CKD-EPI† −5.0 −6.2 −26.4
Accuracy P30*, %
CAPA 82.4 81.2 77.0
CKD-EPI† 79.4 82.6 78.4
age intervals, years 1-6 7-12 13-17
Number 117 102 89
Median mGFR, mL/minute/1.73 m² 54 84 108
Bias, mL/minute/1.73 m²
CAPA 5.2 −7.5 −13.4
CKD-EPI† −4.9 −9.4 −12.1
Accuracy P30*, %
CAPA 79.6 85.5 76.9
CKD-EPI† 85.2 84.5 75.9
*P30 refers to percentage of GFR estimates within 30% of measured GFR.
†The CKD-EPI equation is not intended for use among children. Results presented only for comparison.
Refers to the internal validation set of a mixed cohort of Dutch and Swedish children (n=246). Median mea-
sured glomerular filtration rates (mGFR) are given for the various GFR and age intervals.
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figure 4.1. Individual errors (eGFR-mGFR) of the CAPA and CKD-EPI cystatin C equations at different levels 
of mGFR in the combined data sets (development + validation) (a and B) Swedish adults, N=3495; (C and 
d) Japanese adults, N=763; (e and f) children, N=702. The lines represent 30% limits in relation to mGFR. 
The CKD-EPI equation is not intended for use among children; results presented only for comparison.
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figure 4.1. (continued) Individual errors (eGFR-mGFR) of the CAPA and CKD-EPI cystatin C equations at differ-
ent levels of mGFR in the combined data sets (development + validation) (a and B) Swedish adults, N=3495; 
(C and d) Japanese adults, N=763; (e and f) children, N=702. The lines represent 30% limits in relation to 
mGFR. The CKD-EPI equation is not intended for use among children; results presented only for comparison.
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disCussion
The present study concerns whether use of the certified reference material and minor further 
adjustments of six commercially available cystatin C assays can increase agreement among 
the assays so that a common, virtually assay-independent, cystatin C-based equation for 
estimation of GFR can be established by use of a large population of about 5000 individuals 
with known GFR. The inter-assay CV of 9.7% for four of the original assays, run for several 
years in a quality assessment system, was reduced to 2.8% by the use of certified reference 
material and by further optimizations of the assays. The eGFR equation generated by use of 
the mean cystatin C values of two of the adjusted assays applied in the patient population 
could be used by all six assays, as well as the Alfresa assay, with only minor differences in the 
resulting GFR estimations (Supplemental Figure 4.4B shows the results for 4 of the assays). 
The remaining differences in the GFR estimations by all seven assays are generally too small 
to influence clinical decision making in most cases. For example, at the clinically relevant 
cystatin C concentrations of 1.2, 2.1 and 3.5 mg/L, corresponding to eGFRs of approximately 
15, 30 and 60 mL/minute/1.73 m², the total eGFR ranges determined by the 7 assays in this 
study were 14-16, 29-32 and 59-63 mL/minute/1.73 m², respectively.
Some of the assay adjustments performed in the present study can easily be applied to 
decrease the inter-assay variability of assays other than those included in this study. This is 
particularly evident for the position of the calibrator points (Supplemental Figure 4.2). The 
most frequent decision making concerns whether an individual has normal or decreased GFR 
and it would therefore seem appropriate to have the majority of the calibrator points in the 
corresponding cystatin C concentration interval of about 0.8 to 2.0 mg/L, which corresponds 
to GFR estimations from about 110 and down to 30 mL/minute/1.73 m² by use of the CAPA 
GFR-estimating equation of this work.
The performance of the CAPA equation was compared to that of another recent cystatin 
C-based equation, CKD-EPI, by use of a a cystatin C assay providing results traceable to the 
certified reference material, ERM-DA471/IFCC.57 The populations used to generate the two 
equations differed considerably. Whereas the population used to generate the CKD-EPI 
equation comprised an adult population of Caucasians and African Americans, the popula-
tion used to develop the CAPA equation comprised large subgroups of adults and children 
as well as of Asians and Caucasians. There is also another difference in the generation of 
the two equations. The CKD-EPI equation is based on finding a mathematical-statistical 
connection between measured GFR and cystatin C, sex and age of the individuals of the 
population studied without attempting to express the equation so that it might be given a 
biological interpretation. When we developed the CAPA equation we tried to use not only 
a mathematical-statistical procedure, as described above, but also a procedure subject to 
conditions, that might generate an equation with a possible biological interpretation i.e. in 
which all, or most of, the terms correspond to a physiological process.156,159 These conditions 
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were that the equation should comprise a term close to cystatin C to the power of −1, which 
corresponds to the renal excretion of a freely filtered substance, and that there should be a 
term for non-renal clearance of cystatin C, as we know that such a clearance exists. We gener-
ated both types of equations and compared their diagnostic performances. Because these 
did not differ, we chose to use the equation with a possible biological interpretation. An 
interesting difference between the CKD-EPI and CAPA equations is that the CAPA equation 
does not require a sex factor. This might be of practical value, since sex, like race, is not always 
clearly defined. For example several countries today recognize more than two sexes (www.
nydailynews.com/life-style/health/germany-gender-birth-certificates-article-1.1430859).
Although all-purpose equations have many practical advantages, lower performance in 
certain subgroups defined by e.g. GFR-level, BMI or age is inevitable. In the present study, 
underestimations were noted in patients with a GFR within reference intervals, most notice-
ably among children. However, the P30-accuracy was still acceptable, but it cannot be ruled 
out that population-specific equations would increase performance further. Although the 
CAPA and CKD-EPI cystatin C based equations were produced in different ways, they showed 
similar and sufficient accuracy overall and across subgroups. The CAPA equation has the ad-
vantage of being developed based on more diverse populations. Another advantage is that 
the CAPA equation has a less complex formula expression that does not include a sex factor. 
It should be noted that the sex factor of CKD-EPI did not contribute to decreased differences 
in performance between males and females.
Although the procedures to generate the CAPA and the CKD-EPI equations differed sig-
nificantly in several respects, they had one common element, the use of cystatin C assays 
adjusted to the certified reference material ERM-DA471/IFCC. We believe that this is the criti-
cal step in reducing the number of cystatin C-based GFR estimating equations required for 
clinical use in the future and in reaching the full potential of cystatin C in classifying kidney 
disease.160
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suPPlemental data methods
determination of gfr by plasma clearance of iohexol
Each adult person was given 5 mL of iohexol solution (Omnipaque, 300 mg iodine/mL; GE 
Healthcare, Stockholm, Sweden) intravenously in an antecubital vein. Clearance was calcu-
lated150 from the iohexol concentration at least 4 hours after the injection. For patients with 
low GFR (< 40 mL/minute/1.73 m²), as predicted by their cystatin C and creatinine levels, 
the iohexol concentrations were measured later after the injection (up to 72 hours after), for 
calculation of the GFR. Plasma iohexol concentrations were determined by HPLC.85
testing of agreement between six commercially available cystatin c assays
To reduce the inter-instrument variation, assays using the Abbott, Dako, Gentian and Sentinel 
reagents were run on the same instrument (Architect® ci8200) using the same sample cups. 
The Roche assay was performed using the Roche platform Cobas® 6000. These five assays 
were run at the same laboratory at Uppsala University Hospital in an effort to reduce non-
assay dependent interlaboratory differences, e.g. in sample handling. The samples were pro-
cessed (thawed and centrifuged) in batches and assayed simultaneously on Architect® ci8200 
(from the same assay cup) and on the Cobas® 6000 platform. The tests were performed in 
duplicates to minimize errors due to variation in pipetting. The Siemens assay was run, using 
the same plasma samples as the other five assays, and the Siemens platform BN ProSpec® at 
Siemens Healthcare Diagnostics laboratory in Marburg, Germany. All comparisons between 
the assays used between 200 and 1000 plasma samples representing both low and high GFR 
and correlation coefficients and linear equations were determined for each pair of assays. 
After the first comparative runs, some of the factors known to influence the performance 
of cystatin C assays (see Supplemental Table 4.1) were changed in efforts to improve the 
agreement between assays.
statistical weighting
The statistical weight of each Swedish adult was decreased (from one) to
2295 + 414
*
1
=
1354
,
2 2295 2295
whereas the statistical weight of each Japanese adult was increased (from one) to
2295 + 414
*
1
=
1354
.
2 414 414
The statistical weight of each subject from the pediatric population (n=456) was unchanged 
(ie, equal to one).
60 Chapter 4
supplemental table 4.1. Different assay-related factors affecting measurement of cystatin C.
analytical factors
Selection of antigen used for immunization
Type of microparticle-beads used for coupling of antibodies
Selection of primary and secondary, if any, wavelength for measuring absorbance in relation to the type of 
microparticle-beads used
Amount of antibodies on the beads
Proportion of immunoparticles and sample/calibrator
Buffer composition
Additives used, e.g. PEG 6000, detergents, EDTA, and their concentrations
Procedure for value transfer between the reference material and the company (secondary) calibrator
use of stock secondary calibrator or pre-diluted secondary calibrators
assay optimization
Number of calibrator points (standards) and distribution of their concentrations
Curve fitting model
Measuring range and most important assay-interval
Minimizing of batch-to-batch variation of reagents and calibrators
Pipetting speed and mixing intensity
Period between the first reading-point after mixing of the sample and immunoparticles
Selection of first and last reading time
Factors tested for all six assays are in italic.
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suPPlemental data results
In order to use the immune-precipitation curve for quantitative interpolations, it is very 
important to control all volumes, so the signal development only is reflecting the antigen 
concentrations.158 We noted that this condition was not fulfilled for some assays. The small 
variations of 4-6% observed for the ratio between antiserum volume and total reaction 
volume, resulted in differences in estimated GFR of about 3%. One example is shown in 
Supplemental Figure 4.1. The positions of the calibrator points (the cystatin C-levels of the 
dilutions of the calibrator) will influence the calculation of the dose-response curve for an 
assay, since a non-linear curve-fitting model must be used to construct the calibration curve. 
One example of the increase in agreement between two presently tested cystatin C assays 
by use of the same positions of their calibrator points is shown in Supplemental Figure 4.2.
A B 
supplemental figure 4.1. Influence of ratio between volumes of antiserum and total reaction mixture in 
the Sentinel assay
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A B 
A B 
supplemental figure 4.2. Influence of positions of the calibrator points. Original positions of calibrator 
points in the Dako and Gentian assays (A). Same positions of calibrator points in the two assays (B).
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A B 
A B 
A B 
A B 
supplemental figure 4.3. Cystatin C values (mg/L) of external quality control samples before (A) and after 
(B) assay optimization of four different commercial assays (designated A = Roche, B = Dako, C = Gentian and 
D = Siemens). The figures in the lower boxes indicate the week and the year the tests were performed and 
the CV is given above these figures.
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A B 
A B 
A B 
A B 
supplemental figure 4.4. eGFR using the CAPA equation before (A) and after (B) assay optimization of 4 
assays (designated A = Roche, B = Dako, C = Gentian and D = Siemens)
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supplemental figure 4.5. Highest and lowest eGFR obtained by the CAPA equation before and after opti-
mization of the assays in supplemental Figure 4.4.

Chapter 5
Cystatin C more accurately detects mildly 
impaired renal function than creatinine in 
children receiving treatment for malignancy
Hester N. Blufpand, Jorien Tromp, Floor C.H. Abbink, 
Birgit Stoffel-Wagner, Anneke A. Bouman, Netteke Y.N. Schouten-van Meeteren, 
Joanna A.E. van Wijk, Gertjan J.L. Kaspers and Arend Bökenkamp
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aBstraCt
Background: Monitoring of renal function is crucial in pediatric oncology. The use of creati-
nine to estimate glomerular filtration rate (GFR) is hampered by its dependency on muscle 
mass. Muscle wasting is common in children with cancer, leading to overestimation of GFR. 
Data on cystatin C are sparse in pediatric oncology, although this marker could be particularly 
useful in this population.
Procedure: Inulin clearance, estimated GFR using serum cystatin C according to Filler (eGFR-
cys) and serum creatinine according to Schwartz (eGFR-crea) were measured in 68 children 
with malignancy and 121 controls. We analyzed the difference between measured and 
estimated GFR and performance, bias and accuracy.
results: Multiple linear regression analysis showed overestimation of GFR by eGFR-crea in 
females (B = −21.18; p=0.001), and in patients with malignancy (B = −21.77; p=0.014). eGFR-
cys overestimated GFR in females (B = −10.47; p=0.001), but was independent of treatment 
for malignancy. Agreement with gold standard in detecting GFR below 90 mL/minute/1.73 
m² is better for eGFR-cys (AUC, 0.854) than for eGFR-crea (AUC, 0.675) in the group with 
cancer. They performed comparably in the control group. Bland-Altman analysis showed 
considerable bias for eGFR-crea compared to eGFR-cys (−14.3 vs. −7.3 mL/minute/1.73 m²). 
The proportion of estimates within 30% of true GFR for eGFR-crea (72.1%) was lower than for 
eGFR-cys (82.4%) in the group with cancer. In the control group eGFR-crea (84.3%) outper-
formed eGFR-cys (76.0%). When using the 50% limits of agreement, eGFR-cys outperformed 
eGFR-crea in both groups.
Conclusion: Cystatin C more accurately detects mildly impaired renal function than creati-
nine in children receiving treatment for malignancy.
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introduCtion
Accurate assessment of glomerular filtration rate (GFR) is essential in pediatric oncology 
to stratify severity of chronic kidney disease (CKD) and recognize impaired renal function. 
By adapting drug dosage to renal function, exposure to cytotoxic chemotherapy may be 
optimized in drugs excreted predominantly via the kidney.161 Inulin clearance (GFR-inulin) is 
considered the gold standard for measurement of GFR, but this method is expensive, time-
consuming and inconvenient. Especially in young children who often need a bladder catheter 
for timed urine collection.27,162 Although single-injection clearances of both radioactive and 
non-radioactive substances (ie, 51C- EDTA, iohexol, 125I-iothalamate) have shown to correlate 
well with the renal clearance of inulin and do not require urine collection, they require blood 
sampling for at least five hours to maintain accuracy at low GFR levels in children.32,163 There-
fore, in daily clinical practice assessment of kidney function relies on endogenous markers 
of GFR. Serum creatinine is widely used, but its limitations are well-known.38,162 To overcome 
some of these limitations, the latest K/DOQI guidelines164 strongly advise the calculation of 
estimated GFR from serum creatinine (eGFR-crea) using equations such as those described 
by Schwartz25,106 and Counahan-Barratt.127
In the last decade cystatin C has emerged as an alternative marker to assess glomerular 
function98 Different cystatin C-based equations for the estimation of GFR (eGFR-cys) have 
been developed.58,59 Three meta-analyses have shown that cystatin C is superior to creati-
nine,99,100,165 mainly for the recognition of mild renal impairment, where creatinine performs 
poorly.38 Being involved in muscle metabolism, serum creatinine concentrations are dimin-
ished in conditions with muscle wasting leading to overestimation of GFR.38,166
Because malignancy and its treatment are often associated with muscle wasting, we set out 
to compare the diagnostic performance of a creatinine-based eGFR equation and a cystatin 
C-based equation in pediatric patients with malignancy compared to controls, using a gold 
standard GFR measurement.
methods
study population
Between May 2005 and March 2009 remnant serum was collected for simultaneous measure-
ment of creatinine and cystatin C during 276 inulin clearance studies performed on clinical 
indications at the Department of Pediatrics of the VU University Medical Center. The clear-
ance studies were performed at the outpatient ward under normal hydration conditions. All 
participants were in good clinical condition at the time of testing. Patients were excluded if 
they had received glucocorticosteroids within 10 days prior to the clearance study because of 
the well-documented interaction with cystatin C metabolism.53 Sixty-eight patients during, 
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or up to three months after, treatment for malignancy were studied. The diagnosis spectrum 
included leukemia/lymphoma (N = 9), brain tumor (N = 18), neuro-blastoma (N = 3), osteo-
sarcoma (N = 2), hepatoblastoma (N = 5), rhabdomyosarcoma (N = 4), Wilms tumor (N = 1) 
and retinoblastoma (N = 26). The control group of 121 comprised patients with glomerulo-
nephritis/glomerulopathy (N = 28), nephrotic syndrome (N = 8), tubulointerstitial disease (N 
= 9), and uropathy (N = 52). Twenty-four patients in long-term follow-up after treatment for 
cancer were also included in this group (median interval, 4.7 [range, 1.3-8.6] years from end 
of treatment). The study was performed in accordance to the Helsinki Declaration concerning 
ethical principles for medical research involving human subjects and was approved by both 
the local and the national ethics committee of The Netherlands.
gold standard gfr measurement
Single-injection inulin clearances were performed as described by van Rossum et al.27 with 
blood sampling at 10, 30, 90 and 240 minutes after injection of 5000 mg polyfructosan per 
1.73 m² (Inutest 25%, Fresenius, Linz, Austria). For injection and blood sampling, peripheral or 
central venous lines were used. The tests were performed by dedicated nurses. GFR was cal-
culated using MW/Pharm 3.5 (Mediware, Groningen, The Netherlands), a pharmaco-kinetic 
computer program using Bayesian estimates from patient and population data.27
Biochemical assays
Blood was centrifuged immediately after sampling and serum was stored at −20°C until mea-
surement. Cystatin C was measured, using a particle-enhanced immunonephelometric assay 
(PENIA; Siemens Healthcare, Marburg, Germany) on a Behring Nephelometer II, within three 
months of sampling. Inulin was measured within 14 days using an enzymatic method based 
on the determination of fructose after acid hydrolysis of inulin as described by Jung et al.167 
with some minor modifications.168 Creatinine was measured by the kinetic Jaffé method166 
and converted to IDMS standard. The conversion equation used: creatinineIDMS [mg/dL] = (cre-
atinineJaffé [mg/dL] x 0.012)−0.29, had been calibrated in our laboratory in a large pediatric 
cohort. The creatinine-based GFR estimate was calculated using the ’new’ Schwartz equation, 
which was derived from IDMS-traceable creatinine measurements:25
eGFR-crea (mL/minute/1.73 m²) = height × 0.413/creatinine, with height in cm and creati-
nine in mg/dL. The cystatin C-based GFR estimate was calculated according to Filler:59
log((eGFR-cys [mL/minute/1.73 m²]) = 1.962 +

1.123 × log



1 



serum cystatin C [mg/dL]
with cystatin C in mg/dL. This equation was derived from single-injection 99mcTc-DTPA clear-
ance data using the same nephelometric assay as used in our laboratory.
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statistical analysis
Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL). Descriptive 
statistics of continuous variables are presented as mean (SD) for variables with a Gaussian 
distribution and median [IQR], for variables with a non-Gaussian. We assessed normality 
using the Kolmogorov-Smirnov criteria. Categorical data are presented as proportions. Differ-
ences between the two groups were compared using the appropriate test as indicated (Table 
5.1). Two-tailed P values < 0.05 were considered statistically significant. In extension of the 
concept underlying the Bland-Altman analysis125 for the agreement between two measure-
ments, we compared bias. That is the mean difference between measured and estimated GFR 
(GFR-inulin minus eGFR-crea and GFR-inulin minus eGFR-cys), accuracy and precision of both 
equations. The bias was used as dependent variable for multiple linear regression analysis to 
model the effect of anthropometric, laboratory and clinical data on the performance of the 
two markers. For linear regression analysis, all variables not following a Gaussian distribu-
tion were entered after logarithmic transformation. Cohen’s kappa and receiver-operating 
characteristic (ROC) analysis169 were used to test agreement between the gold standard and 
both estimating equations for the diagnosis of impaired renal function, that is GFR < 90 mL/
minute/1.73 m², according to the K/DOQI guidelines.164
table 5.1. Patient characteristics
malignancy
n=68
Control
n=121
P value
Patient characteristics
Male sex, % 74 60 0.05
Age, years, median [IQR] 3.2 [1.4-7.8] 12.5 [7.9-15.7] < 0.001
Height, cm, median [IQR] 101.0 [83.0-128.0] 146.0 [120.7-166.7] < 0.001
Weight, kg, median [IQR] 16.4 [11.0-24.9] 38.6 [24.4-62.0] < 0.001
Renal function parameters
Creatinine, mg/dL, median [IQR] 0.30 [0.24-0.42] 0.71 [0.52-1.05] < 0.001
Cystatin C, mg/L, median [IQR] 0.80 [0.69-0.94] 1.04 [0.83-1.38] < 0.001
GFR-inulin, mL/minute/1.73 m², mean (SD) 113.2 (25.3) 79.3 (30.7) < 0.001
CKD stage 1,* % 78 45 < 0.001
CKD stage 2,* % 19 28 0.17
CKD stage 3-5,* % 3 27 < 0.001
*CKD stage based on GFR-inulin: stage 1 > 90 mL/minute/1.73 m², stage 2 60-89 mL/minute/1.73 m², stage 
3-5 < 60 mL/minute/1.73 m².
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results
The characteristics of both groups are presented in Table 5.1. There was a higher prevalence 
of boys in the group with cancer, and patients with a malignancy were younger than controls. 
Mean inulin clearance was higher in the group with cancer, but the prevalence of CKD stage 
two (ie, GFR 60 to 90 mL/minute/1.73 m²) was comparable with the control group.
Multiple linear regression analysis of factors influencing the bias between measured and 
estimated GFR (Table 5.2) reveals significant overestimation of kidney function in females 
compared to males for both the Filler and the Schwartz equation. In patients with malig-
nancy, eGFR-crea significantly overestimates true GFR (B = −21.77; 95% CI −39.10 to −4.45; 
P = 0.014). This is not seen when estimating GFR using cystatin C (B = −0.41 95% CI −8.61 
to 7.80, P = 0.922). ROC analysis (Figure 5.1), using a GFR cutoff of 90 mL/minute/1.73 m² 
yielded almost comparable results for eGFR-cys (AUC, 0.905; 95% CI 0.851 to 0.959) and 
eGFR-crea (AUC, 0.932; 95% CI, 0.886 to 0.978) in the control group. By contrast, in the group 
with cancer the AUC for eGFR-crea (0.675; 95% CI, 0.489 to 0.861) was lower than the AUC 
for eGFR-cys (0.854; 95%CI, 0.740 to 0.969). Agreement in the classification of GFR above or 
< 90 mL/minute/1.73 m² expressed as Cohen’s kappa gave similar results: both parameters 
performed comparably in the control group, whereas kappa in the group with cancer was 
0.351 for eGFR-crea vs. 0.560 for eGFR-cys (Table 5.3). In the Bland-Altman graphs (Figure 5.2) 
bias, that is the mean difference between measured and estimated GFR, and precision, that 
is the 95% confidence interval around the bias, are displayed. The mean bias for eGFR-crea 
was −14.3 mL/minute/1.73 m² (95% CI, −101.7 to 73.1) compared to −7.3 mL/minute/1.73 m² 
table 5.2. Factors influencing the difference between GFR-inulin and eGFR equations
GFR-inulin eGFR-crea B 95% Ci P value
GFR-inulin, mL/minute/1.73 m² 0.16 −0.06 to 0.37 0.160
Sex (female = 1) −21.18 −34.11 to −8.25 0.001
Malignancy (yes = 1) −21.77 −39.10 to −4.45 0.014
Height, cm 0.18 −0.47 to 0.82 0.586
Weight, kg −0.25 −0.89 to 0.40 0.449
Age, years 0.67 −2.94 to 4.28 0.715
GFR-inulin eGFR-cys
GFR-inulin, mL/minute/1.73 m² 0.07 −0.03 to 0.18 0.165
Sex (female = 1) −10.47 −16.60 to −4.35 0.001
Malignancy (yes = 1) −0.41 −8.61 to 7.80 0.922
Height, cm −0.24 −0.55 to 0.06 0.118
Weight, kg 0.20 −0.10 to 0.51 0.189
Age, years 0.52 −1.19 to 2.23 0.548
Multiple regression analysis. B refers to the slope of the regression equation with the respective 95% con-
fidence intervals.
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figure 5.1. Diagnostic accuracy for the diagnosis of GFR < 90 mL/minute/1.73 m² in patients with malig-
nancy
table 5.3. Performance of eGFR equations in detecting GFR below 90 mL/minute/1.73 m²
gfr-inulin < 90 ml/minute/1.73 m² κ
yes no
m
al
ig
na
nc
y eGFR-crea < 90
mL/minute/1.73 m²
yes 4 (6%) 1 (2%)
0.35
no 10 (15%) 53 (78%)
eGFR-cys < 90
mL/minute/1.73 m²
yes 8 (12%) 3 4(%)
0.56
no 6 (9%) 51 (75%)
co
nt
ro
l
eGFR-crea < 90
mL/minute/1.73 m²
yes 59 (49%) 12 (10%)
0.66
no 8 (7%) 42 (35%)
eGFR-cys < 90
mL/minute/1.73 m²
yes 55 (46%) 9 (7%)
0.65
no 12 (10%) 45 (37%)
Agreement between the estimates and the gold standard measured by Cohen’s kappa, split between pa-
tients with malignancy and controls. κ, Cohen’s kappa.
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figure 5.2. Bland-Altman plots for A, eGFR-crea, B, eGFR-cys showing bias (solid line) and the 95% LOA (ie, 
mean bias ± 1.96 x SD [gray area]).
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(95% CI, - 48.2 to 33.5) for eGFR-cys. Accuracy measured as the percentage of estimates within 
30% of the gold standard GFR measurement was 72.1% for eGFR-crea vs. 82.4% for eGFR-cys 
in children with malignancy. In the control group eGFR-crea outperformed eGFR-cys (84.3% 
vs. 76.0%). When assessing accuracy using the 50% limits of agreement, the results were 
comparable: 95.6% vs. 94.2% of estimates within 50% of true GFR for eGFR-cys, and 79.4% vs 
92.6% for eGFR-crea in respectively the malignancy and control group.
disCussion
Accurate assessment of GFR is crucial in pediatric oncology. The shortcomings of serum 
creatinine and the Schwartz equation are well-established, especially in patients with muscle 
wasting. Nevertheless it still is common practice to estimate GFR using the Schwartz equation. 
Our data demonstrate that in children during or shortly after treatment for cancer, cystatin 
C more accurately identifies children with mildly impaired renal function. This is important 
since children with impaired renal function should be monitored more closely when admin-
istering cytotoxic drugs. The overestimation of true GFR by eGFR-crea in pediatric patients 
with cancer, which is not observed with eGFR-cys, was also found by Skinner170 and Grönroos 
et al.171 Larsson et al. found significantly lower values for a cystatin C-based estimate of GFR 
compared to the creatinine-based MDRD (Modification of Diet in Renal disease) equation172 
in adult oncological and neurosurgical patients, which was not observed in primary care and 
thoracic-intensive care patients.173 An overestimation of GFR by serum creatinine has been 
reported in other conditions associated with decreased muscle mass such as spina bifida,101 
rheumatic disease,102 liver cirrhosis104 and the elderly174 suggesting diminished creatinine 
production as the most likely etiology for these findings. In contrast to creatinine, cystatin 
C is secreted by all nucleated cells. It is the most potent endogenous inhibitor of cysteine 
proteinases such as cathepsins B, H, L, S, elastase and papain.175 The cysteine proteinases 
and cystatin C play an important role in tumor invasion and spread as reviewed by Kos et 
al.176 This group also reported an association between serum concentrations of cystatin C and 
prognosis in colorectal cancer177 and advanced melanoma176 casting doubt on the diagnostic 
potential of cystatin C as a marker of GFR in patients with malignancy.
Although our patients suffered from different types of malignancies than those of Kos et 
al., our data do not support an association between active malignancy and serum cystatin C. 
Comparing the children with active disease in the study group with the 24 childhood cancer 
survivors in the control group, we found no difference in the bias between true GFR and 
eGFR-cys (study, −7.2 mL/minute/1.73 m²; 95% CI, −19.9 to 15.0 mL/minute/1.73 m² and con-
trols: −14.0 mL/minute/1.73 m²; 95% CI −20.6 to 1.7 mL/minute/1.73 m²; P = 0.290). Stabuc et 
al. also found no relationship between tumor mass and serum cystatin C after correction for 
renal function.178
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The diagnostic performance of eGFR-cys and eGFR-crea in the control group was compa-
rable with previous studies98 suggesting that the calibration of both equations was valid. 
However, both equations showed a significant overestimation of GFR in females, which is 
in line with two recent studies reporting lower cystatin C concentrations in females.58,179 For 
creatinine, this overestimation most likely reflects failure to correct for muscle mass by using 
a single k value for boys and girls in the new Schwartz equation. The marked overestimation 
of GFR by the Schwartz equation in the group with cancer cannot be attributed to gender 
differences because the proportion of females was even lower in this group. Also, the effect 
of female gender on eGFR was comparable for creatinine and cystatin C. Of note, the group 
with cancer comprised only a single adolescent male, therefore failure to correct for puberty-
related changes in muscle mass cannot account for the poor performance of eGFR-crea in 
these patients. Although children in the group with cancer were younger than controls, age 
was not significantly related with bias of neither creatinine- nor cystatin C-based equations. 
Studying pediatric patients with cancer, Lankisch et al.180 found that use of cystatin C was 
particularly beneficial in children under the age of three years. This may reflect differences in 
muscle mass and the lower precision of, in particular non-enzymatic, creatinine assays at very 
low creatinine concentrations.38
Our study has several limitations. Kidney function was significantly lower in the control 
group. It is well-recognized that the diagnostic performance of estimation equations differs 
considerably depending on GFR.110,131 Equations perform best around the mean at which 
they were calibrated. The revised Schwartz equation was calibrated around a mean GFR of 43 
mL/minute/1.73 m², which is considerably lower than the mean GFR in both our control (79.3 
mL/minute/1.73 m²) and malignancy (113.2 mL/minute/1.73 m²) group. The Filler equation 
was calibrated in a diverse population with a mean GFR of around 100 mL/minute/1.73 m², 
which is in between the GFRs of the malignancy and control group. This may have favored 
cystatin C in the group with cancer, while both equations performed equally well in the 
control group with a lower GFR. To overcome this limitation we would have liked to use the 
cystatin C-based equation developed by Schwartz et al. rather than the Filler equation, as 
the former was calibrated in the same population as the creatinine-based Schwartz equation 
we used. Unfortunately, Schwartz et al. used the particle-enhanced immunoturbidimetric 
assay (PETIA) for the calibration of their cystatin C-based equation, which is not traceable to 
the PENIA we used154,181 Alternatively, a control group comprising children with normal or 
near-normal kidney function would have enhanced the results, but performing an invasive 
test such as inulin clearance in healthy children is unacceptable from an ethical point of view.
As can be seen in the Bland-Altman graphs, five patients showed a remarkable over-
estimation of GFR by eGFR-crea exceeding 100 mL/minute/1.73 m², which was not observed 
with eGFR-cys. All five samples were from the group with cancer, which is highly significant 
(χ² = 9.201; P = 0.002). These data points have clearly influenced our results. Still we have cho-
sen not to eliminate these data as outliers because (i) a pre-analytical error can be excluded 
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as cystatin C and creatinine were measured in the same samples and creatinine was even 
measured in duplicate in two independent laboratories, (ii) a fault in inulin clearance mea-
surement is unlikely in view of the good agreement between eGFR-cys and the gold standard 
measurement, (iii) the lower accuracy of eGFR-crea in patients with malignancy is confirmed 
in our analyses looking at concordant classification, and (iv) the severe overestimation of GFR 
by serum creatinine is a well-documented phenomenon in patients with muscle wasting.
According to the K/DOQI guidelines, we used a cutoff of 90 mL/minute/1.73 m² to compare 
the diagnostic performance of both equations. Using a cutoff of 60 mL/minute/1.73 m², 
where changes in dosing regimens are expected, could have been particularly relevant but 
this was not possible due to the small number of patients with GFR < 60 mL/minute/1.73 
m² in the group with cancer. Our study also addressed the precision of the GFR estimates. 
Overall, the scatter between measured and estimated GFR is around 30 to 40%,131 which is in 
line with these findings. There is a broad consensus that neither cystatin C- nor creatinine-
based equations can replace a formal clearance study using a gold standard technique when 
indicated.
In conclusion, in children during or shortly after treatment for malignancy, the Filler 
equation more accurately detects mildly impaired renal function compared to the revised 
Schwartz equation. Future research should analyze if exposure to cytotoxic drugs eliminated 
by glomerular filtration can be optimized using serum cystatin C as suggested by Thomas 
et al.182

Chapter 6
Diversity in renal function monitoring and 
dose modifications during treatment for 
childhood cancer: a call for standardization
Hester N. Blufpand, Nicole Hes, Arend Bökenkamp, 
Marianne D. van de Wetering and Gertjan J.L. Kaspers
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aBstraCt
Despite changes in survival and drug tolerability, nephrotoxicity remains an important com-
plication of chemotherapy. To provide cutting-edge care for children with cancer oncologist 
must be familiar with their nephrotoxic potential. Careful monitoring of renal function during 
treatment is therefore indicated. Well-defined guidelines for this are lacking. We reviewed 
current DCOG protocols and showed that monitoring of renal function during treatment var-
ies widely between protocols. In some protocols recommended renal function measures are 
inappropriate given the chemotherapy prescribed. Advices on dose modifications in case of 
renal dysfunction also vary, even with comparable regimens. These differences are unwanted 
and call for standardization.
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introduCtion
The field of pediatric oncology is rapidly changing as new therapy emerges. Five-year 
survival rates nowadays approximate 80% in Europe.1,183 Despite dramatic improvements 
in patient survival and drug tolerability, toxicity remains an important complication of 
chemotherapeutic drugs and sometimes limits life-saving therapy. Up to 75% of childhood 
cancer survivors (CCS) will experience at least one late-effect of which one-third is severe or 
life-threatening.3,184-187
The kidneys play a central role in the treatment of malignancies, as many chemotherapeu-
tic and supportive care drugs are cleared by the kidneys. Unfortunately, they are also the 
target of nephrotoxicity which can present as a decline in glomerular filtration rate (GFR), 
deterioration of tubular function, arterial hypertension, or a combination of the above. The 
prevalence of renal dysfunction or elevated blood pressure is almost 30% among long-term 
CCS and ranges up to 45% depending on measured outcome variable and study group.12,188,189 
Commonly used drugs known for their nephrotoxic potential are ifosfamide,7-11,13,14,190 cy-
clophosphamide,9,15 high-dose methotrexate (HD-MTX)7,16,17 and the platinum compounds 
cisplatin7,12,18,19 and carboplatin.7,12,18,20 Pediatric oncologists and consulting pediatric 
nephrologists should be familiar with their potential renal adverse effects, particularly as-
sociated laboratory manifestations. Nephrotoxicity may be acute and reversible, but also 
has the potential to cause chronic and irreversible damage, resulting in an increased risk 
for mortality even into adulthood.191,192 This stresses the need for sound assessment of renal 
function before, during and after treatment for childhood cancer.
The present survey was set out to compare current recommendations on renal function 
monitoring in the treatment protocols containing potentially nephrotoxic agents currently 
used by the Dutch Childhood Oncology Group (DCOG).
methods
All treatment and/or study protocols used on January 1, 2012 by the DCOG for the treatment 
of primary malignancies were identified for potential inclusion. Inclusion criterion was the 
use of one of the potentially nephrotoxic agents cisplatin, carboplatin, ifosfamide, HD-MTX 
(defined as over 3.000 mg/m²/day) or cyclophosphamide. Seven protocols (ie, ACNS0423, 
CMLpaed-2, DB-AML01, DIPG study VUmc, ICC APL study 01, ML-DS2006 and TMD Down) 
did not meet this inclusion criterion. We also excluded protocols for relapsed childhood 
cancer and specific treatment arms within in a protocol regarding relapsed and/or refractory 
disease. Thirty-one protocols were included in the analysis, seven neuro-oncology protocols 
(ACNS0121, ACNS0331, ACNS0332, HIT 2000, SIOP CNS-GCT 2, SIOP CPT 2000 and SIOP LGG 
2004), eight hemato-oncology protocols (ALCL99, ALL-10, B-NHL/B-ALL2008, EsPhALL, Euro 
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LB-02, EuroNet-PCL-C1, EuroNet-PHL-LP1 and Interfant-06) and 16 solid tumor protocols 
(EURAMOS-1, EWING99, EWING2008, LCH3, MAKEI96, MAKEI2005, Metastatic RMS, NBL2009, 
NPC GPOH 2003, EPSSG NRSTS 2005, RB-VUMC2010, EPSSG RMS 2005, SIOP 2001, SIOPEL 3, 
SIOPEL 4 and SIOPEL 6). All protocols are internationally used except for the DCOG protocols 
NBL2009, RB-VUmc2010, ALL-10 and B-NHL/B-ALL2008.
The information extracted from the protocols included cumulative chemotherapy doses, 
timing and method of renal function assessment and recommendations on dose modifica-
tion in case of renal dysfunction. The collected data were reviewed and the descriptives 
summarized in tables. Other than the use of descriptive statistics no statistical tests were 
used. For any additional information on included protocols the corresponding author can be 
contacted.
results
Cumulative dose of nephrotoxic medication
Table 6.1 provides an overview of cumulative doses of the five potentially nephrotoxic 
chemotherapeutic agents used in the 31 protocols. The majority of nephrotoxic agents are 
administered intravenously. In eight protocols one nephrotoxic drug is prescribed, in 16 
protocols two, in five protocols three and in two protocols a combination of four nephro-
toxic drugs are used. In general, treatment protocols for hematological malignancies have 
the lowest nephrotoxic potential. They less often contain potentially nephrotoxic drugs and 
cumulative doses are lower.
assessment of renal function
The method and timing of renal function assessment, categorized by type of malignancy is 
presented in Table 6.2. Renal function is split into glomerular by serum GFR markers, gold 
standard GFR measurement or 24 hour urinary creatinine clearance and the detection of tu-
bular dysfunction by measurement of plasma bicarbonate, serum electrolytes or calculation 
of fractional excretions of electrolytes. There is great variability in timing and method of renal 
function measurement between the different protocols. The most striking is that, despite 
the use of at least one potentially nephrotoxic drug, not all protocols regularly advise to 
measure renal function. For example protocols containing HD-MTX, despite the risk of acute 
glomerular toxicity five out of nine protocols do not advise on assessment of glomerular 
function during HD-MTX treatment. Three protocols do not even mention renal function at 
all. Overall, protocols for solid tumors, containing the highest nephrotoxic potential, more 
often mention to assess renal function.
In every phase of the treatment serum concentrations of creatinine and/or BUN are the 
most commonly advised measures of renal function, recommended in 84% of the protocols 
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 6
at baseline or during therapy and in about 50% during follow-up. Although it is the most 
reliable parameter to base doses of chemotherapy, fluids and supportive care drugs on, GFR 
measurement at baseline and during therapy is recommended in only half of the neuro-
oncology and two-thirds of the solid-tumor protocols, while 25% of the hemato-oncology 
protocols advise this method. Creatinine-clearance in 24-hour urine is recommended less 
often.
table 6.2. Timing and method of renal function assessment
start
n (%)
during
n (%)
follow-up
n (%)
Serum creatinine and/or BUN
Neuro-oncology protocols (7) 5 (71) 6 (86) 6 (86)
Hemato-oncology protocols (8) 8 (100) 7 (88) 2 (25)
Solid tumor protocols (16) 13 (81) 13 (81) 7 (54)
Total (31) 26 (84) 26 (84) 15 (48)
GFR measurement (gold standard)
Neuro-oncology protocols (7) 3 (43) 5 (71) 3 (43)
Hemato-oncology protocols (8) 2 (25) 0 (0) 0 (0)
Solid tumor protocols (16) 10 (63) 10 (63) 4 (25)
Total (31) 15 (48) 15 (48) 7 (23)
24-hour urine creatinine clearance
Neuro-oncology protocols (7) 0 (0) 0 (0) 0 (0)
Hemato-oncology protocols (8) 0 (0) 3 (38) 1 (18)
Solid tumor protocols (16) 3 (19) 2 (13) 1 (6)
Total (31) 3 (10) 5 (16) 2 (6)
Serum electrolytes
Neuro-oncology protocols (7) 5 (71) 5 (71) 5 (71)
Hemato-oncology protocols (8) 6 (75) 3 (38) 0 (0)
Solid tumor protocols (16) 4 (25) 8 (50) 5 (31)
Total (31) 15 (48) 16 (52) 10 (32)
Plasma bicarbonate
Neuro-oncology protocols (7) 0 (0) 0 (0) 0 (0)
Hemato-oncology protocols (8) 1 (13) 0 (0) 0 (0)
Solid tumor protocols (16) 5 (31) 6 (38) 3 (19)
Total (31) 6 (19) 6 (19) 3 (10)
Fractional excretion of electrolytes
Neuro-oncology protocols (7) 1 (14) 1 (14) 0 (0)
Hemato-oncology protocols (8) 0 (0) 0 (0) 1 (13)
Solid tumor protocols (16) 8 (50) 5 (31) 3 (19)
Total (31) 9 (29) 6 (19) 4 (13)
BUN, blood urea nitrogen; GFR, glomerular filtration rate; N, number
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Serum electrolytes are the most frequently advised tubular measures, particularly at baseline 
(protocols for hematological and central nervous system malignancies) and during treatment 
(central nervous system malignancies). Recommendations on monitoring for renal tubular 
acidosis is limited to (a minority of ) solid tumor protocols, as are recommendations regarding 
fractional excretions of electrolytes, which is used in one third of solid tumor protocols. Frac-
tional excretion of calcium and phosphate are most commonly recommended. Five protocols 
do not specify which electrolytes to be measured, leaving it to the physician’s discretion.
Monitoring for renal toxicity after completion of therapy is advised less often in com-
parison with before and during treatment. This applies to all renal function measures. One 
quarter of protocols containing nephrotoxic drugs do not provide any recommendations 
on renal toxicity monitoring after completion of treatment. Twenty-four of the included 
protocols contain recommendations for long-term follow-up. Only 18 of these protocols give 
specific recommendations with respect to timing, frequency and method. Here again, the 
great variability, even with comparable cumulative dosages of nephrotoxic agents, is striking. 
Of note, only part of the protocols clearly state whether recommended laboratory evalua-
tions summarized in Table 6.2 are to evaluate renal function or, for instance, in the context of 
tumorlysis, cerebral salt wasting or the syndrome of inappropriate secretion of antidiuretic 
hormone (SIADH).
dose modification in case of renal dysfunction
Table 6.3 gives an overview of recommended dose modifications for cisplatin, carboplatin, 
ifosfamide, cyclophosphamide and HD-MTX in case of impaired renal function. Only 24 of the 
31 protocols advise on dose adjustments if glomerular function is impaired. Dose modifica-
tions based on tubular dysfunction are not mentioned. The spectrum of GFR thresholds and 
recommended dose modifications is broad.
Carboplatin
All 11 protocols containing carboplatin give recommendations for dose modifications in 
case of impaired renal function. Recommendations vary from renal function-based dosing 
with a target AUC of 5 mg/mL.minute at a GFR threshold of 100 mL/minute/1.73 m² to a 
25% dose reduction when GFR falls below 60 mL/minute/1.73 m². Six protocols advise dose 
adjustments using the Newell or the Calvert’s formula. However, four of these protocols do 
not specify at which GFR threshold, leaving it to the discretion of the physician. Besides renal 
function based dosing, dose modifications vary from dose reductions (25-35%), to a one 
week delay, to replacement by cisplatin. Three protocols advise to adjust dosage based on 
serum creatinine levels, either when creatinine exceeds the upper limit for age by 50% or the 
fixed cutoff of 1.2 mg/dL (106 μmol/L).
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Cisplatin
All 12 protocols containing cisplatin provide recommendations on dose modifications. GFR 
thresholds for these modifications vary from 30 to 80 mL/minute/1.73 m², to serum creatinine 
exceeding 1.5 times the age-adjusted upper limit or a fixed threshold of 1.2 mg/dL (106 
μmol/L). Recommendations on type of dose modifications vary from delayed administration 
by one week to replacement by carboplatin. In one protocol, specific recommendations are 
made for different GFR thresholds.
Ifosfamide
Unlike cisplatin and carboplatin, only two-thirds of the protocols containing ifosfamide 
recommend on adjustments in the event of nephrotoxicity. Indications to adapt treatment 
vary from GFR thresholds between 40 and 80 mL/minute/1.73 m², to serum creatinine levels 
exceeding 1.5 times the age-adjusted upper limit or an absolute cutoff of 1.2 mg/dL (106 
μmol/L). Recommendations vary from delayed administration by one week, to dose reduc-
tion by 30% or substitution by cyclophosphamide.
Cyclophosphamide
In 19 of the protocols cyclophosphamide is administered. Nevertheless, only three protocols 
advise on dose modifications in case of renal dysfunction. Dose reduction, eventually followed 
by the replacement by procarbazine, is advised if renal function is diminished. In one protocol 
the threshold for a dose reduction of 25% is a GFR below 10 mL/minute/1.73 m², while another 
protocol advises a GFR cutoff of 60 mL/minute/1.73 m² for the same modification.
High-dose methotrexate
Clear protocol statements on dose modifications regarding HD-MTX are sparse. The only rec-
ommendations are made for a GFR below 60-70 mL/minute/1.73 m² and most often include 
delay of treatment, although it is not always clearly stated for how long. One protocol advises 
a dose reduction by 50% based on a GFR below the age-adjusted lower limit and to withhold 
further MTX below the absolute threshold of 30 mL/minute/1.73 m².
disCussion
In this survey we have summarized and compared current practice of renal function monitor-
ing before, during and after treatment for childhood cancer in the Netherlands by reviewing 
protocols containing at least one of the potentially nephrotoxic drugs carboplatin, cisplatin, 
ifosfamide, cyclophosphamide or HD-MTX. These protocols cover a wide variety of childhood 
malignancies and are (inter)nationally used in clinical practice. Frequency and method for 
monitoring renal function vary greatly between the different protocols and do not seem to 
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correlate with cumulative dose or type of chemotherapy used in the protocols, even when 
regimens are quite similar. Recommendations on dose modification in case of renal dysfunc-
tion also show great variety. These differences are unwanted from a clinical and research 
perspective and call for a standardized approach to the assessment of renal function dur-
ing treatment for childhood cancer, bearing in mind the limitations of the different tests in 
clinical practice. This already has been achieved for the follow-up of CCS, where well-defined, 
evidence-based surveillance protocols have been published by the United Kingdom Chil-
dren’s Cancer Study Group,14 the Children’s Oncology Group7 and DCOG193 but still needs to 
be implemented for children during treatment.
The rationale for renal function monitoring in protocols is often primarily to answer the 
study question(s) regarding drug safety and toxicity. Therefore, many protocols state that 
additional laboratory evaluations may be indicated for good clinical care of the individual 
patient. The fact that recommended evaluations are often included to serve the study aims 
is illustrated by Table 6.3. All protocols advise to assess glomerular function (either by serum 
markers, gold standard method or creatinine clearance), but only part advise on how dosage 
should be adapted if these test results are abnormal. Recommendations in protocols should 
be standardized to serve the aims of the study as well as good patient care and should be 
based on the nephrotoxic potential of the proposed treatment. Physicians have to realize 
which of the different functions of the kidneys are at risk and choose the renal function tests 
accordingly. Based on the well-documented toxicity of certain chemotherapeutic drugs, 
we propose a modular approach for rational kidney function monitoring. Protocols should 
also include recommendations on how to individualize monitoring in case of impaired 
renal function or severe (non-renal) toxicity. Table 6.4 provides a rationale for this. Of note, 
there are more contributors to nephrotoxicity than chemotherapy, including radiotherapy, 
certain supportive care drugs and the disease itself (e.g. renal involvement and tumorlysis 
syndrome). These have to be included in the risk assessment of the nephrotoxic potential of 
a treatment plan.
Measurement of GFR is the single most important parameter in clinical practice and has 
shown to be the best indicator of renal function in children.23,24,113 Gold standard techniques 
measure the excretion of exogenous molecules eliminated exclusively by glomerular 
filtration. Various markers are available (e.g. inulin, iohexol, iothalamate, 51Cr-EDTA and 
99mTc-DTPA). Although highly accurate, these methods are too invasive, time-consuming and 
costly for clinical practice. Their use is therefore limited to situations where conventional GFR 
markers are unreliable (e.g. in very young children and children with poor nutritional status) 
or when an exact measurement of GFR is required for drug dosing. Traditional endogenous 
GFR markers are serum creatinine and BUN. The latter is strongly influenced by protein and 
fluid intake making it a poor marker of GFR in the pediatric oncology setting. Creatinine, a 
metabolite from muscle creatine, is strongly related with growth, muscle mass and the intake 
of meat. As muscle mass increases with growth, creatinine reference values vary with age.123 
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A fixed creatinine cutoff, as used in some protocols, is therefore not appropriate. Recently, 
an international standard for creatinine measurement (IDMS) has been established which 
has led to lower creatinine readings than older tests. All new protocols need to be adapted 
accordingly. The major drawback of creatinine is its dependency on muscle mass, which 
is often diminished in children with malignancy. Muscle wasting leads to lower creatinine 
production, resulting in lower serum creatinine concentrations and overestimation of true 
GFR.113 GFR in children can be estimated (eGFR) from serum creatinine and height using 
the Schwartz equation.25 International guidelines advise the use of estimated GFR instead 
of creatinine concentrations to monitor GFR in daily practice.99 A more accurate alternative 
is the 24-hour creatinine clearance, often used because it corrects for variable serum levels 
during the day. However, the problem of tubular secretion and difficulty of urine collection, 
especially in children who have not been toilet trained remains.
In the last decades, cystatin C has emerged as an alternative marker to assess GFR. It is 
a low-molecular weight protein produced by all nucleated human cells at a fairly constant 
rate.194 As its production is independent of muscle mass, it has a constant reference range 
after the first year of life.90,98,195 Cystatin C has higher sensitivity for the recognition of mildly 
impaired renal function which makes it an ideal marker of GFR in pediatric oncology. Indeed, 
our previous study has demonstrated that it more accurately detects impaired renal function 
in children with cancer than creatinine.103 Analogous to the Schwartz equation for creatinine, 
several equations have been formulated to estimate GFR from serum cystatin C.61 The use of 
cystatin C is hampered in a limited number of circumstances. A major drawback is the dose-
dependent stimulation by glucocorticoids,53 leading to underestimation of renal function. 
Furthermore, hypothyroidism is associated with lower cystatin C levels and hyperthyroidism 
with higher levels. Cystatin C is increasingly available in local clinical chemistry laboratories, 
although still more expensive than creatinine.
Renal tubular dysfunction is a major side effect of platinum analogues and ifosfamide. This 
may lead to significant loss of electrolytes resulting in decreased serum concentrations. In 
order to evaluate if the decreased serum concentration reflect renal loss, fractional excretions 
of electrolytes should be measured in paired serum and urine samples:
fractional excretion (%) = 100 x concentrationurine * creatinineserum
concentrationserum * creatinineurine
For phosphate, the tubular reabsorption (ie, 1 minus fractional excretion) or the tubular 
maximum of phosphate reabsorption (TmP/GFR) can be calculated. These calculations are 
only useful if there are signs of a deficiency and before supplementation is started.
Solid evidence on the timing and method of dose modifications of nephrotoxic chemo-
therapy is lacking. In the debate on how to dose the platinum analogue carboplatin it has 
become clear that renal function-based dosing results in more predictable exposure than 
flat dosing based body surface area or weight.65 Even with normal renal function systemic 
clearance is highly variable leading to unpredictable exposure.196 Therefore, in case of renal 
impairment, dose modifications based on renal function is preferred over flat dosing. This 
may allow compensation for patient variations in renal function that might otherwise result 
in either underdosing (inadequate treatment) or overdosing (risk of toxicity), bearing in mind 
that traditional renal function markers often overestimate true GFR in children with cancer. 
More research on timing and method of dose modifications is warranted. Future research 
should furthermore focus on interventions that prevent or minimize renal dysfunction. These 
results will allow researchers and physicians to come to consensus on how and when to 
adjust medications in the event of nephrotoxicity.
In conclusion, currently used treatment protocols are heterogeneous with regard to moni-
toring of renal function and dose adjustments in case of renal impairment. In some protocols 
recommended renal function measures are inappropriate given the chemotherapeutic drugs 
prescribed. These differences are unwanted form a clinical and research perspective and call 
for standardization.
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summary
aims: Renal function-based carboplatin dosing results in more consistent drug exposure 
than flat dosing. We aimed to validate the Newell dosing equation using estimated glo-
merular filtration rate (GFR) and study which renal function marker most accurately predicts 
carboplatin clearance in children.
methods: In 30 children with a wide spectrum of solid tumours, 78 carboplatin clearance 
values were obtained from individual fits using NONMEM. Observed carboplatin clearance 
was compared with predicted clearance calculated according to the Newell dosing equation 
using three different GFR estimates, one creatinine-based (eGFR-Schwartz), one cystatin 
C-based (eGFR-CKiD1) and one based on creatinine and cystatin C (eGFR-CKiD2). Bias and 
precision of the predictions was examined.
results: Both CKiD equations were accurate with a bias of 1.7 (95% CI −1.7 to 5.1) and −3.3 
(95% CI −7.0 to 0.35) mL/minute for respectively eGFR-CKiD1 and CKiD2, whereas the bias 
of eGFR-Schwartz significantly differed from zero (−16.2; 95% CI −21.5 to −10.9 mL/minute). 
eGFR-CKiD1 gave the lowest bias and imprecision, the other two eGFR equations showed 
overprediction of carboplatin clearance as reflected by negative bias and higher mean pre-
diction error values. The proportion of variance in observed clearance that can be explained 
by the predicted clearance was lowest for Schwartz (R²=0.58), the explained variance was 
0.65 for both CKiD equations.
Conclusions: The two cystatin C-based CKiD equations outperform the widely used 
creatinine-based Schwartz equation in predicting carboplatin clearance. We recommend the 
use of estimated GFR based on cystatin C for carboplatin dosing in children unless a gold 
standard GFR measurement is available.
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introduCtion
Carboplatin is a second-generation platinum-containing compound commonly used in pae-
diatric oncology, mainly for solid tumours.197 Although generally not labelled for paediatric 
patients, the use of carboplatin is on the rise because it is associated with less renal, and 
neurological toxicity than cisplatin198 For the treatment of solid tumours in adults carboplatin 
dosing based on renal function is recommended. This is derived from the observation that 
carboplatin is almost exclusively (up to 80%) eliminated by glomerular filtration. Its pharma-
cokinetics is, therefore, mainly determined by the patient’s renal function.63,64,199 This linear 
relationship between carboplatin clearance and glomerular filtration rate (GFR) prompted 
the development of carboplatin dosing equations based on renal function both in adults63 
and children.72,73 Renal function-based dosing results in more reproducible and reliable drug 
exposure than flat dosing,65,66 while real-time monitoring with adaptive dosing has been as-
sociated with more consistent platinum exposure in children.67 The importance of controlling 
carboplatin exposure is illustrated by the relation between the carboplatin area under the 
concentration-time curve (AUC; equals dose divided by drug clearance), toxicity,69,70,200 and 
clinical efficacy.68 Renal function-based dosing is of particular importance in children as it 
corrects for changes in renal function during childhood.24 The different dosing equations 
were all developed using a gold standard GFR measurement. Although highly accurate, these 
methods are not widely available and often too invasive and time-consuming for routine 
measurement of GFR. Therefore, current guidelines in clinical nephrology advise the use 
of estimated GFR (eGFR) based on the serum concentrations of creatinine or cystatin C.55,56 
Carboplatin dosing using estimated GFR may therefore be a more practical alternative to 
calculate the appropriate carboplatin dose. This is being studied extensively in adults, but 
not yet in children.
The aim of the present study was to validate the Newell dosing equation using estimated 
GFR and study which endogenous renal function marker most accurately predicts carbo-
platin clearance in children. We compared the predictive performance of the widely used 
creatinine-based Schwartz equation with a cystatin C-based equation and an equation 
combining both markers.
methods
Patients and treatment
To be eligible patients had to be between 0 and 18 years old and scheduled to receive car-
boplatin, either as single-agent therapy or as part of a multimodal chemotherapy regime. 
The protocols according to which the included patients were treated are listed in Table 7.1. 
The study was carried out in concordance with the principles of the Declaration of Helsinki 
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and was approved by the Institutional Review Board of VU University Medical Centre. Written 
informed consent was signed by all patients or parents/guardians, as appropriate, before 
participating in the study. In the majority of clearance studies a flat carboplatin dose based 
on body surface area (67%) or body weight (24%) was given. One patient received a dose 
to achieve a target AUC of 4.1 mg/mL.minute and two patients received doses to achieve a 
target AUC of 6.6 mg/mL.minute, using the Newell formula.72
Carboplatin administration, blood sampling and platinum analysis
Carboplatin was administered intravenously, diluted in 5% dextrose at doses ranging from 
25 mg to 970 mg (median 340 mg). The drug was administered by study physicians or nurses, 
who punctually recorded dosing and sampling times in case report forms. After administra-
tion of carboplatin, all infusion lines were changed to prevent contamination of the samples 
(details to be published separately). At various time points venous blood (2 mL) was collected 
into tubes containing lithium heparin anticoagulant. For hospitalized patients samples were 
obtained at 2.5, 8, 10, and 23 hours after the start of infusion. To minimize the burden for 
outpatients, a limited sampling strategy with two samples (1.5 and 5 hours after start of 
infusion) was applied. All samples were immediately placed in an ice bath and centrifuged 
table 7.1. Treatment protocols
disease and protocol no. of 
patients
duration infusion
(hours)
Concomitant drugs and 
dose (mg/m²)
Carboplatin dose
(mg/m²)
Retinoblastoma*
RB-VUmc 2010
14 1 Vincristine 1.5
Etoposide 150
560 x 1 day
Wilms tumor†
SIOP WT 2004
2 1 Etoposide 150 x 3 days 200 x 3 days
DIPG
Individualized protocol
1 23 Etoposide 338 x 4 days
Melphalan 70 x 3 days
AUC 4.1§ x 4 days
Neuroblastoma
NBL 2004
2 1 Etoposide 40
Melphalan 45 x 4 days
500 x 3 days
Medulloblastoma
ACNS 0332
2 0.25 Vincristine 1.5 35 x 5 days
Low grade glioma
SIOP LGG 2004
4 1 Vincristine 1.5 550 x 1 day
Germ cell tumor
SIOP CNS GCT II
2 1 Etoposide 100 x 3 days 600 x 1 day
Hepatoblastoma
SIOPEL 4
2 1 Doxorubicin 20 x 2 days AUC 6.6§ x 1 day
sPNET‡
GPOH MET-HIT 2000-BIS4
1 24 Etoposide 100 x 4 days 200 x 4 days and
500 x 4 days
Abbreviations: AUC, area under the time-concentration curve; DIPG, diffuse intrinsic pontine glioma;
sPNET, supratentorial primitive neuroectodermal tumor.
*for children < 1 year: carboplatin 18.7 mg/kg †for children < 12 kg: 2/3 of carboplatin dose ‡for children 
7-12 months: 4/5 of carboplatin dose § in mg/mL.minute
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(1500 x g at 4°C for 10 minutes), to separate the plasma from whole blood. In order to separate 
total from protein bound platinum, ethanol precipitation was used as described previously.201 
An aliquot of plasma (0.5 mL) was thoroughly mixed with 1.5 mL of ice cold (−20°C) ethanol 
and incubated for several hours at −20°C to denaturize the plasma proteins. This mixture 
was centrifuged again at 4°C and 1500 x g for 10 minutes. The supernatant was carefully 
transferred to a 2.0 mL tube and stored together with the plasma samples at −20°C until 
assay by flameless atomic absorption spectrophotometry (AA 800, Perkin Elmer, Waltham, 
MA, USA).201
renal function
Renal function was assessed before each course of carboplatin. Creatinine was measured 
using an enzymatic method (Modular Analytics, Roche Diagnostics, Mannheim, Germany), 
which is traceable to isotope dilution mass spectrometry.122 Cystatin C was measured from a 
frozen serum sample within one run using a particle-enhanced immunonephelometric assay 
(Siemens Healthcare, Marburg, Germany) on a Dade Behring Nephelometer II. Estimated GFR 
was calculated according to three equations: the creatinine-based bedside Schwartz equa-
tion (eGFR-Schwartz) and two recently improved equations from the Chronic Kidney Disease 
Study in Children (CKiD), i.e. the cystatin C-based eGFR-CKiD 1 equation and an equation 
based on serum creatinine and cystatin C (eGFR-CKiD 2) (Table 7.2).25,60
table 7.2. Equations used for calculation of estimated GFR
Equation 1 eGFR-Schwartz [mL/minute/1.73 m²] = 41.3 × 
height [m]
creatinine [mg/dL]
Equation 2 eGFR-CKiD 1 [mL/minute/1.73 m²] = 40.9 × 
1.8 0.931
cystatin C [mg/L]
Equation 3 eGFR-CKiD 2 [mL/minute/1.73 m²] = 41.6 × 
height [m] 0.433
creatinine [mg/dL]  × 


1.8 0.479
cystatin C [mg/L]
Abbreviations: AUC, area under the time-concentration curve; eGFR, estimated glomerular filtration rate.
Pharmacokinetic and statistical analysis
Individual fits of the observed carboplatin-time data, measured as free platinum, were 
obtained by fitting a two-compartment model using the non-linear mixed effect model-
ling program NONMEM (version VI, level 2.0 ICON Development Solutions, Ellicot City, MD, 
USA).202 Carboplatin clearance values obtained from these individual fits were compared with 
predicted carboplatin clearance values calculated using the Newell equation:72
Predicted clearance = TargetAUC × (GFR [mL/minute] + 0.36 × body weight [kg]),
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in which GFR was calculated according to the equations listed in Table 7.2. As the different 
eGFR equations yield standardized GFR in mL/minute/1.73m², GFR was converted to abso-
lute GFR in mL/minute before use in the Newell formula. Bias (i.e. mean difference between 
observed and predicted carboplatin clearance) and limits of agreement (mean bias ± 
1.96*standard deviation) were evaluated according to the Bland-Altman analysis.125 Further-
more, performance of the carboplatin clearance predictions was assessed by calculating: (i) 
the percentage mean prediction error (%MPE), a measure of bias; (ii) the percentage mean 
absolute prediction error (%MAPE), a measure of imprecision; (iii) the interclass coefficient 
(ICC) which measures true variance as a proportion of total variance, and (iv) the proportion 
of predicted clearance values that were within ± 20% of corresponding observed values (20% 
accuracy). This cut-off was based on the generally accepted finding that the therapeutic 
window of carboplatin comprises an AUC of 5–7 mg/mL.minute.
Dosing regimens that lead to an AUC of 4 mg/mL.minute or lower (i.e. a bias of minus 20% 
related to a target AUC of 5 mg/mL.minute) can therefore be regarded as subtherapeutic.
%MPE = ∑ prediction error  × 100% and %MAPE = ∑ | prediction error | ×100%
N N
with prediction error defined as: 
(predicted clearance − observed clearance)
observed clearance
Predicted clearance results were plotted against observed clearance results and least squares 
linear regression was performed to calculate R².
Since most treatment regimens advise to adjust dosing in young children to a per kilogram 
of body weight dose, we explored whether predictive performance in infants (defined as 
younger than one year or weight below 10 kilograms) differed from predictive performance 
in older children. Continuous variables are presented as median [interquartile range; IQR]. 
Qualitative variables are displayed as numbers (%). Binary outcome measures of the three 
dosing strategies were compared using the McNemar test, continuous measures using the 
Wilcoxon signed rank test. Diagnostic graphs and additional statistical analyses were made 
using IBM SPSS statistics 20 (Chicago, IL, USA) and GraphPad Prism 5.0 (San Diego, CA, USA). 
All tests were done at a two-sided significance level of 0.05.
results
Patients
In total 78 clearance studies in 30 children were included. The patient characteristics are sum-
marized in Table 7.3. A third of the patients was female and 47% was treated for retinoblas-
toma. Two patients had primary renal disease and all patients had normal renal function at 
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diagnosis, defined as creatinine and cystatin C levels below the age-appropriate upper limit. 
In 26 clearance studies (33%) patients were younger than one year and/or weighed less than 
10 kilogram. Twenty-two (73%) patients were studied during multiple courses. Four children 
were studied twice, eight were studied three times, and 10 children were studied during four 
carboplatin courses (median of three clearance studies per patient with 21.0 [7.2-28.8] days 
between successive clearance studies). Twenty-three courses (30%) were conducted at the 
outpatient ward.
Pharmacokinetics and comparison of equations
The 256 carboplatin ultrafiltrable plasma concentrations ranged between 0.0 and 68.8 
(median 1.2) mg/L. These values were used to calculate observed carboplatin clearance, 
which ranged from 12.7 to 95.7 (median 47.2) mL/minute. The use of the CKiD equations 
resulted in a mean bias of 1.7 (95% CI −1.7 to 5.1) and −3.3 (95% CI −7.0 to 0.35) mL/
minute for respectively eGFR-CKiD 1 and eGFR-CKiD 2, whereas the bias of eGFR-Schwartz 
significantly differed from zero (−16.2; 95% CI −21.5 to −10.9 mL/minute. The use of the 
cystatin C-based eGFR-CKiD 1 equation gave the lowest bias and imprecision (Table 7.4). 
This is also shown in the Bland-Altman plots in Figure 7.1, the bias line of eGFR-CKiD 1 is 
closest to zero and the grey area between the limits of agreement is the narrowest. The 
use of the other two eGFR equations resulted in overprediction of carboplatin clearance 
as reflected by the negative bias and higher %MPE values (Table 7.4). Figure 7.2 illustrates 
that the use of the Schwartz equation structurally overestimates the observed carboplatin 
table 7.3. Patient characteristics
number of clearance studies 78
Age, years 3.1 [0.9-5.1]
Body weight, kg 15.7 [9.4-20.0]
BSA, m² 0.65 [0.43-0.78]
BMI, kg/m² 16.8 [15.4-18.7]
Weight for height SDS 0.4 [−0.6-1.3]
BMI SDS 0.3 [−0.5-1.3]
Creatinine, mg/dL 0.3 [0.2-0.3]
Cystatin C, mg/L 0.69 [0.63-0.79]
eGFR-Schwartz, mL/minute/1.73 m² 138.9 [115.2-165.5]
eGFR-CKiD 1, mL/minute/1.73 m² 99.2 [87.7-108.9]
eGFR-CKiD 2, mL/minute/1.73 m² 111.5 [100.7-124.7]
Carboplatin clearance, mL/minute 47.2 [30.5-64.8]
Data are presented as median [IQR]
*To convert to μmol/L multiply by 88.4
Abbreviations: BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; 
SDS, standard deviation score.
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table 7.4. Performance of predicted carboplatin clearance values based on clearance based on different 
estimates of GFR
method Bias
(ml/minute)
mPe
(%)
maPe
(%)
iCC accuracy
(%)
Schwartz Total
N=78
−16.2 37.4 42.5 0.58 46
CKiD 1 1.7 −2.4 25.5 0.79 56
CKiD 2 −3.3 9.7 26.1 0.77 64
Schwartz Infants
N=26
−10.6 36.9 42.7 0.22 50
CKiD 1 4.5 −8.9 27.6 0.39 59
CKiD 2 0.9 6.6 26.5 0.40 59
Schwartz Older 
children
N=52
−21.7 37.7 42.4 0.36 44
CKiD 1 −5.1 1.5 24.3 0.56 50
CKiD 2 −11.3 11.5 25.9 0.54 73
Abbreviations: ICC, interclass correlation coefficient; MAPE, mean absolute prediction error; LOA, limits
of agreement; MPE, mean prediction error
Data for infants (< 1 year or 10 kilograms) and older children are displayed separately.
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figure 7.1. Bland-Altman plots for eGFR-Schwartz (A), eGFR-CKiD 1 (B) and eGFR-CKiD 2 (C), showing bias 
(solid line) and limits of agreement (grey area).
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clearance, whereas the use of the CKiD 1 equation yielded results on both sides of the 20% 
limits of observed clearance. The use of the combined CKiD 2 equation also tends towards 
overestimation of observed carboplatin clearance, although this equation has the highest 
proportion of predicted values within ± 20% of observed clearance (P-value 0.011 and 
NS when comparing with eGFR-Schwartz and eGFR-CKiD 1 respectively) (Table 7.4). The 
proportion of the variance in observed clearance that can be explained by the predicted 
clearance (R²) was lowest for Schwartz (R² = 0.58), while the explained variance was 0.65 for 
both CKiD equations.
We found no systematic differences in predictive performance between the infant group 
and the older children (Table 7.4). In both groups the Schwartz equation has the largest bias 
and imprecision, whereas the CKiD equations perform comparably.
disCussion
This study is the first to externally validate the Newell dosing formula using estimated GFR, 
comparing the use of different renal function markers. We have demonstrated that the use 
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figure 7.2. Predicted versus observed carboplatin clearance for eGFR-Schwartz (A), eGFR-CKiD 1 (B) and 
eGFR-CKiD 2 (C). The dotted lines represent the 20% accuracy limits.
110 Chapter 7
of the cystatin C-based CKiD 1 equation in the Newell formula results in the most accurate 
prediction of the carboplatin clearance in children.
Knowledge of renal function is important for the dosage of medications that are excreted 
by the kidneys. Since GFR is the predominant determinant of carboplatin clearance, the prin-
ciple of individual carboplatin dosing based on renal function is widely accepted. When GFR 
is measured using a gold standard technique, a strong relation with carboplatin clearance 
exists.72 It is widely accepted that GFR is best measured as the plasma or urinary clearance of 
inulin or exogenous markers that share the ideal GFR marker features of inulin (e.g. 51Cr-EDTA, 
99Tc-DTPA, 125I-iothalamate or iohexol).24,29 These methods are invasive and involve undesir-
able effects such as radiation exposure and the need for multiple blood samples or bladder 
catheterization. Therefore, current international guidelines advocate the use of estimated 
GFR for drug dosing203 and the detection, evaluation, and management of kidney disease.55,56 
A wide range of paediatric eGFR equations have been developed in recent years, of which the 
creatinine-based bedside Schwartz equation is the most widely-used.25 In the care for adults 
it has become common practice to predict carboplatin clearance using estimated GFR. How-
ever, no dosing strategy has been found to be applicable to all patients without bias.74,204-206 
The main limitation of most formulae is that they rely on serum creatinine, which reflects 
GFR but is also influenced by tubular secretion and nonrenal factors such as age, gender, and 
muscle mass. In children muscle mass increases with age, so that serum creatinine can only be 
used to monitor renal function after correction for anthropometric data or age.207 Therefore, 
the problem of muscle mass dependency is even greater in paediatric patients and severely 
hampers the use of creatinine in children. Moreover, creatinine concentrations remain within 
the age-dependent reference range until there is at least 50% loss of renal function.105 In 
patients with reduced muscle mass or malnourishment, decreased creatinine production 
results in overestimation of GFR.38 The poor predictive performance of the creatinine-based 
Schwartz equation in our hands most likely reflects these limitations of creatinine and is in 
line with our previous findings in children with cancer.103 The use of eGFR-Schwartz resulted 
in significant overestimation of carboplatin clearance with the risk of overdosing and toxicity. 
Similar findings have been reported in pharmacokinetic studies in adults.74,206
Recently, the small molecular weight protein cystatin C has emerged as a potentially 
superior endogenous marker of GFR.98-100 It is produced by all nucleated cells at a constant 
rate and is almost freely filtered across the glomerular membrane. Moreover, filtered cystatin 
C is completely reabsorbed and degraded in the proximal tubular cells. Therefore, it does 
not re-enter circulation and there is no tubular secretion.175 In adults cystatin C has proven 
to predict carboplatin clearance at least as reliable as serum creatinine, and a model based 
on both renal function markers as well as nonrenal covariates related to muscle mass has 
proven to be superior to those based on either marker alone.182,208 This is in line with findings 
in the field of clinical nephrology that GFR prediction equations based upon both cystatin C 
and creatinine have better diagnostic performance than prediction equations based upon 
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only one of these GFR-markers.25,60,61 In our hands the formula based on both markers has a 
comparable accuracy as the formula based on cystatin C alone (−3.3 and 1.7 ml/min respec-
tively), but was slightly more precise (64% and 56% of predictions within 20% of observed, 
respectively). By adding cystatin C to the prediction model, the contribution of creatinine is 
decreased and predictive performance improved. It is noteworthy that the use of the CKiD 
1 equation results in less overestimation of carboplatin clearance, reducing the risk of toxic-
ity. Also, the absolute degree of underestimation by the CKiD 1 equation is low (Figure 7.2). 
However, prospective validation studies comparing predictive performance and toxicity of 
these different dosing strategies are needed.
Several versions of the original Calvert formulation exist in paediatric literature and 
the debate which one is the best to determine GFR for renal function-based dosing is still 
on-going. In a simulation study with paediatric patients aged six months to 16 years, the 
results of carboplatin dose calculations were primarily determined by the choice of the GFR 
estimating equation rather than dosing equation.209 Even minor variations in gold standard 
GFR techniques have shown to result in significant changes in carboplatin dose.210 The 
various equations for estimating GFR and dosing have complicated a standard application 
of renal function-based dosing of carboplatin in paediatrics and while individual targeting 
of carboplatin exposure would be ideal, many paediatric treatment protocols still use a flat, 
fixed dose.211 As many paediatric oncology patients are included in national and international 
trials, it is imperative that the methodology of estimating GFR and carboplatin dose is stan-
dardized, so that the outcome data for these trials are not confounded by this factor.
We acknowledge some limitations to this study. First, we did not use a gold standard GFR 
technique for direct comparison with the eGFR equations. Therefore, we did not study the 
whether eGFR-adjusted carboplatin dosing can replace a gold standard GFR measurement. 
Many studies have examined the accuracy of GFR estimation models and international guide-
lines recommend the use of estimated GFR to monitor renal function in adults and children 
with kidney disease.55,56 Cystatin C-based eGFR equations have proven to correspond very 
closely to measured GFR in children, also in those at high risk for renal injury such as patients 
being treated for malignancy.103,212 External validation of the Newell formula in 38 patients 
using 51Cr-EDTA as gold standard GFR measurement yielded a 20% accuracy of 79%,66 which 
is somewhat higher than the 64% of the CKiD 2 equation in our study. However, 51Cr-EDTA is 
not available in all countries and centres and it is debatable whether the increased precision 
of this complex GFR measurement, outweighs the simplicity of a GFR estimating equation 
based on cystatin C. Second, our study population differed with regard to age-spectrum 
from the study populations in which the different equations were calibrated. Schwartz et al. 
included children aged between one and 16 years for the calibration of all three eGFR equa-
tions and Newell et al. studied only four children younger than one year. To the best of our 
knowledge there are no equations specifically designed for infants. Despite these shortcom-
ings we did not find a systematically worse predictive performance of the different equations 
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in infants compared to the older children. This is consistent with available data showing a 
poor predictive relationship between age and carboplatin clearance.213,214 Finally, all of the 
patients included in this study had normal renal function (creatinine ranged between 0.22 
and 0.33 mg/dL), defined as creatinine and cystatin C levels below the age-appropriate upper 
limit. Our results are therefore primarily applicable to patients with normal renal function and 
should be confirmed in patients with diminished GFR. It should be noted, however, that most 
children with cancer have normal or near-normal renal function.
In conclusion, for carboplatin dosing in children the use of estimated GFR based on cystatin 
C is preferred over the widely used creatinine-based Schwartz equation. Further prospective 
studies are needed to directly compare a gold standard GFR measurement with cystatin C in 
this setting.
Chapter 8
A simple formula based on cystatin C for 
individualized carboplatin dosing in children
Hester N. Blufpand, Bram J. Wilhelm, Gertjan J.L. Kaspers, Floor C.H. Abbink, 
Richard J. Honeywell, Frits J. Peters, Birgit Stoffel-Wagner and Arend Bökenkamp
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aBstraCt
Purpose: As carboplatin clearance is linearly related to glomerular filtration rate, the prin-
ciple of renal function-based dosing is widely accepted, although not always practiced. The 
prediction of carboplatin clearance could be improved by adding plasma cystatin C to other 
patient characteristics routinely used for dosing. We aimed to evaluate the usefulness of 
cystatin C as a predictor of carboplatin clearance in children and develop a simple model 
that can be used for dosing.
methods: We performed a population pharmacokinetic analysis on 78 clearance studies 
performed in 30 children with a wide spectrum of solid tumors, using non-linear mixed effect 
modeling. The influence of six covariates (sex, age, body weight, height, BMI, BSA, creatinine 
and cystatin C) on carboplatin pharmacokinetics was evaluated. The final model was vali-
dated using bootstrap analysis.
results: A two-compartment model was fitted to the time-concentration data. The best 
equation was: carboplatin clearance = 2.63 × 
cystatin C −0.637
0.695  × 


weight 0.790
15.72
with clearance in L/h, cystatin C in mg/L and weight in kilograms. The mean parameters 
obtained from the 1,000 bootstrap runs were almost identical to the estimates obtained 
from the original dataset, indicating the model is robust. Observed carboplatin concentra-
tions were accurately predicted by the final model. The correlation between observed and 
predicted clearance was almost perfect (R² = 0.92; P < 0.001). Bias (%MPE) and imprecision 
(%MAPE) of the final model were 1.8% and 15.6% respectively.
findings: A model based on cystatin C and weight gives the best prediction of carboplatin 
clearance in children. This simple model can be used for individualized dosing of carboplatin.
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introduCtion
Carboplatin is frequently used for the treatment of pediatric solid tumors and its use has 
gained popularity because it is associated with less toxicity than cisplatin.197,198 Carboplatin is 
almost exclusively cleared by glomerular filtration; its pharmacokinetics is therefore mainly 
determined by the patient’s renal function.63,64 Due to the linear relationship between carbo-
platin clearance and glomerular filtration rate (GFR), the principle of dosing based on renal 
function is widely accepted. To this end several dosing equations have been developed.63,72,73 
Renal function-based carboplatin dosing results in more reproducible and reliable drug 
exposure than flat dosing65,66 and real-time monitoring with adaptive dosing has been as-
sociated with more consistent platinum exposure in children.67 The importance of controlling 
carboplatin exposure is illustrated by the relationship between carboplatin area under the 
concentration-time curve (AUC), toxicity69,70,200 and clinical efficacy.68 Renal function-based 
dosing corrects for the marked interpatient variability in systemic exposure seen after flat 
dosing72,215 and for the physiological changes in renal function during childhood.24 Cur-
rently available dosing equations for children were all developed using a gold standard GFR 
measurement. Although accurate, these methods are not widely available and often are too 
cumbersome and costly for routine GFR measurement. In clinical practice the gold standard 
technique is often substituted by an estimated GFR (eGFR), leading to variable bias and 
imprecision.74,75 An alternative is a population pharmacokinetic analysis.71 The advantage of 
this approach is the potential use of simple measures of renal function (ie, serum creatinine), 
as opposed to gold standard techniques or complex eGFR equations. Moreover, it allows 
evaluating covariates that influence carboplatin clearance. This approach has been shown 
to reliably predict carboplatin clearance however not without bias.71,216,217 This may be due to 
the shortcomings of creatinine, which reflects GFR, but is also affected by renal tubular secre-
tion and muscle mass. Cystatin C (CysC) does not share these limitations. In adults, it has been 
proven to predict carboplatin clearance with a similar reliability as creatinine, and models 
based on a combination of creatinine and CysC have been demonstrated to be superior to 
those based on either marker alone.182,208 CysC is particularly promising for children since the 
problem of muscle mass dependency is even greater among them as muscle mass increases 
with age. However, the use of CysC for carboplatin dosing in children has not been prospec-
tively evaluated. The aim of the present study was to assess the value of CysC as a predictor of 
carboplatin clearance in children and to develop a simple model that can be used for dosing.
116 Chapter 8
methods
Patients and treatment
Thirty children were included in this prospective pharmacokinetic study. To be eligible pa-
tients had to be between 0 and 18 years old. The protocols according to which the included 
patients were treated are listed in Table 8.1. The study was carried out in concordance with 
the principles of the Declaration of Helsinki and was approved by the Institutional Review 
Board of VU University Medical Center. Written informed consent was signed by all patients 
or parents/guardians, as appropriate, before participating in the study.
Carboplatin administration, blood sampling and biochemical analyses
Carboplatin was administered intravenously, diluted in 5% dextrose (median 340 mg; range 
25-970 mg). After administration of carboplatin, all infusion lines were changed to prevent 
contamination of the samples. For hospitalized patients, blood samples (2mL) were obtained 
at 2.5, 8, 10 and 23 hours after start of infusion into lithium heparin tubes. To minimize the 
burden for outpatients, a limited sampling strategy with two samples (1.5 and 5 hours after 
start of infusion) was applied. All samples were immediately placed in an ice bath and cen-
trifuged (1500 x g at 4°C for 10 minutes), to separate the plasma from whole blood. In order 
to separate total from protein-bound platinum, ethanol precipitation was used as described 
previously.201 Renal function was assessed before each course of carboplatin. Creatinine was 
measured using an enzymatic method (Modular Analytics, Roche Diagnostics, Mannheim, 
Germany), which is traceable to isotope dilution mass spectrometry.122 CysC was measured 
from a frozen serum sample within one run using a particle-enhanced immunonephelomet-
ric assay (Siemens Healthcare, Marburg, Germany) on a Dade Behring Nephelometer II.
table 8.1. Baseline characteristics, treatment and biochemical variables
number median iQr
Patient characteristics
Female/male, N 11/19
Age, years 3·1 0·9 to 5·1
Body weight, kg 15·7 9·4 to 20·0
Height, cm 98·5 72·0 to 110·0
BSA, m² 0·65 0·43 to 0·78
BMI, kg/m² 16·8 15·4 to 18·7
Weight for height SDS 0·4 −0·6 to 1·3
BMI SDS 0·3 −0·5 to 1·3
Biochemical variables
Creatinine, mg/dL* 0·27 0·22 to 0·33
Cystatin C, mg/L 0·69 0·63 to 0·79
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Population pharmacokinetic modeling
A model of carboplatin, measured as free platinum, was developed using the non-linear 
mixed effect modeling program NONMEM (version 7.2 ICON Development Solutions, Ellicot 
City, MD)202 and assistant software Xpose and Pirana. All parameters were estimated using 
first-order conditional estimation method with interaction. On the basis of visual inspection 
of the data, a two-compartment model was selected.202 The pharmacokinetic parameters 
table 8.1. (continued)
diagnosis and treatment
Retinoblastoma; RB-VUmc 2010
 Carboplatin 560 mg/m² x 1 day (in 1 h)†
 Vincristine 1·5 mg/m² x 1 day
 Etoposide 150 mg/m² x 1 day
14
Wilms tumor SIOP WT 2004
 Carboplatin 200 mg/m² x 3 days (in 1 h)§
 Etoposide 150 mg/m² x 3 days
2
DIPG; Individualized protocol
 Carboplatin AUC 4·1 x 4 days (in 23 h)
 Etoposide 338 mg/m² x 4 days
 Melphalan 70 mg/m² x 3 days
1
Neuroblastoma; NBL 2004
 Carboplatin 500 mg/m² x 3 days (in 1 h)
 Etoposide 40 mg/m² x 1 day
 Melphalan 45 mg/m² x 4 days
2
Medulloblastoma; ACNS 0332
 Carboplatin 35 mg/m² x 5 days (in 0·25 h)
 Vincristine 1·5 mg/m² x 1 day
2
Low grade glioma; SIOP LGG 2004
 Carboplatin 550 mg/m² x 1 day (in 1 h)
 Vincristine 1·5 mg/m² x 1 day
4
Germ cell tumor; SIOP CNS GCT II
 Carboplatin 600 mg/m² x 1 day (in 1 h)
 Etoposide 100 mg/m² x 3 days
2
Hepatoblastoma; SIOPEL 4
 Carboplatin AUC 6·6 x 1 day (in 1 h)
 Doxorubicin 20 mg/m² x 2 days
2
sPNET‡ GPOH MET-HIT 2000-BIS4
 Carboplatin 200 mg/m² x 4 days (in 24 h)‡
 Etoposide 100 mg/m² x 4 days
and
 Carboplatin 500 mg/m² x 4 days
 Etoposide 250 mg/m² x 4 days
1
Abbreviations: AUC, area under the time-concentration curve; BMI, body mass index; BSA, body surface 
area; DIPG, diffuse intrinsic pontine glioma; eGFR, estimated glomerular filtration rate; IQR, interquartile 
range; SD, standard deviation; sPNET, supratentorial primitive neuroectodermal tumor. AUC is expressed in 
mg/mL.minute. †for children < 1 year: carboplatin 18·7 mg/kg, §for children < 12 kg: 2/3 of carboplatin dose, 
‡for children 7-12 months: 4/5 of carboplatin dose
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estimated with the model included systemic carboplatin clearance (Cl), volume of distribu-
tion of the central compartment (Vd), and inter-compartmental exchange rates (k12 and 
k21). The precision of the estimates was evaluated by the percentage relative standard error. 
Exponential models were used to describe between subject variability (BSV) and between 
occasion variability (BOV). The residual error, describing the remaining difference between 
observed and predicted drug concentrations, was modeled using a mixed proportional and 
additive error model.218
Different models describing the possible relation between carboplatin clearance and 
renal function were tested. In model I, the base reference (covariate-free) model, no relation 
between renal function and carboplatin clearance was assumed. Models II and III correspond 
to the Newell formula72, in which carboplatin clearance is predicted using eGFR based on 
creatinine25 or CysC60. In models IV and V the weight variable in the Newell formula was 
reestimated on our dataset. Model VI was used to analyze the best fitting relation between 
carboplatin clearance, demographic and anthropometric data and renal function. Eight co-
variates were considered: sex, age, height, body weight, body mass index, body surface area, 
serum creatinine and serum CysC. All continuous covariates were evaluated using the power 
model with covariates centered to their median value. First, univariate analysis of each covari-
ate was performed to determine its significance independent of other covariates. A covariate 
was considered statistically significant in the univariate analysis if the addition reduced the 
objective function value (OFV), which equals minus twice the log likelihood of the data by at 
least 3.84 (P < 0.05). The final model was built, using a forward stepwise approach, followed 
by a backward elimination process. With the backward elimination covariates were deleted 
one by one from the full model to confirm their relevance. Covariates that could be deleted 
without an increase in the OFV of at least 6.63 (p < 0.01) were removed from the model. 
This process was repeated until no more covariates could be removed, resulting in the final 
model (model VI). This model was internally validated by bootstrap analysis, using Wings for 
NONMEM. From the original dataset random draws of individual data with replacement were 
obtained (bootstrap sample). The final model was refitted to each new bootstrap sample, and 
this process was repeated 1,000 times with different random draws.
model prediction and statistical analyses
Since one objective of this study was to establish a model which could be used for individual-
ized dosing, we compared individual observed clearance values with values predicted by 
the final model. We calculated bias (ie, mean difference between observed and predicted 
carboplatin clearance), accuracy (proportion of predicted values within ± 20% of the cor-
responding observed value), percentage mean prediction error (%MPE; a measure of bias) 
and percentage mean absolute prediction error (%MAPE; a measure of precision).219
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Predicted values were plotted against observed values and least squares linear regression 
performed to calculate R². Diagnostic graphs and additional statistical analyses were made 
using IBM SPSS statistics 20 (Chicago, IL) and GraphPad Prism 5.0 (San Diego, CA).
results
Patients and pharmacokinetic parameters
A total of 256 platinum concentrations from 30 children (78 clearance studies) were available 
for analysis. Free platinum concentrations ranged between 0.0 and 68.8 (median 1.2) mg/L. 
The demographic and clinical characteristics of the patients are summarized in Table 8.1. 
Two patients had primary renal disease. All patients had normal renal function at diagnosis, 
defined as creatinine and CysC levels below the age-appropriate upper limit. In 26 clearance 
studies (33%) patients were younger than one year and/or weighed less than 10 kilograms. 
Carboplatin clearance was significantly lower in infants than in older children (57 [45-75] vs 
23 [18-27] ml/min respectively; P < 0.001). Twenty-three courses (30%) were conducted at the 
outpatient ward.
Covariate analyses and bootstrap evaluation
We found substantial variability in the parameter estimates of the base model (model I), with 
a BSV for carboplatin clearance of 28%. Significant covariates in the univariate analyses that 
explained BSV in clearance were CysC, weight, height and age (P < 0.001 for all). In contrast to 
CysC, addition of creatinine to the univariate analysis did not significantly improve the model. 
Addition of CysC significantly improved the model (P < 0.01) accounting for 26% of the BSV 
in clearance whereas this was only 17% for creatinine. Also, in model II (Newell formula with 
creatinine-based eGFR), a significantly higher OFV was observed compared to model III in 
which CysC-based eGFR was used (OFV 630.255 and 607.065 respectively; P < 0.001). Both 
models had significantly lower OFV compared to the basic model (∆OFV 20.317 and 43.507 
for models II and III respectively; P < 0.001 for both) and accounted for 72% (model II) and 
80% (model III) of the BSV in clearance. Reestimating the weight variable on our own dataset 
slightly improved the prediction, explaining another 4% and 5% of the BSV in clearance 
(models IV and V respectively).
The final covariate model was: carboplatin Cl = 2.63 × 
cystatin C −0.637
0.695  × 


weight 0.790
15.72
with clearance in L/h (for mL/min multiply by 16.67), weight in kilograms and CysC in mg/L. 
The covariates weight and CysC reduced the BSV of carboplatin clearance from 28% to 
2% (∆OFV −63.750; P < 0.001) and deletion of either covariate from the model resulted in 
a significant increase in the OFV, indicating that this model should be considered the best 
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fitting and final. Model VI reduced the BSV in clearance by 59%, when comparing with model 
III. Figure 8.1 shows the goodness-of-fit of the data. Observed carboplatin concentrations 
were generally in good agreement with individual concentrations predicted by the final 
model. Furthermore, the magnitude of the weighed residuals was small and not associated 
with predicted concentrations, indicating that the model accurately describes the data. The 
final model was subjected to internal validation by bootstrap analysis. The mean parameter 
estimates obtained from the 1,000 bootstrap runs were almost identical to the estimates 
obtained from the original dataset (Table 8.2), indicating that the final model is robust.
Performance of the final model
The individual observed carboplatin clearance values and predicted clearance values calcu-
lated with our final model are plotted in Figure 8.2. The model predictions are symmetrically 
distributed around the line of identity and the correlation is almost perfect (R² = 0.92; P < 
0.001), indicating that model performance is good. Table 8.3 shows bias, precision and ac-
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figure 8.1. Goodness-of-fit plots. Individual predicted carboplatin concentrations versus observed con-
centrations. The dotted line is the line of identity, the solid line is the line best fitting the data (y = 1·09 × 
−0·32). Inset, predicted concentrations versus conditional weighted residuals.
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curacy of the individual predicted clearances calculated with our final model and the Newell 
equation with CysC-based eGFR (model II). The mean bias of our final model is 0.04 L/h is 
significantly lower than the bias of the Newell equation (paired t-test; P = 0.001). Mean pre-
diction error (%MPE; a measure of bias), absolute mean prediction error (%MAPE; a measure 
of imprecision) and 20% accuracy were comparable.
disCussion
This work represents the first population pharmacokinetic analysis of carboplatin in children 
that considers CysC. We present a simple and accurate model based on weight and CysC to 
predict carboplatin clearance. With this model the dose for a patient can easily be calculated 
table 8.2. Model estimates and pharmacokinetic parameters obtained by NONMEM and bootstrap analysis
Carboplatin clearance = 2.63 × (cystatin C/0.695))−0.637 × (weight/15.72)0.790
nonmem analysis Bootstrap analysis
Clearance, l/h 2·63 (7·9) 2·615 (9·2)
θ on cystatin C −0·637 (24·8) −0·667 (27·0)
θ on weight 0·790 (10·0) 0·797 (11·2)
volume of distribution, l 5·7 (6·0) 5·664 (7·5)
θ on weight 0·774 (11·3) 0·790 (12·7)
k12, h−1 0·050 (32·1) 0·058 (43·1)
k21, h−1 0·032 (75·1) 0·048 (69·0)
Bsv on clearance, % 2·5 (92·9) 2·4 (105·9)
Bov on clearance, % 2·6 (37·3) 2·8 (48·5)
residual error* Proportional, % 26·1 (12·0) 25·8 (14·7)
additive, mg/l 0·28 (30·7) 0·25 (9·8)
Data are presented as median (%RSE)
*The proportional component of residual error is expressed as %, while the additive component is ex-
pressed as standard deviation Abbreviations: BOV, between-occasion variability; BSV, between-subject 
variability; %RSE, percentage relative standard error.
table 8.3. Comparison of predictive performance of our final model and the Newell formula based on 
cystatin C
measure newell final model
Mean bias, L/h 0·10 0·04
LOA, L/h −1·6 to 1·8 −1·8 to 1·9
MPE, % −2·4 0·2
MAPE, % 25·5 24·7
Accuracy, % 56 54
Abbreviations: LOA, limits of agreement; MPE, mean prediction error; MAPE, mean absolute prediction error
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since carboplatin pharmacokinetics is linearly related to dose (dose = target AUC x carbo-
platin clearance). Our model reduced the BSV in clearance by 92%, when comparing to a 
covariate-free model, stressing the need for pharmacokinetically guided carboplatin dosing 
in children. Furthermore, our results indicate that CysC is a better predictor of carboplatin 
clearance than the widely used creatinine.
Although the concept of renal function-based carboplatin dosing is widely accepted and 
supported by solid evidence,63,65,66 it has not replaced traditional dosing based on body sur-
face area or weight in children yet.220 The debate over the best method to determine GFR for 
carboplatin dosing has likely complicated the standard application of renal function-based 
dosing in children. When GFR is measured using a gold standard technique, a strong relation 
with carboplatin clearance exists.63,72 However, these techniques are invasive and involve 
undesirable effects such as radiation exposure and the need for multiple blood samples or 
bladder catheterization. In clinical practice GFR is often substituted by eGFR, however at 
the expense of accuracy.74,75,204,221,222 This is in line with our findings in a previous analysis 
(Blufpand et al., unpublished results). In that study the use of eGFR based on CysC was found 
     	 
  





	








	


	




	











figure 8.2. Predicted versus observed carboplatin clearance. Predicted carboplatin clearance calculated 
using the final model. The dotted line is the line of identity, the solid line is the line best fitting the data with 
equation y = 1·01x + 0·04
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to be an acceptable, but slightly biased alternative (%MPE = −2% and %MAPE = 26%). The use 
of creatinine-based eGFR resulted in significant bias and imprecision (%MPE and %MAPE of 
−37% and 43% respectively). Lindauer et al.217 also reported enormous bias and imprecision 
(%MPE and %MAPE both 77%) when using the Newell equation based on eGFR-creatinine. In 
their hands population pharmacokinetic models showed lower bias and imprecision; this is in 
keeping with the findings by Schmitt et al.208 and our results that model VI has a significantly 
lower OFV than model III. The major advantage of this approach is the use of simple measures 
of renal function as opposed to the isotopic tracer technique used by Newell et al.72.
After testing several covariates, we found that weight and CysC concentration strongly 
influence carboplatin clearance. Our final model, like the Newell equation, consists of a renal 
component and a weight variable, describing the non-renal component of carboplatin clear-
ance. In our hands CysC was a better renal predictor of carboplatin clearance than creatinine. 
This is in agreement with previous findings that the influence of CysC on clearance was 
greater than for creatinine, while deletion of CysC from the final model resulted in more bias 
and imprecision than deletion of creatinine208. This confirms the benefit of CysC as a marker 
of renal elimination of drugs when used in conjunction with other demographical or anthro-
pometric covariates. In contrast to our results, a model based on both renal function markers 
performed significantly better than a model based on either one, indicating that creatinine 
and CysC are not completely redundant markers of GFR. The model including creatinine and 
CysC had a predictive performance comparable to our final model (OFV 585.138 and 586.822, 
respectively). This difference between their results and ours most likely reflects the limitations 
of creatinine, which is influenced by nonrenal factors such as age, gender and muscle mass. 
As muscle mass increases with age in childhood, the problem of muscle mass dependency 
is even greater in pediatric patients and severely hampers the use of creatinine in children. 
CysC is also associated with some sources of error of which the influence by disorders of 
thyroid function and high-dose glucocorticoid therapy are the most important in the setting 
of dosing of anti-cancer drugs. However, extra-renal elimination is significantly smaller than 
for creatinine88. The best covariate model based on creatinine (BSV 3%) was:
carboplatin clearance = 2.77 × 
creatinine −0.204
0.27  × 


weight 0.47
15.72  × 


height 1.07
98.5
We acknowledge some limitations of this study. First, all patients included in this study had 
normal renal function. Thus, our results are primarily applicable to patients with normal renal 
function and should be confirmed in patients with diminished GFR. However, since most 
children with cancer have (near-) normal renal function, our results are applicable to the vast 
majority of this population. Second, we did not externally validate our final model. However, 
internal validation by bootstrap analysis indicates the model is robust since the parameter 
estimates obtained from the bootstrap runs were almost identical to the estimates obtained 
from the original dataset. Prospective validation of our model, evaluating predictive per-
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formance and toxicity is essential. This is currently being addressed in our institution. Third, 
we did not use a gold standard GFR technique for direct comparison with our final model. 
Therefore, we did not study whether renal function-based carboplatin dosing can replace a 
dosing equation based on a gold standard GFR measurement. This was beyond the scope 
of our project. Finally, our patients were relatively young and it remains to be established 
whether our model is similarly useful in older children
In conclusion, we developed and internally validated a simple model, based on cystatin C 
and body weight, for individualized carboplatin dosing in children. Future studies are needed 
to externally validate this model.
Chapter 9
Failure to correct for renal function results 
in highly imprecise carboplatin exposure 
in children
Hester N. Blufpand, Arend Bökenkamp, Bram J. Wilhelm, Floor C.H. Abbink, 
Richard J. Honeywell, Frits J. Peters and Gertjan J.L. Kaspers
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aBstraCt
introduction: Although the concept of renal function-based carboplatin dosing is well-
established in children, this dosing method is not routinely practiced. Failure to correct for 
renal function may result in highly variable carboplatin exposure, with the risk of adverse 
effects or suboptimal treatment. We set out to compare carboplatin exposure in children 
after flat dosing with targeted exposure.
methods: In 30 children with a wide spectrum of solid tumors, the area under the concen-
tration-time curve (AUC) was calculated after 78 courses of carboplatin using NONMEM. 
Observed AUC values were compared with target values, calculated as 1.325 mg/mL.minute 
per 100 mg/m² of protocol dose. Bias, precision and accuracy within 20% of target AUC were 
calculated.
results: Median observed AUC as a percentage of target AUC was 89% (range 43%–236%). 
AUC within 20% of target was achieved in 42% of courses. This proportion was slightly lower 
in infants (27%) than in older children (44%; P = 0.139). In infants, most measurements fell 
below 80% of the target value (62%), as opposed to 23% underestimation in older children 
(P = 0.001).
Conclusion: Flat carboplatin dosing results in highly variable drug exposure, particularly in 
infants, with the risk of toxicity as well as a lower cure-rate. This once more underscores the 
importance of renal function-based carboplatin dosing in children.
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introduCtion
The platinum complex carboplatin is frequently used for the treatment of pediatric solid 
tumors. Although generally not labeled for pediatric patients, its use has gained popularity 
in the last decades because carboplatin displays less nonhematologic toxicities than cis-
platin.197,198 The primary cytotoxic action of carboplatin is mediated by platinum covalently 
binding to DNA, leading to the formation of intra- and interstrand crosslinks. This results in 
cell cycle arrest and eventually cell death.223 Carboplatin has a narrow therapeutic window 
between efficacy and toxicity and considerable interpatient variability in drug tolerability 
and response exists in children.72,215 Studies have shown that therapeutic and toxic effects 
associated with carboplatin administration are better correlated with plasma carboplatin 
concentrations and the area under the concentration-time curve (AUC), than the dose.68,69 As 
carboplatin is almost exclusively eliminated by glomerular filtration, dosing based on renal 
function with the intention of achieving a specific, protocol-dependent AUC is recommended 
to minimize toxicity and maintain the target concentrations required for efficacy.63,64,197 
Indeed, renal function-based dosing of carboplatin results in more reproducible and reliable 
drug exposure than flat dosing in children.65-67 Nevertheless, this dosing approach is not 
routinely practiced, particularly when carboplatin is administered at conventional doses.220 
The objective of this study was to evaluate systemic carboplatin exposure after flat dosing in 
children and study its relationship with clinical toxicity.
methods
Patients and treatment
Thirty children were included in this prospective pharmacokinetic study. To be eligible pa-
tients had to be between 0 and 18 years old and scheduled to receive carboplatin, according 
to the protocols listed in Table 9.1. For the patients dosed according to body surface area or 
body weight, the target AUC was 1.325 mg/mL.minute per 100 mg/m² of the protocol dose 
of carboplatin that each patient was scheduled to receive. The value of 1.325 mg/mL.minute 
per 100 mg/m² was determined from the median carboplatin plasma clearance in the 22 
pediatric patients the Newell dosing formula was developed in.72 The study was carried out 
in concordance with the principles of the Declaration of Helsinki and was approved by the 
Institutional Review Board of VU University Medical Center. Written informed consent was 
signed by all patients or parents/guardians, as appropriate, before participating in the study.
Carboplatin administration and blood sampling
Carboplatin was administered intravenously, diluted in 5%. After administration of carbopla-
tin, all infusion lines were changed to prevent contamination of the samples. Blood samples 
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(2 mL) for pharmacokinetic analysis were obtained from a central line into lithium heparin 
tubes. For hospitalized patients, samples were obtained at 2.5, 8, 10 and 23 hours after the 
start of infusion. To minimize the burden for outpatients, a limited sampling strategy with two 
samples (1.5 and 5 hours after the start of infusion) was applied. Free platinum was isolated 
using ethanol precipitation and measured by flameless atomic absorption spectrophotom-
etry (AA 800, Perkin Elmer, Waltham, MA) as described previously.201
Pharmacokinetics-pharmacodynamic relationship
To investigate possible relationships between carboplatin exposure (AUC) and clinical toxic-
ity, data were collected for the period immediately after carboplatin administration until 
the next course. Hemoglobin, thrombocyte, leukocyte and neutrophil levels were measured 
before and as often as clinically indicated after the course, however at least once.
statistical analysis
Observed carboplatin AUC values were plotted against targeted values and least squares 
linear regression performed to calculate R². The binary outcome carboplatin exposure within 
20% of the target AUC (20% accuracy), a measure of bias and precision, was calculated. Since 
table 9.1. Treatment protocols
disease and protocol no. of 
patients
duration infusion
(hours)
Concomitant drugs 
(mg/m²)
Carboplatin dose
(mg/m²)
Retinoblastoma*
RB-VUmc 2010
14 1 Vincristine 1.5
Etoposide 150
560 x 1 day
Wilms tumor†
SIOP WT 2004
2 1 Etoposide 150 x 3 days 200 x 3 days
DIPG
Individualized protocol
1 23 Etoposide 338 x 4 days
Melphalan 70 x 3 days
AUC 4.1§ x 4 days
Neuroblastoma
NBL 2004
2 1 Etoposide 40
Melphalan 45 x 4 days
500 x 3 days
Medulloblastoma
ACNS 0332
2 0.25 Vincristine 1.5 35 x 5 days
Low grade glioma
SIOP LGG 2004
4 1 Vincristine 1.5 550 x 1 day
Germ cell tumor
SIOP CNS GCT II
2 1 Etoposide 100 x 3 days 600 x 1 day
Hepatoblastoma
SIOPEL 4
2 1 Doxorubicin 20 x 2 days AUC 6.6§ x 1 day
sPNET‡
GPOH MET-HIT 2000-BIS4
1 24 Etoposide 100 x 4 days 200 x 4 days and
500 x 4 days
Abbreviations: AUC, area under the time-concentration curve; DIPG, diffuse intrinsic pontine glioma;
sPNET, supratentorial primitive neuroectodermal tumor. *for children < 1 year: carboplatin 18.7 mg/kg 
†for children < 12 kg: 2/3 of carboplatin dose ‡for children 7-12 months: 4/5 of carboplatin dose § in mg/
mL.minute
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most treatment regimens advise to adjust dosing in young children to a per kilogram of body 
weight dose, we compared infants (defined as younger than one year or body weight below 
10 kilograms) with older children using nonparametric methods (Wilcoxon rank sum test for 
continuous variables and McNemar’s test for binary outcome measures). Linear regression 
analysis was used to indicate correlations between observed AUC values and percentage fall 
in cells. Continuous variables are presented as median [interquartile range; IQR]. Qualitative 
variables are displayed as numbers (%). Diagnostic graphs and statistical analyses were made 
using IBM SPSS statistics 20 (Chicago, IL) and GraphPad Prism 5.0 (San Diego, CA). A two-
sided P-value below 0.05 was considered statistically significant.
results
Patients and treatment
Seventy-eight courses of carboplatin were studies in the 30 children included. The demo-
graphic and clinical characteristics of the patients are summarized in Table 9.2. A third of 
the patients was female and 47% was treated for retinoblastoma. Two patients had primary 
renal disease. All patients had normal renal function at diagnosis, defined as creatinine and 
cystatin C levels below the age-appropriate upper limit. Twenty-two (73%) patients were 
studied during multiple courses. Four children were studied twice, eight were studied three 
times and 10 children were studied during four carboplatin courses (median of three clear-
ance studies per patient with 21.0 [7.2-28.8] days between clearance studies). In 26 clearance 
studies (33%) patients were younger than one year and/or weighed less than 10 kilograms. 
Twenty-three courses (30%) were conducted at the outpatient ward.
table 9.2. Baseline characteristics
number of clearance studies 78
Female/male, N 11/19
Age, years 3.1 [0.9-5.1]
Body weight, kg 15.7 [9.4-20.0]
BSA, m² 0.65 [0.43-0.78]
BMI, kg/m² 16.8 [15.4-18.7]
Weight for height SDS 0.4 [−0.6-1.3]
BMI SDS 0.3 [−0.5-1.3]
Creatinine, mg/dL 0.3 [0.2-0.3]
Cystatin C, mg/L 0.69 [0.63-0.79]
Data are presented as median [IQR] Abbreviations: BMI, body mass index; BSA, body service area; eGFR, 
estimated glomerular filtration rate; IQR, inter quartile range; SD, standard deviation.
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Pharmacokinetics
For the patient population as a whole, absolute observed carboplatin AUC values ranged 
from 0.3 to 15.6 mg/mL.minute and showed a highly significant relationship with observed 
AUC values (range 0.5 to 8.0 mg/mL.minute) (Figure 9.1). The correlation between target and 
observed AUC was weaker in the infant (R² = 0.137) than in the older children group (R² = 
0.589). The median observed AUC as a percentage of target AUC was 89% [74-123%] and 
ranged between 43% and 236%. Forty-two percent of patients received a carboplatin expo-
sure within 20% of the target AUC (Figure 9.2). In the infant group the median drug exposure 
was 75% [60-87] of the target AUC, compared to 106% [82-131] in the older children (P = 
0.135). The proportion of observed AUC values within ± 20% of respective targeted AUC did 
not differ between the infant and children age group (27% and 44%, respectively; P = 0.139). 
However, as can be seen in Figure 9.2, most of the measurements outside the 20% limits of 
the target AUC in the infant group fell below 80% of the target value (62% underestimation 
of target), as opposed to 23% underestimation in older children (P = 0.001).
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figure 9.1. Absolute observed AUC versus target AUC. The solid line is the line of identity
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Clinical toxicity
Toxicities observed after treatment with carboplatin containing regimens included cytope-
nia, mucositis, nausea, vomiting, alopecia, tubulopathy and infection. Severe hematological 
toxicity (CTC grade 3 or 4)224 was observed in 24%, 32% and 85% for anemia, thrombocyto-
penia and neutropenia, respectively. No treatment deaths were observed in this study. There 
was no significant relationship between the percentage fall in hemoglobin, thrombocytes, 
leukocytes or neutrophil count and either carboplatin AUC.
disCussion
Our results indicate that flat dosing of carboplatin in children is reasonably accurate (unbi-
ased) with an observed mean AUC value of 101% of target value, however highly imprecise 
with 58% of observed AUC values outside ± 20% of the target value.
These results once more stress that failure to correct for the patient’s renal function results 
in impredictable carboplatin exposure with the risk of adverse health effects. Although 
various measures such as aggressive hydration have helped to reduce the incidence of 
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figure 9.2. Observed AUC as proportion of target AUC. The horizontal lines indicate median AUC values.
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nephrotoxicity, prolonged or high-dose courses still predispose patients to renal and other 
toxicities, of which myelosuppression is the most relevant and dose-limiting toxicity. Equally 
if not more important is the risk of underdosing and lower cure-rate. In our hands, 36% of 
the study population received an AUC below 20% of the target AUC. For infants this propor-
tion was as high as 62%. This is clinically relevant as evidenced by the finding that a dose 
reduction of only 10% may expose patients to a poorer outcome.225 Although the concept of 
renal function-based dosing is widely accepted and supported by solid evidence66 it is not 
routinely applied in children.220 This most likely reflects the fact that dosing formulas rely on 
complex gold standard GFR measurements.72,73,226
In adults the carboplatin AUC has been correlated to clinical toxicity, with more severe 
toxicity seen in patients with higher AUC levels.63,200 We did not find a significant relation-
ship between carboplatin exposure and hematological or renal toxicity. This is in keeping 
with findings by Thomas et al.66 who also did not find a relationship between the percentage 
fall in thrombocyte of leukocyte count and carboplatin AUC. In this study as well as ours, 
the majority of patients (80%) were treated with combinations of myelosuppresive drugs; 
hence, relationships between carboplatin AUC values and hematologic toxicity were not 
anticipated. Concomitant chemotherapy varied between patients both in terms of the 
drugs and the doses used, further reducing the likelihood of identifying any independent 
effect of carboplatin. Moreover, the frequency of blood sampling (on average weekly) may 
have resulted in an inaccurate estimation of nadir hematologic cell counts, such that not all 
relationships between carboplatin exposure and toxicity were detected. Furthermore, 36% 
of our study population received an AUC of less than 80% of targeted. This high proportion 
of patients with low exposure also may have contributed to the lack in correlation between 
AUC and clinical toxicity in our study population. In two patients with considerable toxicity 
(including nausea, vomiting and cytopenia), renal function-based dosing targeting an AUC 
of 6.5 mg/mL.minute resulted in a dose reduction of 15% and clearly better clinical condition. 
We acknowledge some other limitations of this study. We did not evaluate clinical response 
data due to the potential role of concomitant chemotherapy on tumor response. In studies 
with adult patients, carboplatin exposure has been shown to correlate with outcome and 
clinical efficacy.68,227 Pharmacokinetic studies evaluating this relationship in children are war-
ranted. Finally, our patients were relatively young and it remains to be established whether 
these results can be extrapolated to older children.
In conclusion, flat dosing of carboplatin results in highly imprecise drug exposure with the 
risk of toxicity and lower cure-rate, once more stressing the need for renal function-based 
dosing of this drug in children.
Chapter 10
General discussion
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PediatriC onConePhrology
This thesis focuses on the intersection between childhood cancer and the kidneys, or 
‘pediatric onconephrology’. The association between kidney disease and cancer has been 
long recognized, but this field is now rapidly evolving. A Google search using the term 
onco-nephrology returned 3010 hits; none of these hits was for an entry before 2010. Indeed, 
certain nephrologic complications such as tumorlysis syndrome228 and renal late-effects22 are 
unique for the field of pediatric oncology, whereas others such as acute kidney injury229 have 
close association with childhood cancer. Children with cancer are susceptible to a variety 
of potentially serious renal complications related to their malignancy or its treatment. The 
interaction between the renal clearance of drugs used in the treatment of childhood cancer 
and toxicity sometimes poses complex situations. The double-edged sword of chemotherapy 
toxicity is best exemplified by the drugs methotrexate and, to a lesser extent, carboplatin. 
These drugs are both nephrotoxic and cleared primarily by the kidney; thus drug-induced 
glomerular dysfunction leads to delayed elimination and the resulting sustained, elevated 
plasma concentrations may lead to a marked enhancement of other toxicities. Another ex-
ample is the group of vascular endothelial growth factor (VEGF) inhibitors that is increasingly 
used for the treatment of pediatric central nervous system tumors. These drugs are associ-
ated with chronic kidney disease, proteinuria and hypertension.230 More insight into the renal 
complications of VEGF inhibitors has resulted in a better understanding of the functioning 
of the glomerular filter, valuable information for both oncologists and nephrologists.231 The 
advances in cancer management present new challenges for (pediatric) oncologists and 
nephrologists. In the care for adults with cancer, the field of onconephrology has recently 
earned attention by specialty societies such as the American Society of Nephrology and the 
National Kidney Foundation, as well as several prominent journals.232,233 Although treatment 
of childhood cancers differs from treatment given to adults and children often have unique 
patterns of toxicities as compared to their adult counterparts, a similar evolution is needed 
in pediatric oncology to address kidney problems. Understanding of the different renal func-
tion measures is a fundamental first step in correct assessment of renal function.
Since treatment for childhood cancer is often embedded in clinical research protocols, 
so are the recommendations for toxicity monitoring. The first childhood cancer protocol 
for acute lymphoblastic leukemia dated from 1954 and was eight pages long.234 More than 
50 years later, protocols containing over 200 pages are no exception, with new protocols 
frequently adding components but rarely eliminating them. Treatment protocols have 
obviously evolved over time, driven by new knowledge as well as increasing regulatory 
requirements. Moreover, protocols originate from disease-based research groups. This has 
resulted in a diversion of approaches to protocol development, as evidenced by the high 
degree in variability in protocol-based recommendations for renal function monitoring and 
chemotherapy dosing of nephrotoxic drugs across clinical pediatric oncology studies (Chap-
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ter 6). This is unwanted from a clinical and research standpoint and calls for standardization. 
Such a risk-based, standardized approach for surveillance, screening, management as well 
as prevention of adverse effects has already successfully been implemented for childhood 
cancer survivors.14,193,235
renal funCtion in Childhood CanCer
Accurate assessment of renal function in children is essential. However, in comparison with 
adults this has received less attention, perhaps in part because of the lower burden of chronic 
kidney disease (CKD) in the pediatric population.105 As stated in our review in Chapter 2, a 
fundamental parameter to evaluate renal function is the glomerular filtration rate (GFR). GFR 
is the classic measure of renal function and describes the amount of plasma that is filtered by 
the glomeruli per unit of time. Since GFR cannot be measured directly, it relies on the concept 
of clearance, which measures how quickly a marker present in the bloodstream is eliminated 
by the kidneys. The classic gold standard to determine GFR is the renal clearance of inulin. In 
1934, while studying water reabsorption in the renal tubules of amphibians, Richards found 
that the polysaccharide inulin (a fructose polymer made from the Jerusalem artichoke) is 
freely filtered through collodion membranes and not absorbed. Inulin is one of the few 
molecules that satisfies the requirements of an ideal marker of glomerular filtration, namely 
exclusive elimination by glomerular clearance and neither tubular secretion nor extra-renal 
excretion. Measuring the renal clearance of inulin is complicated and expensive and there is 
limited availability of inulin, restricting its use in pediatric clinical practice. Therefore, alterna-
tive gold standard methods for the measurement of GFR have been developed. Recently the 
Swedish Council on Health Technology Assessment has graded the evidence on frequently 
used alternative methods and compared them to the renal clearance of inulin (Table 10.1).152 
The most accurate alternatives still involve urine collection, radiation exposure and the risk 
of contrast-induced nephrotoxicity, limiting their use in children. Moreover, there is limited 
availability of these techniques, even in tertiary care centers. A survey among all treatment 
centers of the Dutch Childhood Oncology Group revealed that not all centers have a method 
to actually measure GFR at their disposal. This underscores the importance of other accurate 
options for estimation of GFR in childhood cancer patients.
Alternative options are frequently based on serum creatinine. This is the most commonly 
used endogenous marker of renal function and although widely available and inexpensive, 
its usefulness is hampered in children with cancer. This is mainly due to its dependency on 
muscle mass, which is often diminished in this patient group. As creatinine production is 
proportional to muscle mass, its concentration varies in children on the basis of gender, age 
and race.113 Interindividual variation in creatinine accounts for 93% of its biological vari-
ability.236 A serum creatinine level of 80 μmol/L in a 17-year-old boy would be considered 
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normal whereas this same creatinine level in a 4-year-old would represent advanced renal 
impairment. This illustrates the need for narrow age-specific reference ranges as reported by 
Pottel et al. (Table 3.1).123 However, assessing GFR from serum concentrations alone requires 
implicit judgments that are difficult for pediatric oncologists, including reciprocal transfor-
mations, consideration of non-GFR determinants and conversion to the GFR scale. Given the 
challenges that serum levels present to clinicians in distinguishing normal from abnormal 
and to researchers in assessing and comparing renal function among children of all ages 
and sizes, the utility of accurate GFR estimation, expressed in mL/minute/1.73 m² is obvious. 
Textbox 10.1 demonstrates the importance of relying on estimated GFR instead of serum 
concentrations of creatinine. In this example creatinine levels remained below the age-
specific upper-limit for a long time because of the poor nutritional status of the patient. This 
resulted in overestimation of GFR and severe toxicity. In adults with cancer the prevalence of 
renal impairment also is routinely underestimated when physicians evaluate renal function 
using serum concentrations of a marker alone, as shown by the results in the BIRMA study. 
Sixty-five percent of patients with normal serum creatinine levels had a decreased GFR.42 As 
the limitations of creatinine in children are far greater than in adults, this number is likely to 
be even higher in this patient group.
Currently, the most robust pediatric eGFR formulas come from the Chronic Kidney Disease 
in children (CKiD) studies by Schwartz et al.25,60 The ‘bedside’ Schwartz equation is most com-
monly used and based on the patient’s creatinine concentration and height to calculate GFR. 
The mandatory height information likely contributes to the problem of physicians relying on 
serum levels of endogenous markers alone. It precludes automatic reporting of estimated 
GFR by the clinical laboratory, since most laboratory systems cannot easily access anthropo-
metric patient data. Flagging of decreased GFR values by the laboratory can alert clinicians to 
the possibility of renal impairment and may prompt additional investigations or treatment, 
including dose adjustments of drugs that are cleared by the kidneys.
table 10.1. Accuracy of alternative index methods for measurement of GFR.152
index method sufficient accuracy strength of evidence
51Cr-EDTA renal clearance
Iothalamate renal clearance
Yes ⊕⊕⊕⊕
51Cr-EDTA plasma clearance
Iohexol plasma clearance
Yes ⊕⊕⊕⊖
DTPA renal clearance
Iohexol renal clearance
Inulin plasma clearance
Yes ⊕⊕⊖⊖
Urinary creatinine clearance (24 h) No ⊕⊕⊕⊕
DTPA plasma clearance No ⊕⊕⊖⊖
Iothalamate plasma clearance Data not available ⊕⊖⊖⊖
Requirements for sufficient accuracy: P10 ≥ 50%, P30 ≥ 80% (the percentage of results measured with the 
index method that fall ± 10% and 30%, respectively, of corresponding renal inulin clearance value and 
the percentage of bias ≤ ± 5% (the median error between the index method and renal clearance of inulin)
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The use of a height-independent equation108 showed comparable diagnostic accuracy as 
the bedside Schwartz equation (Chapter 3) and might be a good solution to this problem. 
We were the first to externally validate this equation and further studies are needed to deter-
mine its accuracy and robustness across different age groups and CKD stages. Given the low 
burden of CKD in the pediatric population, validation in large cohorts of children with (near) 
normal renal function is needed.
Cystatin C is licensed for use as a measure of renal function in most European countries and 
the United States for over 10 years. In certain countries such as Sweden and China, cystatin C 
is routinely measured. Given its independency from muscle metabolism, cystatin C has been 
proposed as a more reliable renal function marker than creatinine, particularly in patients 
with severe muscle wasting. Interindividual variation in cystatin C accounts for 25% of its 
textbox 10.1.
A five-year old girl with a blanc medical history was diagnosed with a large, fast growing 
intra-abdominal germ cell tumor. At diagnosis she had a creatinine level of 28 μmol/L 
(eGFR according to Schwartz 157 mL/minute/1.73 m²) and mild hydronehrosis with 
symptoms of urinary incontinence caused by tumor compression. She started treatment 
according to the MAKEI 2005 protocol for extra-cranial germ cell tumors, consisting of 
three pre-operative PEI courses (cisplatin 20 mg/m²/day days 1-5, etoposide 100 mg/
m²/day days 1-3 and ifosfamide 1500/m²/day days 1-5). At initiation of the first course 
her creatinine level was 38 μmol/L, which still was below the age-specific upper-limit of 
our laboratory (42 μmol/L). However, this corresponds to a fall in GFR of 25%. On day 
two of the course her creatinine level started increasing rapidly. On day four it was 85 
μmol/L and the last dose of cisplatin was omitted. Her creatinine level was highest on day 
10 (327 μmol/L), after that it gradually decreased in three weeks to around 100 μmol/L. 
Besides nephrotoxicity she suffered severe other toxicities including nausea, vomiting, 
mucositis, cytopenia, sepsis, urinary electrolyte wasting and hypertension, all requiring 
hospitalization and medical treatment. After four weeks her clinical condition and labora-
tory parameters had stabilized and it was decided to switch to the less toxic modified JEB 
courses according to UK Germcell III protocol (carboplatin AUC 7.9 mg/mL.minute on day 
2, etoposide 100 mg/m²/day days 1-3 and vincristine 2 mg/m²/day on day 3). The carbo-
platin dose was based on a gold standard GFR measurement (29 mL/minute/1.73 m²). 
Regardless aggressive hydration her creatinine level started rising right away (maximum 
205 μmol/L) and she suffered the same symptoms as during the first course, although 
less severe. After she recovered from the second course the tumor was resected. Eighteen 
months after diagnosis she has persistent glomerular dysfunction with a stable creatinine 
level of around 110 μmol/L (estimated GFR 40 mL/minute/1.73 m²), renal Fanconi syn-
drome and hypertension.
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biological variability, compared to 93% for creatinine.236 Thus, the upper limit of the popula-
tion reference interval for cystatin C is seldom more than 4 standard deviation scores from 
the mean value for any healthy individual (compared to 13 standard deviation scores for 
creatinine). Cystatin C is associated with some sources of error, as displayed in Table 10.2. The 
most relevant source of error in the setting of childhood cancer is glucocorticoid therapy, 
which is routinely used in children with cancer. However, results regarding this association 
are discordant. In vitro data show a dose-dependent increase in cystatin C production in 
HeLa cells exposed to high doses of dexamethasone237 and several clinical studies also report 
an increase in the production of cystatin C after receiving high doses of glucocorticoids.53,238 
Bökenkamp et al.53 report increased levels of cystatin C in children on steroid therapy. These 
authors found a very weak, but statistically significant (B = −0.0023; P = 0.045) negative rela-
tionship between steroid dose and cystatin C. However, in this study a paired analysis in 16 
children with leukemia, before and during dexamethasone therapy, revealed no significant 
change in cystatin C or cystatin C-based eGFR. Abbink et al.239 report a significant negative 
relationship between cystatin C-based eGFR and prednisone dose in children (of which 40% 
with a malignancy). For every 1 mg/m² of prednisone per day, the cystatin C-based eGFR 
underestimated actual GFR by 0.2 mL/minute/1.73 m². For low to moderate steroid doses of 5 
to 20 mg/m²/day this results in a negligible error in GFR estimation of 1 to 4 mL/minute/1.73 
m², particularly in patients with normal renal function. Moreover, the use of glucocorticoids 
table 10.2. Sources of error in estimating GFR using creatinine or cystatin C
source of error example
Creatinine
Factors affecting production
Race/ethnicity
Muscle wasting diseases
Extremes of muscle mass
Extremes of body size
Diet and nutritional status (e.g. cooked meat high protein diets)
Factors affecting tubular secretion Decreased by drug-induced inhibition (e.g. trimethoprim)
Factors affecting extra-renal elimination
Dialysis
Increased by large volume losses of extracellular fluid
Higher GFR
Higher biological variability in non-GFR determinants relative to GFR
Higher measurement error in serum creatinine and GFR
Interference with assay e.g. high bilirubin, glucose and ketones levels, certain drugs
Cystatin C
Factors affecting cystatin C production
Race/ethnicity
Disorders of thyroid function
High-doses of glucocorticoids
Factors affecting extra-renal elimination Increased by severe decrease in GFR
Higher GFR
Higher biological variability in non-GFR determinants relative to GFR
Higher measurement error in serum cystatin C and GFR
Interference with assay Heterophilic antibodies
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did not affect cystatin C’s ability to accurately detect impaired renal function. Similar find-
ings were reported in 33 adults taking low to high doses of prednisone; notwithstanding a 
dose-dependent increase in cystatin C values, this marker was still found to detect impaired 
renal function with more accuracy than creatinine.54 Foster et al.96 and Schwartz et al.60 also 
reported no relationship between low to moderate glucocorticoid doses and cystatin C 
concentrations, which is in keeping with results in children with nephrotic syndrome treated 
with prednisone 20-60 mg/m²/day.240 Although we excluded patients on glucocorticoids 
in Chapter 5, these findings do not indicate that the use of cystatin C as a renal function 
marker in children with cancer on glucocorticoid therapy should be ruled out. These data 
illustrate the importance of taking glucocorticoid therapy into account when interpreting 
serum cystatin C concentrations. Moreover, it stresses the need for specific reference intervals 
for patients on glucocorticoids. When high doses of glucocorticoids are administered, the 
cystatin C-based eGFR should be corrected as proposed by Abbink et al.239 For renal function-
based carboplatin dosing the use of cystatin C is less of a problem since glucocorticoids are 
mostly used in the treatment of hematological malignancies, whereas carboplatin is used for 
solid tumors. Future clinical studies should focus on the dose-effect of this group of drugs 
in children with cancer in more detail to provide specific reference intervals and estimating 
equations.
As with creatinine, GFR estimates based on cystatin C are more accurate than the serum 
concentration alone. When comparing the most accurate estimating equations for adults, 
the smaller magnitude of the coefficients for cystatin C, compared to those for creatinine, is 
striking.57,241 This presumably reflects less contribution of muscle mass to cystatin C produc-
tion than to creatinine production. Indeed, in children with cancer who often have moderate 
to severe muscle wasting, cystatin C-based estimated GFR using the Filler equation was less 
biased and more accurate than estimated GFR based on creatinine (Chapter 5). We found 
that creatinine, in contrast to cystatin C, significantly overestimated measured GFR in chil-
dren with cancer. Furthermore, 82% of cystatin C-based GFR estimates were within 30% of 
measured GFR, as opposed to 72% of creatinine-based estimates. These findings are in line 
with those by Chew et al.242 who found that two creatinine-based GFR estimating equation 
significantly overestimated GFR measured by 99mTc-DTPA, as opposed to five cystatin C-based 
equations, in 57 adult oncology patients. The most accurate cystatin-based equation in their 
cohort established a 30% accuracy of 89% compared to 56% of the best creatinine-based 
equation. Larsson et al.173 found significantly lower values for a cystatin C-based GFR estimate 
compared to a creatinine-based estimate in adults with cancer, which was not observed in 
non-oncological patients. This is confirmed by Nehus et al.212 who compared several esti-
mating equations in 141 children (with normal renal function) at high risk for renal injury, 
including 44 with cancer and/or stem cell transplantation, with GFR measured by 99mTc-DTPA.
As cystatin C is expressed in malignant tissue there has been concern whether cystatin C 
concentrations might be influenced by tumor load. An initial report by Kos et al.176 found such 
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an association, however the authors failed to correct for renal function. Later studies, includ-
ing the one described in Chapter 5, have not demonstrated a correlation between cystatin C 
concentrations and tumor burden.178,243-245
Cystatin C can be measured by different immunoassays, leading to variation in reported 
concentrations. However, analytic variation in cystatin C appears less common compared 
to creatinine.55 In 2010 the International Federation of Clinical Chemistry released a 
reference material for cystatin C measurement and reagent manufacturers are now in the 
process of recalibrating their assays against this standard.62 This will enable standardized 
reporting of cystatin C and cystatin C-based estimated GFR. As described in Chapter 4, our 
assay-independent eGFR equation (CAPA equation) based on this reference material showed 
excellent accuracy in children, with 80% of eGFR values within 30% of measured GFR. This 
is comparable with the cystatin C formula developed by Schwartz et al. in the CKiD study 
(83%) and higher than values reported by Filler et al.,59 Zappitelli et al.61 and Larsson al.246 
Our CAPA equation has three important advantages; it is simple, it can be used from child-
hood into adulthood and it enables automatic reporting of estimated GFR values because it 
does not rely on anthropometric data. We compared the CAPA equation to the 2012 Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation, which was also 
traceable to the reference material.57 Although comparison with the CKD-EPI equation is not 
completely fair in children, since this equation is not intended for them, it is interesting to see 
that performance of the CAPA equation is comparable to the CKD-EPI equation.
Besides assay standardization, health-economic aspects might also have influenced imple-
mentation of cystatin C in routine clinical practice. While serum creatinine measurement is 
based on an enzymatic reaction, the protein cystatin C is measured using antibody-coated 
latex particles (immunonephelometry or immunoturbidimetry). This is why nowadays a 
cystatin C measurement is around three times more expensive than a creatinine measure-
ment, varying on laboratory and patient volume. A recent cost-effectiveness analysis in 
Sweden showed that if cystatin C is ordered when impaired renal function is suspected, the 
more accurate estimate reduces the costs of care; the higher analytical cost in this context is 
negligible.152
Combining different endogenous renal function markers improves estimation of GFR. There 
is a large body of evidence that equations combining creatinine and cystatin C perform bet-
ter than equations based on either of these markers alone.55,56,60,61,241 An alternate approach 
to combined formulas was suggested by Grubb et al.135 According to this approach GFR is 
estimated using two univariate formulas at the same time, for example the creatinine-based 
bedside Schwartz equation and the cystatin C-based CAPA equation. The two eGFR values 
are compared and if they agree within 15–20%, they can be averaged to provide an accurate 
non-invasive GFR estimate. If there is disagreement between the two estimates and a reason 
can be found -such as decreased muscle mass- then the eGFR determined from cystatin C 
would be used. Similarly, with the use of high-dose glucocorticoid therapy, the eGFR deter-
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mined from creatinine would be preferred. When there is no obvious reason for a significant 
discrepancy, it may be necessary to use a gold standard GFR technique. Relying on univariate 
formulas based on a single marker unaffected by the patient’s characteristics may be more 
accurate in pediatric oncology patients than relying on combined formulas. A discrepancy 
between the two markers will prompt the clinician to choose the most appropriate marker. 
Still, this approach needs further validation in large cohorts of childhood cancer patients.
External validation is the highest degree of validation for prediction models. Therefore 
future research should focus on external validation of GFR estimating models, such as our 
CAPA equation, in children with cancer. This is of importance because estimating equations 
perform best in children with comparable characteristics as the population the equation was 
developed in. As children with cancer often have normal renal function, in contrast to the 
populations most equations were developed in, estimating equations require validation in 
this particular population. Moreover, diagnostic accuracy of estimating equations needs to 
be validated across different age groups, particularly in infants as their renal function rapidly 
changes in the first months of life.
Besides an accurate estimate of GFR, cystatin C has also been recognized as a prognostic 
biomarker of cardiovascular and renal comorbidities and risk for death in adults. Recent 
publications showed that the use of cystatin C improved the role of estimated GFR in risk 
categorization of death from any cause, cardiovascular causes and end-stage renal disease, 
while these risks were not detected by creatinine-based estimated GFR.247,248 Moreover, in 
adults with multiple myeloma, cystatin C-based eGFR was an independent predictor of over-
all survival.249 It would be interesting to see if cystatin C also is an independent prognostic 
factor for (late) nephrotoxicity in children with cancer. This will enable physicians to carefully 
monitor high-risk patients or even adapt treatment upfront.
recommendations
If a child has a normal body composition, we recommend using the bedside Schwartz equa-
tion to derive GFR from serum creatinine rather than relying on the serum creatinine level 
alone. If height is not available, the Pottel equation for GFR estimation should be used. In 
children with reduced muscle mass (ie, weight for height SDS ≤ −2) or other situations in 
which serum creatinine is less accurate (Table 10.2), we recommend to derive GFR from se-
rum cystatin C. In situations in which both cystatin C and creatinine are assumed unreliable, 
a formal clearance study is recommended. To overcome the problem of physicians relying 
on serum levels only, we recommend automatic reporting of eGFR by clinical laboratories. 
Flagging decreased GFR values by the laboratory can alert clinicians to the possibility of 
renal impairment and may indicate the need for additional investigations or treatments, 
including adjustments of doses of drugs that are cleared by the kidneys. Furthermore, selec-
tion of a single creatinine-based equation and a single cystatin C-based equation for future 
childhood cancer protocols would facilitate comparison of nephrotoxicity across different 
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treatment protocols. Given the increasing emphasis on treatment-related adverse health 
effects including renal dysfunction, pediatric oncologists must become experts in assessing 
the appropriateness of clinical and laboratory measures of renal function. Physicians should 
remain aware of the caveats for any marker or estimating equation which may influence the 
accuracy in an individual patient.
CarBoPlatin dosing
In line with previous findings, our pharmacokinetic study in children with a solid tumor 
showed that flat dosing of carboplatin results in highly imprecise carboplatin exposure, with 
the most marked outliers seen in very young children (Chapter 9). More than 100 years ago 
Dr. Abraham Jacobi, the father of pediatrics in the United States, recognized the importance 
of and need for age-appropriate drug dosing when he wrote, “Pediatrics does not deal with 
miniature men and women, with reduced doses and the same class of disease in smaller bod-
ies, but … has its own independent range and horizon”.250 As our knowledge of normal growth 
and development has increased, so has our insight that developmental changes profoundly 
affect the responses to and handling of medications in children and produce a need for age-
dependent adjustments in doses. For drugs predominantly cleared by the kidneys, dose- and 
schedule-adjustments should also be based on renal function. The dosing approaches we 
nowadays apply often rely on relative body size and generally assume that a linear relation-
ship between body size (e.g. body weight) and body surface area (BSA) exists among children 
and adults. However, growth is not a linear process and age-associated changes in body 
composition and organ function are dynamic and can be discordant during the first decade 
of life, especially in children with a disease.251 Maturation of renal function is such a dynamic 
process that begins at 9 weeks of gestation and is complete by early childhood. GFR shows 
a rapid increase during the first two weeks of life, followed by a more steadily increase until 
adult values are reached at 8 to 12 months of age.24,252 Similarly, tubular secretion is immature 
at birth and reaches adult capacity during the first year of life. The developmental changes 
in renal function can dramatically alter the plasma clearance of drugs with extensive renal 
elimination such as carboplatin, which was studied in this thesis. The use of inappropriate 
scaling of adult carboplatin doses to children may result in unwanted toxicity as evidenced 
by the high rate of sustained ototoxicity that Qaddoumi et al.70 report in 60 young children 
with intraocular retinoblastoma. The authors report severe, hearing aid requiring, ototoxicity 
in 17% of their study population, which is significantly higher than previously published re-
ports from Dutch,253 American254 and French255 investigators. The authors noted that younger 
age at start of treatment was the only significant predictor for sustained hearing loss, which 
can be attributed to BSA-adjusted dosing in their study as opposed to dosing based on 
body weight in the other three studies. Infants have a relatively large BSA compared to older 
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children. Therefore, it is common practice to normalize infant chemotherapy doses to body 
weight instead of BSA, which results in a decrease in dose (e.g. an average sized 3-month-old 
baby would receive a carboplatin dose of 170 mg if calculated based on BSA, whereas this 
dose would be around 100 mg when normalized to body weight). A similar experience has 
occurred in infants receiving intensified treatment for leukemia. An effort to improve event-
free survival in these high risk patients resulted in a 25% induction mortality rate, related to 
dose calculated by BSA rather than body weight.256 Although Kearns et al.251 warn that failure 
to account for the developmental changes in organ function can result in potentially toxic 
drug exposure in young children; our results indicate that failure to correct for renal function 
also leads to marked subtherapeutic carboplatin exposure in infants (Chapter 9), with the 
risk of not achieving cure. Thus, for carboplatin dosing in children scaling to body size only is 
insufficient. Renal function and its changes during childhood must be taken into account to 
achieve optimal drug exposure.
Indeed, it is well-established that renal function-based carboplatin dosing leads to more 
reproducible and reliable drug exposure than flat dosing, both in adults and children.63,66,72 
Besides the relationship between the plasma clearance of carboplatin and GFR, the observa-
tion that carboplatin toxicity is more closely related to the area under the time-concentration 
curve (AUC) than dose has resulted in devising a more effective dosing strategy for carbo-
platin. Most pediatric dosing strategies are based on the adult dosing formula described by 
Calvert et al.:63
Dose (mg) = TargetAUC (mg/mL.minute) × GFR (mL/minute) + 25, with varying degrees of 
modification.72,73,226,257,258 These formulas all consist of a component describing the renal clear-
ance of carboplatin as well as a component describing the non-renal clearance. In adults the 
non-renal clearance is fixed (25 mL/minute). Given the wide range of body sizes encountered 
in pediatrics a fixed value would be inappropriate in children and may result in overestima-
tion of carboplatin doses.66 Therefore, the non-renal clearance of carboplatin is often scaled 
to body weight. Looking across different dosing regimens in pediatric clinical protocols for 
various malignancies in Europe and the United States we noticed that correction for renal 
function is seldom recommended, only in children with impaired renal function (Chapter 6). 
This most likely reflects that the most reliable pediatric dosing formula by Newell et al.72 re-
quires an isotopic clearance method to measure GFR. The complexity and invasiveness of this 
technique precludes routine application of the renal function-based approach. Therefore, we 
externally validated the Newell formula using estimated GFR based on creatinine, cystatin 
C and a combination of both markers (Chapter 7). As anticipated from the physiology of 
creatinine, the use of a creatinine-based eGFR resulted in a biased and imprecise prediction 
of carboplatin clearance, with only 46% of predictions within 20% of observed values (20% 
accuracy). Lindauer et al.217 also reported large bias and imprecision in children when using 
the Newell equation with a creatinine-based GFR estimate. This is in line with findings in 
adult patients with a testicular germ cell tumor.259 In this recent study 20% accuracy ranged 
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from 54% to 72%, depending on the eGFR equation, when using creatinine-based eGFR in 
the Calvert formula (of note, the lower accuracy in children might be explained by the better 
precision of adult estimating equations57,60). The mediocre performance of creatinine-based 
equations most likely reflects the limitations of creatinine summarized in Table 10.2. In our 
hands the use of a cystatin C-based GFR estimate yielded 20% accuracy values up to 64%, 
which still is lower than Thomas et al.66 report. These authors used the Newell formula72 with 
GFR determined by 51Cr-EDTA clearance, the gold standard this formula was developed on. In 
their hands 30 out of 38 patients (79%) achieve results within 20% of the target value. Given 
the limited availability and abovementioned drawbacks of 51Cr-EDTA, it remains debatable 
whether the increased precision of this complex GFR measurement outweighs the simplicity 
of an estimate of GFR based on cystatin C.
As substitution of a gold standard GFR measurement by an estimated GFR in the Newell 
formula introduces extra variability in the prediction of carboplatin clearance, we aimed to 
develop a direct dosing model after determining factors that influence carboplatin clearance 
in children, using population pharmacokinetic analyses (Chapter 8). Population pharmaco-ki-
netics has produced dosing models with good precision and minimal bias in adults.182,208,216,217 
In an analysis in 57 children, interindividual variation in carboplatin pharmacokinetics 
decreased 33% by taking into account creatinine, body weight and nephrectomy status.71 
Superiority of a population pharmacokinetic model, compared to the Newell equation with 
creatinine-based eGFR, was reported in children receiving high doses of carboplatin.217 The 
advantage of these models is the use of simple measures of renal function, as opposed to the 
complex isotopic tracer technique used by Newell et al.72
Our study was the first to consider cystatin C for carboplatin dosing in children:
carboplatin clearance =2.63 × 
cystatin C −0.637
0.695  × 


weight 0.790
15.72
This model reduced the interindividual variation in carboplatin pharmacokinetics by 92%, 
which underscores the need for pharmacokinetically guided carboplatin dosing in children. 
Our model proved to be accurate and robust when internally validated by bootstrap analy-
sis. However, it remains to be established whether our model is similarly useful in children 
with different ages and renal function than our study population. Therefore, future research 
should focus on prospective external validation of our model in a diverse population. This is 
currently being addressed at our institution.
When optimizing dosing strategies for carboplatin, the focus often is on overdosing and 
the risk of toxicity. However, as our results in Figure 9.2 show, failure to correct for renal func-
tion results in underdosing (actual AUC below 80% of target AUC) in up to 62% of patients. 
This is a clinically relevant finding as shown in a trial with adults treated for testicular can-
cer.225 A trend (HR, 0.51; 95% CI, 0.24–1.07; P = 0.08) towards poorer outcome was observed 
in the subgroup following a dose reduction of only 10%. These results once more stress the 
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importance of delivering an accurate dose to achieve the desired AUC. A ‘therapeutic drug 
monitoring’ approach with adaptive dosing might also be helpful in ensuring accurate drug 
exposure. This is particularly important in high-dose protocols where even small variations in 
exposure above the target AUC can potentially result in life-threatening toxicity.67
We were not able to demonstrate a significant correlation between carboplatin exposure 
and clinical toxicity (Chapter 9), which is in line with previous findings.66 This is most likely 
reflects that most patients were treated with combinations of myelosuppresive drugs and 
that concomitant chemotherapy varied between patients with regard to the drugs and doses 
used. Platinum DNA-adduct levels in peripheral blood leukocytes are considered a measure 
of carboplatin toxicity at the cellular level and were related to dose and AUC in previous stud-
ies.67,260 This pharmacokinetic-pharmacodynamic finding supports the use of renal function-
based carboplatin dosing to achieve targeted exposure. However, the relationship between 
platinum DNA-adduct levels and carboplatin exposure are not unambiguous. Higher levels in 
patients with higher exposure were reported by Veal et al.67 and Ghazal et al.,260 however not 
by other authors.215,261,262 In adult patients DNA-adduct levels in peripheral blood leukocytes 
appear to be closely related to disease response.263 However, unlike cisplatin261,262 no relation-
ship between levels of platinum DNA-adducts and subsequent response to carboplatin treat-
ment have been reported in children. Therefore, future research should focus on carboplatin’s 
pharmacokinetic-pharmacodynamic relationship in children treated with conventional doses 
and relate this to tumor response and clinical outcome.
recommendations
Considering carboplatin’s pharmacokinetic profile and the highly variable drug exposure 
seen after flat dosing, we recommend renal function-based carboplatin dosing in children. 
Flat dosing of carboplatin in children should be abandoned. The radio-isotopic tracer method 
used by Newell remains the most accurate method for renal function-based carboplatin dos-
ing in children. If this technique is unavailable or unfeasible for reasons as costs and complex-
ity, renal function-based dosing using cystatin C is preferred.
Chapter 11
Summary
Nederlandse samenvatting voor niet-ingewijden

Summary 149
11
summary
Annually around 650 children are diagnosed with cancer in the Netherlands. Over the past 25 
years, the survival rate of childhood cancer has steadily improved. Nowadays eight of every 
ten children who are diagnosed with cancer will survive more than five years beyond their 
diagnosis and the majority of them will become long-term survivors. This success has led 
to a stronger emphasis on other outcome measures besides survival, such as disease- and 
treatment-related adverse effects. The kidneys play a central role in the treatment for cancer 
as many drugs are cleared by the kidneys. Moreover, nephrotoxicity is an important adverse 
effect of treatment for childhood cancer and may lead to irreversible damage. Proactive 
monitoring of renal function may facilitate timely preventive or remedial intervention. This 
is of particular importance when carboplatin, a chemotherapeutic drug that is both nephro-
toxic and cleared by the kidneys, is administered. Precise carboplatin dosing based on renal 
function results in more controlled drug exposure and less toxicity. The aim of this thesis was 
to gain insight into the assessment of renal function in children with cancer, both for toxicity 
monitoring and carboplatin dosing.
The background of this thesis is addressed in Chapter 1: childhood cancer; renal (late) 
effects of treatment for childhood cancer; monitoring of renal function in childhood; carbo-
platin-based therapy and population pharmacokinetics to optimize drug dosing. In the first 
part of this thesis we focus on assessment of renal function during childhood, in particular in 
children with a malignancy.
In Chapter 2 we summarize the different methods available to the pediatrician to determine 
the glomerular filtration rate (GFR) in children. We discuss the advantages and disadvantages 
of creatinine, the most widely used endogenous renal function marker and cystatin C, a 
promising alternative endogenous filtration marker. We emphasize the limitations of rely-
ing on serum concentrations of endogenous renal function markers alone and recommend 
to estimate GFR instead, using equations developed for children. With the most commonly 
used estimating equation by Schwartz et al., GFR can be calculated from the patient’s height 
and serum creatinine concentration. The mandatory height information precludes automatic 
reporting of estimated GFR in children.
We therefore externally validated two height-independent GFR estimating equations in a 
cohort of children with known GFR in Chapter 3. The equation by Pottel et al. demonstrated 
similar diagnostic accuracy as the Schwartz equation and could be used in situations when 
the patient’s height is unknown. Furthermore, this equation allows automatic reporting of 
estimated eGFR by the laboratory. This would be a step forward in pediatric clinical care 
where physicians often still rely on endogenous markers alone.
It has become evident that equations based on cystatin C or a combination of cystatin C 
and creatinine are superior in children, particularly those with reduced muscle mass. However, 
cystatin C has not yet gained widespread use, mainly because of the lack of assay standardiza-
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tion and the use of different assay calibrators. The recent introduction of a certified reference 
material enables production of cystatin C assays with good inter-assay agreement. This may 
allow the development of uniform cystatin C-based estimating equations. The results of the 
first study in which an assay-independent cystatin C-based estimating equation that can be 
used in children as well as in adults are presented in Chapter 4. We used the certified refer-
ence material with some further assay adjustments and developed an equation based on 
cystatin C and age, the CAPA equation. This simple GFR estimating equation, without terms 
for sex and race, had sufficient overall accuracy. Its diagnostic performance was comparable 
to that of the widely used cystatin C-based CKD-EPI equation, which was also developed 
using standardized cystatin C. Not only can the CAPA equation be used both in children and 
adults, it also allows automatic reporting of estimated GFR by the laboratory in children since 
it does not rely on anthropometric data.
Chapter 5 provides evidence that cystatin C-based GFR estimating equations are better 
suited for children with cancer. The use of estimated GFR based on creatinine in these pa-
tients resulted in overestimation of measured GFR, which was not observed with estimated 
GFR based on cystatin C, nor in controls. Furthermore, the use of cystatin C-based estimated 
GFR results in more accurate detection of mildly impaired renal function in children treated 
for cancer than creatinine-based estimated GFR.
The results of the survey in Chapter 6 quantify the high degree of variability in protocol-
based recommendations for renal function monitoring and dose modifications seen across 
clinical studies for children with cancer. The variability occurred in all aspects of renal function 
assessment that can impact patient care and outcome, including the frequency of monitor-
ing, renal function thresholds for dose modification, the magnitude of dose modification and 
recommendations to omit or substitute drugs. In some protocols recommended renal func-
tion measures are even inappropriate given the chemotherapy prescribed. This variability 
is unwanted from a clinical and research perspective and calls for a standardized approach, 
utilizing existing evidence to drive such standards.
The second part of this thesis is based on a prospective observational pharmacokinetic 
study in 30 children receiving carboplatin-based chemotherapy. The results of the external 
validation of the Newell dosing formula using different endogenous renal function markers 
are presented in Chapter 7. The use of cystatin C-based estimated GFR in the Newell dosing 
formula proved to be more accurate than estimated GFR based on serum creatinine. The use 
of the latter resulted in significant overestimation of carboplatin clearance with the risk of 
overdosing and toxicity.
To further optimize dosing of carboplatin in children, we performed a population phar-
macokinetic analysis studying covariates that influence carboplatin clearance. The results 
of this analysis are discussed in Chapter 8. The most important predictors of carboplatin 
clearance were measures related to body size: age, height, and body weight. Serum cystatin 
C, in contrast to serum creatinine, was the only measure of renal function that significantly 
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influenced carboplatin clearance. We developed and internally validated a simple model 
based on body weight and cystatin C that can be used for carboplatin dosing in children. 
This model proved to be accurate and robust and reduced the between-subject variability in 
carboplatin clearance by 92%, stressing the need for an individualized renal function-guided 
dosing approach in children.
Chapter 9 addresses the importance of controlling carboplatin exposure. We demonstrat-
ed that flat dosing based on body surface area or body weight results in highly variable and 
often imprecise drug exposure, emphasizing the importance of renal function-based dosing.
Finally, in Chapter 10 a general discussion with a reflection on the findings described in 
this thesis, the implications for clinical practice and directions for future research are pre-
sented. In short, future pediatric clinical studies should contain appropriate, standardized 
and evidence-based recommendations for renal toxicity monitoring and dose modifications. 
Reliance solely on serum concentrations of endogenous markers should be abandoned and 
recommendations in protocols should include the use of GFR estimating equations. Further-
more, considering the toxicity profile and factors that impact carboplatin clearance, justifies 
a personalized, renal function-based dosing approach of this drug, using a gold standard GFR 
measurement or cystatin C.
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samenvatting
Kanker bij kinderen is zeldzaam, in Nederland wordt jaarlijks bij ongeveer 650 kinderen en 
jongvolwassenen onder de 18 jaar een vorm van kanker vastgesteld. Sinds de jaren zestig zijn 
de 5-jaars overlevingskansen van deze kinderen sterk gestegen van nog geen 25% tot onge-
veer 80% nu. In de nabije toekomst wordt verwacht dat dit percentage verder zal toenemen. 
Deze positieve ontwikkeling heeft echter ook een keerzijde, veel levensreddende behande-
lingen geven een verhoogd risico op gezondheidsproblemen op korte en lange termijn. Ach-
tennegentig procent van de overlevers van kinderkanker ontwikkelt in het leven tenminste 
één gezondheidsprobleem waarvan 68% ernstig, invaliderend of zelfs levensbedreigend is. 
Het voorkomen en tijdig herkennen van behandelingsgerelateerde bijwerkingen wordt dan 
ook steeds belangrijker. Nierschade als gevolg van de behandeling voor kinderkanker is een 
belangrijk gezondheidsprobleem. Het kan zich acuut presenteren tijdens de behandeling en 
weer overgaan, maar het kan ook in blijvende schade resulteren. Acute nierschade kan ertoe 
leiden dat de behandeling moet worden aangepast om verdere achteruitgang van de nier-
functie te voorkomen terwijl chronische nierschade een risicofactor voor hart- en vaatziekten 
is. Nierschade na behandeling voor kinderkanker komt bij ongeveer 5% van de overlevers 
voor en kan oplopen tot wel 84% indien zij behandeld zijn met medicijnen die schadelijk zijn 
voor de nieren. Carboplatine is chemotherapie die schadelijk is voor de nieren. De werking 
van carboplatine berust op de vorming van dwarsverbindingen in het DNA, waardoor de 
celdeling wordt verstoord. Bij ongeveer één vierde van de kinderen met kanker is carbopla-
tine onderdeel van de antikankerbehandeling. Het venijn van carboplatine zit in het feit dat 
het uitgescheiden wordt door de nieren, maar het de nieren ook schade kan berokkenen. 
Het is daarom beter om bij het berekenen van de carboplatine dosis rekening te houden 
met de nierfunctie. Het nauwgezet controleren van de nierfunctie bij kinderen met kanker 
is dus van groot belang, om nierschade in een vroeg stadium op te kunnen sporen – en een 
passende behandeling in te stellen- maar ook om carboplatine nauwkeuriger te doseren. Dit 
proefschrift richt zich op deze aspecten van zorg voor kinderen met kanker. Het doel van dit 
proefschrift is om inzicht te verkrijgen in hoe de nierfunctie het beste gemeten kan worden 
bij kinderen met kanker, zowel voor het monitoren van behandelingsgerelateerde schade als 
het doseren van carboplatine.
In hoofdstuk 1 wordt de achtergrond van dit proefschrift beschreven: kinderkanker, 
behandelingsgerelateerde nierschade, het testen van de nierfunctie bij kinderen en behan-
deling met carboplatine. Het eerste deel van dit proefschrift richt zich op hoe de nierfunctie 
bij kinderen, in het bijzonder die met kanker, gemeten moet worden.
In hoofdstuk 2 wordt een overzicht gegeven van de beschikbare methoden om de snel-
heid waarmee de nieren het bloed zuiveren (de klaring) te bepalen. Het meten van de ware 
nierfunctie is kostbaar, arbeidsintensief en belastend voor het kind. Deze zeer nauwkeurige 
test is daardoor niet geschikt voor de dagelijkse praktijk. Om dit te ondervangen wordt 
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gebruik gemaakt van bloedwaardes van lichaamseigen stoffen, zoals creatinine en cystatine 
C. Deze stoffen worden uitgescheiden door de nieren en bij een verminderde nierfunctie 
worden de bloedwaardes hoger omdat het aanbod gelijk blijft, maar de klaring ervan af-
neemt. Creatinine is een afbraakproduct van spierweefsel en hoewel het in de dagelijkse 
praktijk het meest gebruikt wordt, heeft het als belangrijk nadeel dat het afhankelijk is van 
de spiermassa. Hierdoor is creatinine niet een geschikte maat voor de nierfunctie bij kinde-
ren met een afwijkende spiermassa, zoals kinderen met kanker die vaak een verminderde 
spiermassa hebben. Cystatine C lijkt een betere maat voor de klaringsfunctie van de nieren 
omdat het onafhankelijk is van de spiermassa. Cystatine C wordt in de dagelijkse praktijk 
echter nog niet zo vaak toegepast als creatinine omdat de bepaling ervan tot voor kort 
niet gestandaardiseerd was en verschilde per ziekenhuis. Bloedwaardes van creatinine 
of cystatine C op zichzelf zijn echter een slechte maat voor de nierfunctie, beter is het om 
gebruik te maken van schattingsformules gebaseerd op deze bloedwaardes. In richtlijnen 
wordt dan ook aanbevolen bij elke bloedwaarde van creatinine of cystatine C standaard een 
geschatte klaring te rapporteren. Hiervoor zijn verschillende schattingsformules beschikbaar 
die gebaseerd zijn creatinine, cystatine C of een combinatie van beide. De meest gebruikte 
schattingsformule voor kinderen is gebaseerd op de lichaamslengte van het kind en de 
bloedwaarde van creatinine. Omdat de lengte van een kind niet altijd bekend is kan deze 
formule niet in alle situaties worden toegepast.
In hoofdstuk 3 hebben wij twee schattingsformules voor de nierfunctie, waarvoor geen 
lengte nodig is, getest in groep kinderen, waarvan een deel met kanker. Wij hebben deze 
formules vergeleken met bovengenoemde nauwkeurige, maar complexe nierfunctiemeting. 
Eén van de twee geteste formules bleek nauwkeurig genoeg om de nierfunctie bij kinderen 
mee te bepalen. Doordat deze formule niet is gebaseerd op de lichaamslengte kan de klaring 
van een kind direct door het laboratorium gerapporteerd worden, wat het beoordelen van 
de nierfunctie in de praktijk vergemakkelijkt.
hoofdstuk 4 beschrijft de resultaten van een internationale samenwerking om een 
schattingsformule gebaseerd op cystatine C te ontwikkelen die zowel voor volwassenen 
als kinderen gebruikt kan worden. De door ons ontwikkelde schattingsformule is simpeler 
dan bestaande schattingsformules en blijkt even nauwkeurig als de complexere schattings-
formules die wij momenteel gebruiken voor kinderen en volwassen. Ook deze formule maakt 
directe rapportage van de klaring door het laboratorium mogelijk.
In hoofdstuk 5 tonen wij aan dat cystatine C inderdaad een geschiktere maat is voor de 
nierfunctie dan creatinine bij kinderen met kanker. Hiervoor hebben wij de ware nierfunctie 
van deze kinderen vergeleken met schattingsformules gebaseerd op cystatine C en creatini-
ne. Cystatine C blijkt nauwkeuriger in staat te zijn een verminderde nierfunctie te detecteren. 
De formule gebaseerd op creatinine blijkt bovendien de nierfunctie te overschatten. Beide 
bevindingen konden wij overigens niet aantonen in kinderen zonder kanker.
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hoofdstuk 6 geeft een overzicht van 31 in Nederland toegepaste nationale en internatio-
nale behandelprotocollen voor kinderkanker die voor de nieren schadelijke chemotherapie 
bevatten. Er blijken grote verschillen te bestaan tussen de adviezen die gegeven worden 
voor het meten van de nierfunctie tijdens behandeling, bijvoorbeeld de frequentie waarmee 
dat moet gebeuren en welke nierfunctie test daarvoor gebruikt moet worden. Daarnaast 
variëren de adviezen over dosisaanpassingen van chemotherapie bij een verminderde 
nierfunctie. Zowel met betrekking tot hoe sterk de nierfunctie verminderd moet zijn voordat 
een dosisaanpassing noodzakelijk is, als adviezen over het weglaten en vervangen van che-
motherapie. Deze variabiliteit is bijzonder ongewenst, zowel voor de patiënt als vanuit een 
wetenschappelijk perspectief en vraagt om standaardisatie.
Het tweede deel van dit proefschrift is gebaseerd op een geneesmiddelenonderzoek 
uitgevoerd bij 30 kinderen die carboplatine toegediend kregen. Bij deze kinderen werden 
bloedspiegels carboplatine gemeten en er werd gekeken naar de bijwerkingen die zij had-
den. Daarnaast werd het aantal DNA dwarsverbindingen in witte bloedcellen gemeten. 
Op basis van de bloedspiegels hebben wij bepaald hoe snel de carboplatine uitscheiding 
(carboplatineklaring) door de nieren is. Met de carboplatineklaring en nierfunctie kan voor 
elke individuele patiënt een carboplatine dosis ‘op maat’ berekend worden. Uit eerder we-
tenschappelijk onderzoek bij kinderen weten we dat het nauwkeuriger is om carboplatine 
te doseren door rekening te houden met de nierfunctie. Hiervoor zijn doseringsformules 
beschikbaar. Deze worden in de praktijk echter zelden gebruikt omdat ze gebaseerd zijn op 
een ingewikkelde nierfunctie test die te invasief en kostbaar is om te gebruiken voor het 
berekenen van elke carboplatine dosis.
In hoofdstuk 7 hebben wij onderzocht of de Newell doseringsformule ook gebruikt kan 
worden met de geschatte klaring in plaats van bovengenoemde complexe nierfunctie test. 
Hiervoor hebben wij drie schattingsformules voor de nierfunctie vergeleken, één gebaseerd 
op creatinine, één gebaseerd op cystatine C en één gebaseerd op beide. De twee formules 
gebaseerd op cystatine C bleken nauwkeurig genoeg. Dit in tegenstelling tot de formule 
gebaseerd op creatinine, deze overschatte de carboplatineklaring aanzienlijk met het risico 
op overdosering en bijwerkingen.
hoofdstuk 8 beschrijft de resultaten van een studie waarin wij geëvalueerd hebben welke 
factoren van invloed zijn op de carboplatineklaring met als doel een betere doseringsfor-
mule te ontwikkelen. Een belangrijke bevinding van deze studie is dat de bloedwaarde van 
creatinine, in tegenstelling tot de bloedwaarde van cystatine C, niet van invloed is op de 
carboplatineklaring. De door ons ontwikkelde doseringsformule voor carboplatine bij kin-
deren is dan ook gebaseerd op cystatine C en daarnaast gewicht. Door rekening te houden 
met deze twee factoren kan carboplatine op maat gedoseerd worden. Onze formule blijkt 
nauwkeurig in staat de carboplatineklaring te voorspellen.
De resultaten in hoofdstuk 9 benadrukken waarom het op maat doseren van carboplatine 
belangrijk is. Geen rekening houden met de nierfunctie, wat veelal de standaard is in huidige 
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behandelprotocollen, resulteerde in onvoorspelbare en onnauwkeurige (zowel te lage als 
te hoge) blootstelling aan carboplatine, hetgeen het belang van doseren op geleide van de 
nierfunctie onderstreept.
Tot slot worden in hoofdstuk 10 onze studieresultaten in perspectief geplaatst en worden 
aanbevelingen voor de kliniek en toekomstig onderzoek gegeven. Daarnaast staan in dit 
hoofdstuk de belangrijkste conclusies van dit proefschrift:
1. De nierfunctie van kinderen met kanker kan, indien zij een normale lichaams-samenstel-
ling hebben, bepaald worden door middel van schattingsformules die gebruik maken 
van bloedwaardes van creatinine. Bij kinderen met een verminderde spiermassa dient 
er gebruik gemaakt te worden van een schattingsformule gebaseerd op cystatine C. 
Bloedwaardes op zichzelf staand zijn niet precies genoeg om de nierfunctie te bepalen. 
Als cystatine C niet kan worden bepaald, dan moet de ware nierfunctie gemeten worden.
2. De aanbevelingen in behandelprotocollen voor kinderkanker die betrekking hebben op 
de nierfunctie variëren enorm en dat is onwenselijk.
3. In toekomstige behandelprotocollen moeten de aanbevelingen die betrekking hebben 
op het meten van de nierfunctie, het doseren van carboplatine en dosisaanpassingen 
bij een verminderde nierfunctie gestandaardiseerd worden. Deze aanbevelingen dienen 
gebaseerd te zijn op wetenschappelijk onderzoek.
4. Indien er geen rekening wordt gehouden met de nierfunctie is de blootstelling aan 
carboplatine onvoorspelbaar en variabel. Dit kan leiden tot ongewenste bijwerkingen en 
de kans op onderbehandeling.
5. Bij het bereken van de carboplatine dosis voor kinderen moet er rekening gehouden 
worden met de nierfunctie door gebruik te maken van betrouwbare doseringsformules. 
Nieuwe doseringsformules moeten eerst getest worden in een nieuwe patiëntengroep 
alvorens ze wijdverspreid worden toegepast.
References

References 159
 [1] Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev 36: 277-85, 2010
 [2] Dutch Childhood Oncology Group: Dutch Childhood Oncology Group Annual Report 2012 
(SKION jaarverslag) 2012
 [3] Curry HL, Parkes SE, Powell JE, et al: Caring for survivors of childhood cancers: the size of the 
problem. Eur J Cancer 42: 501-8, 2006
 [4] Gatta G, Botta L, Rossi S, et al: Childhood cancer survival in Europe 1999-2007: results of EURO-
CARE-5--a population-based study. Lancet Oncol 15: 35-47, 2014
 [5] Robison LL, Hudson MM: Survivors of childhood and adolescent cancer: life-long risks and re-
sponsibilities. Nat Rev Cancer, 2013
 [6] Darmon M, Ciroldi M, Thiery G, et al: Clinical review: specific aspects of acute renal failure in 
cancer patients. Crit Care 10: 211, 2006
 [7] Jones DP, Spunt SL, Green D, et al: Renal late effects in patients treated for cancer in childhood: a 
report from the Children’s Oncology Group. Pediatr Blood Cancer 51: 724-31, 2008
 [8] Stohr W, Paulides M, Bielack S, et al: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: 
a report from the Late Effects Surveillance System. Pediatr Blood Cancer 48: 447-52, 2007
 [9] DeFronzo RA, Colvin OM, Braine H, et al: Proceedings: Cyclophosphamide and the kidney. Cancer 
33: 483-91, 1974
 [10] Loebstein R, Atanackovic G, Bishai R, et al: Risk factors for long-term outcome of ifosfamide-
induced nephrotoxicity in children. J Clin Pharmacol 39: 454-61, 1999
 [11] Brade WP, Herdrich K, Varini M: Ifosfamide--pharmacology, safety and therapeutic potential. 
Cancer Treat Rev 12: 1-47, 1985
 [12] Skinner R, Parry A, Price L, et al: Persistent nephrotoxicity during 10-year follow-up after cisplatin 
or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45: 
3213-9, 2009
 [13] Prasad VK, Lewis IJ, Aparicio SR, et al: Progressive glomerular toxicity of ifosfamide in children. 
Med Pediatr Oncol 27: 149-55, 1996
 [14] Skinner R, Cotterill SJ, Stevens MC: Risk factors for nephrotoxicity after ifosfamide treatment in 
children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br 
J Cancer 82: 1636-45, 2000
 [15] Bode U, Seif SM, Levine AS: Studies on the antidiuretic effect of cyclophosphamide: vasopressin 
release and sodium excretion. Med Pediatr Oncol 8: 295-303, 1980
 [16] Gronroos MH, Jahnukainen T, Mottonen M, et al: Long-term follow-up of renal function after 
high-dose methotrexate treatment in children. Pediatr Blood Cancer 51: 535-9, 2008
 [17] Widemann BC, Balis FM, Kempf-Bielack B, et al: High-dose methotrexate-induced nephrotoxicity 
in patients with osteosarcoma. Cancer 100: 2222-32, 2004
 [18] Stohr W, Paulides M, Bielack S, et al: Nephrotoxicity of cisplatin and carboplatin in sarcoma pa-
tients: a report from the late effects surveillance system. Pediatr Blood Cancer 48: 140-7, 2007
 [19] Brock PR, Koliouskas DE, Barratt TM, et al: Partial reversibility of cisplatin nephrotoxicity in chil-
dren. J Pediatr 118: 531-4, 1991
 [20] English MW, Skinner R, Pearson AD, et al: Dose-related nephrotoxicity of carboplatin in children. 
Br J Cancer 81: 336-41, 1999
 [21] Hudson MM, Ness KK, Gurney JG, et al: Clinical ascertainment of health outcomes among adults 
treated for childhood cancer. Jama 309: 2371-81, 2013
 [22] Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, et al: Early and late renal adverse effects 
after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 10, 
2013
160 References
 [23] Stevens LA, Coresh J, Greene T, et al: Assessing kidney function--measured and estimated glo-
merular filtration rate. N Engl J Med 354: 2473-83, 2006
 [24] Schwartz GJ, Furth SL: Glomerular filtration rate measurement and estimation in chronic kidney 
disease. Pediatr Nephrol 22: 1839-48, 2007
 [25] Schwartz GJ, Munoz A, Schneider MF, et al: New equations to estimate GFR in children with CKD. 
J Am Soc Nephrol 20: 629-37, 2009
 [26] Shannon JA, Smith HW: The Excretion of Inulin, Xylose and Urea by Normal and Phlorizinized Man. 
J Clin Invest 14: 393-401, 1935
 [27] van Rossum LK, Cransberg K, de Rijke YB, et al: Determination of inulin clearance by single injec-
tion or infusion in children. Pediatr Nephrol 20: 777-81, 2005
 [28] van Rossum LK, Mathot RA, Cransberg K, et al: Optimal sampling strategies to assess inulin clear-
ance in children by the inulin single-injection method. Clin Chem 49: 1170-9, 2003
 [29] Filler G, Huang SH, Yasin A: The usefulness of cystatin C and related formulae in pediatrics. Clin 
Chem Lab Med 50: 2081-91, 2012
 [30] Perrone RD, Steinman TI, Beck GJ, et al: Utility of radioisotopic filtration markers in chronic renal 
insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and 
inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 16: 224-35, 1990
 [31] Chantler C, Barratt TM: Estimation of glomerular filtration rate from plasma clearance of 51-chro-
mium edetic acid. Arch Dis Child 47: 613-7, 1972
 [32] Schwartz GJ, Furth S, Cole SR, et al: Glomerular filtration rate via plasma iohexol disappearance: 
pilot study for chronic kidney disease in children. Kidney Int 69: 2070-7, 2006
 [33] Shore RM, Koff SA, Mentser M, et al: Glomerular filtration rate in children: determination from the 
Tc-99m-DTPA renogram. Radiology 151: 627-33, 1984
 [34] Earley A, Miskulin D, Lamb EJ, et al: Estimating equations for glomerular filtration rate in the era 
of creatinine standardization: a systematic review. Ann Intern Med 156: 785-95, W-270, W-271, 
W-272, W-273, W-274, W-275, W-276, W-277, W-278, 2012
 [35] Schutte JE, Longhurst JC, Gaffney FA, et al: Total plasma creatinine: an accurate measure of total 
striated muscle mass. J Appl Physiol 51: 762-6, 1981
 [36] Vinge E, Lindergard B, Nilsson-Ehle P, et al: Relationships among serum cystatin C, serum creati-
nine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 59: 
587-92, 1999
 [37] Doolan PD, Alpen EL, Theil GB: A clinical appraisal of the plasma concentration and endogenous 
clearance of creatinine. Am J Med 32: 65-79, 1962
 [38] Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights 
into old concepts. Clin Chem 38: 1933-53, 1992
 [39] Boer DP, de Rijke YB, Hop WC, et al: Reference values for serum creatinine in children younger 
than 1 year of age. Pediatr Nephrol 25: 2107-13, 2010
 [40] Ceriotti F, Boyd JC, Klein G, et al: Reference intervals for serum creatinine concentrations: assess-
ment of available data for global application. Clin Chem 54: 559-66, 2008
 [41] Shannon JA: The Renal Excretion of Creatinine in Man. J Clin Invest 14: 403-10, 1935
 [42] Janus N, Launay-Vacher V, Byloos E, et al: Cancer and renal insufficiency results of the BIRMA 
study. Br J Cancer 103: 1815-21, 2010
 [43] Walser M: Assessing renal function from creatinine measurements in adults with chronic renal 
failure. Am J Kidney Dis 32: 23-31, 1998
 [44] Jung K: Low-molecular-mass proteins in serum and their relationship to the glomerular filtration 
rate. Nephron 47: 160, 1987
References 161
 [45] Jung K, Schulze BD, Sydow K, et al: Diagnostic value of low-molecular mass proteins in serum for 
the detection of reduced glomerular filtration rate. J Clin Chem Clin Biochem 25: 499-503, 1987
 [46] Grubb A, Simonsen O, Sturfelt G, et al: Serum concentration of cystatin C, factor D and beta 
2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 218: 499-503, 1985
 [47] Simonsen O, Grubb A, Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a 
measure of the glomerular filtration rate. Scand J Clin Lab Invest 45: 97-101, 1985
 [48] Abrahamson M, Olafsson I, Palsdottir A, et al: Structure and expression of the human cystatin C 
gene. Biochem J 268: 287-94, 1990
 [49] Tangri N, Stevens LA, Schmid CH, et al: Changes in dietary protein intake has no effect on serum 
cystatin C levels independent of the glomerular filtration rate. Kidney Int 79: 471-7, 2011
 [50] Jenkins MA, Brown DJ, Ierino FL, et al: Cystatin C for estimation of glomerular filtration rate in 
patients with spinal cord injury. Ann Clin Biochem 40: 364-8, 2003
 [51] Stevens LA, Schmid CH, Greene T, et al: Factors other than glomerular filtration rate affect serum 
cystatin C levels. Kidney Int 75: 652-60, 2009
 [52] Al-Malki N, Heidenheim PA, Filler G, et al: Cystatin C levels in functionally anephric patients under-
going dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 4: 1606-10, 
2009
 [53] Bokenkamp A, Laarman CA, Braam KI, et al: Effect of corticosteroid therapy on low-molecular 
weight protein markers of kidney function. Clin Chem 53: 2219-21, 2007
 [54] Risch L, Herklotz R, Blumberg A, et al: Effects of glucocorticoid immunosuppression on serum 
cystatin C concentrations in renal transplant patients. Clin Chem 47: 2055-9, 2001
 [55] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Workgroup: Clinical Practice Guideline 
for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3: 1-150, 2012
 [56] National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: 
Evaluation, Classification and Stratification. Am J Kidney Dis 39: S1-266, 2002
 [57] Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creati-
nine and cystatin C. N Engl J Med 367: 20-9, 2012
 [58] Grubb A, Nyman U, Bjork J, et al: Simple cystatin C-based prediction equations for glomerular 
filtration rate compared with the modification of diet in renal disease prediction equation for 
adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 
51: 1420-31, 2005
 [59] Filler G, Lepage N: Should the Schwartz formula for estimation of GFR be replaced by cystatin C 
formula? Pediatr Nephrol 18: 981-5, 2003
 [60] Schwartz GJ, Schneider MF, Maier PS, et al: Improved equations estimating GFR in children with 
chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 
82: 445-53, 2012
 [61] Zappitelli M, Parvex P, Joseph L, et al: Derivation and validation of cystatin C-based prediction 
equations for GFR in children. Am J Kidney Dis 48: 221-30, 2006
 [62] Grubb A, Blirup-Jensen S, Lindstrom V, et al: First certified reference material for cystatin C in 
human serum ERM-DA471/IFCC. Clin Chem Lab Med 48: 1619-21, 2010
 [63] Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple 
formula based on renal function. J Clin Oncol 7: 1748-56, 1989
 [64] Duffull SB, Robinson BA: Clinical pharmacokinetics and dose optimisation of carboplatin. Clin 
Pharmacokinet 33: 161-83, 1997
 [65] Allen S, Wilson MW, Watkins A, et al: Comparison of two methods for carboplatin dosing in chil-
dren with retinoblastoma. Pediatr Blood Cancer 55: 47-54, 2010
162 References
 [66] Thomas H, Boddy AV, English MW, et al: Prospective validation of renal function-based carbopla-
tin dosing in children with cancer: A United Kingdom Children’s Cancer Study Group Trial. J Clin 
Oncol 18: 3614-21, 2000
 [67] Veal GJ, Errington J, Tilby MJ, et al: Adaptive dosing and platinum-DNA adduct formation in chil-
dren receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer 96: 725-31, 
2007
 [68] Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor 
response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-8, 1992
 [69] Newell DR, Siddik ZH, Gumbrell LA, et al: Plasma free platinum pharmacokinetics in patients 
treated with high dose carboplatin. Eur J Cancer Clin Oncol 23: 1399-405, 1987
 [70] Qaddoumi I, Bass JK, Wu J, et al: Carboplatin-associated ototoxicity in children with retinoblas-
toma. J Clin Oncol 30: 1034-41, 2012
 [71] Chatelut E, Boddy AV, Peng B, et al: Population pharmacokinetics of carboplatin in children. Clin 
Pharmacol Ther 59: 436-43, 1996
 [72] Newell DR, Pearson AD, Balmanno K, et al: Carboplatin pharmacokinetics in children: the devel-
opment of a pediatric dosing formula. The United Kingdom Children’s Cancer Study Group. J Clin 
Oncol 11: 2314-23, 1993
 [73] Marina NM, Rodman JH, Murry DJ, et al: Phase I study of escalating targeted doses of carboplatin 
combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. 
J Natl Cancer Inst 86: 544-8, 1994
 [74] Craig AJ, Samol J, Heenan SD, et al: Overestimation of carboplatin doses is avoided by radionu-
clide GFR measurement. Br J Cancer 107: 1310-6, 2012
 [75] Donahue A, McCune JS, Faucette S, et al: Measured versus estimated glomerular filtration rate in 
the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol 47: 373-9, 
2001
 [76] Sheiner LB: The population approach to pharmacokinetic data analysis: rationale and standard 
data analysis methods. Drug Metab Rev 15: 153-71, 1984
 [77] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER), et al: Guidance for Industry: population pharmacokinetics, 1999
 [78] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER), et al: General Considerations for pediatric pharmacokinetic 
studies for drugs and biological products, 1998
 [79] Stevens LA, Levey AS: Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 
20: 2305-13, 2009
 [80] Friedman A: Laboratory Assessment and Investigation of Renal Function, in Avner E, Harmon 
W, Niaudet P, et al (eds): Pediatric Nephrology (ed 6th). Baltimore, Lippincott Williams & Wilkins, 
2009, pp 491-504
 [81] Shemesh O, Golbetz H, Kriss JP, et al: Limitations of creatinine as a filtration marker in glomerulo-
pathic patients. Kidney Int 28: 830-8, 1985
 [82] Rehling M, Moller ML, Thamdrup B, et al: Simultaneous measurement of renal clearance and 
plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenedi-
aminetetra-acetate and inulin in man. Clin Sci (Lond) 66: 613-9, 1984
 [83] Brochner-Mortensen J, Haahr J, Christoffersen J: A simple method for accurate assessment of the 
glomerular filtration rate in children. Scand J Clin Lab Invest 33: 140-3, 1974
 [84] Back SE, Krutzen E, Nilsson-Ehle P: Contrast media as markers for glomerular filtration: a pharma-
cokinetic comparison of four agents. Scand J Clin Lab Invest 48: 247-53, 1988
References 163
 [85] Krutzen E, Back SE, Nilsson-Ehle I, et al: Plasma clearance of a new contrast agent, iohexol: a 
method for the assessment of glomerular filtration rate. J Lab Clin Med 104: 955-61, 1984
 [86] Bajaj G, Alexander SR, Browne R, et al: 125Iodine-iothalamate clearance in children. A simple 
method to measure glomerular filtration. Pediatr Nephrol 10: 25-8, 1996
 [87] Barbour GL, Crumb CK, Boyd CM, et al: Comparison of inulin, iothalamate and 99mTc-DTPA for 
measurement of glomerular filtration rate. J Nucl Med 17: 317-20, 1976
 [88] Filler G, Yasin A, Medeiros M: Methods of assessing renal function. Pediatr Nephrol 29: 183-92, 
2014
 [89] Popper H, Mandel E: Filtrations- und reabsorptionsleitung in der nierenpathologie. Ergebnisse 
der inneren medizin und kinderheilkunde 53: 259-63, 1937
 [90] Bokenkamp A, Domanetzki M, Zinck R, et al: Reference values for cystatin C serum concentrations 
in children. Pediatr Nephrol 12: 125-9, 1998
 [91] Price CP, Finney H: Developments in the assessment of glomerular filtration rate. Clin Chim Acta 
297: 55-66, 2000
 [92] Herget-Rosenthal S, Marggraf G, Husing J, et al: Early detection of acute renal failure by serum 
cystatin C. Kidney Int 66: 1115-22, 2004
 [93] Nejat M, Pickering JW, Walker RJ, et al: Rapid detection of acute kidney injury by plasma cystatin 
C in the intensive care unit. Nephrol Dial Transplant 25: 3283-9, 2010
 [94] Bokenkamp A, Dieterich C, Dressler F, et al: Fetal serum concentrations of cystatin C and beta2-
microglobulin as predictors of postnatal kidney function. Am J Obstet Gynecol 185: 468-75, 2001
 [95] Cataldi L, Mussap M, Bertelli L, et al: Cystatin C in healthy women at term pregnancy and in their 
infant newborns: relationship between maternal and neonatal serum levels and reference values. 
Am J Perinatol 16: 287-95, 1999
 [96] Foster J, Reisman W, Lepage N, et al: Influence of commonly used drugs on the accuracy of cys-
tatin C-derived glomerular filtration rate. Pediatr Nephrol 21: 235-8, 2006
 [97] Ylinen EA, Ala-Houhala M, Harmoinen AP, et al: Cystatin C as a marker for glomerular filtration rate 
in pediatric patients. Pediatr Nephrol 13: 506-9, 1999
 [98] Bokenkamp A, Domanetzki M, Zinck R, et al: Cystatin C--a new marker of glomerular filtration rate 
in children independent of age and height. Pediatrics 101: 875-81, 1998
 [99] Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker 
of kidney function: a meta-analysis. Am J Kidney Dis 40: 221-6, 2002
 [100] Roos JF, Doust J, Tett SE, et al: Diagnostic accuracy of cystatin C compared to serum creatinine 
for the estimation of renal dysfunction in adults and children--a meta-analysis. Clin Biochem 40: 
383-91, 2007
 [101] Pham-Huy A, Leonard M, Lepage N, et al: Measuring glomerular filtration rate with cystatin C and 
beta-trace protein in children with spina bifida. J Urol 169: 2312-5, 2003
 [102] Mangge H, Liebmann P, Tanil H, et al: Cystatin C, an early indicator for incipient renal disease in 
rheumatoid arthritis. Clin Chim Acta 300: 195-202, 2000
 [103] Blufpand HN, Tromp J, Abbink FC, et al: Cystatin C more accurately detects mildly impaired renal 
function than creatinine in children receiving treatment for malignancy. Pediatr Blood Cancer 57: 
262-7, 2011
 [104] Orlando R, Mussap M, Plebani M, et al: Diagnostic value of plasma cystatin C as a glomerular 
filtration marker in decompensated liver cirrhosis. Clin Chem 48: 850-8, 2002
 [105] Hogg RJ, Furth S, Lemley KV, et al: National Kidney Foundation’s Kidney Disease Outcomes Qual-
ity Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: 
evaluation, classification, and stratification. Pediatrics 111: 1416-21, 2003
164 References
 [106] Schwartz GJ, Haycock GB, Edelmann CM, Jr., et al: A simple estimate of glomerular filtration rate 
in children derived from body length and plasma creatinine. Pediatrics 58: 259-63, 1976
 [107] De Souza VC, Rabilloud M, Cochat P, et al: Schwartz formula: is one k-coefficient adequate for all 
children? PLoS One 7: e53439, 2012
 [108] Pottel H, Hoste L, Martens F: A simple height-independent equation for estimating glomerular 
filtration rate in children. Pediatr Nephrol 27: 973-9, 2012
 [109] Blufpand HN, Westland R, van Wijk JA, et al: Height-independent estimation of glomerular filtra-
tion rate in children: an alternative to the schwartz equation. J Pediatr 163: 1722-7, 2013
 [110] Rule AD, Bergstralh EJ, Slezak JM, et al: Glomerular filtration rate estimated by cystatin C among 
different clinical presentations. Kidney Int 69: 399-405, 2006
 [111] Myers GL, Miller WG, Coresh J, et al: Recommendations for improving serum creatinine measure-
ment: a report from the Laboratory Working Group of the National Kidney Disease Education 
Program. Clin Chem 52: 5-18, 2006
 [112] Blirup-Jensen S, Grubb A, Lindstrom V, et al: Standardization of Cystatin C: development of pri-
mary and secondary reference preparations. Scand J Clin Lab Invest Suppl 241: 67-70, 2008
 [113] Schwartz GJ, Work DF: Measurement and estimation of GFR in children and adolescents. Clin J Am 
Soc Nephrol 4: 1832-43, 2009
 [114] Smith HW: Measurement of the filtration rate, The Kidney: Structure and Function in Health and 
Disease. New York, Oxford University Press, 1951, pp 836-887
 [115] National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: 
evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266, 2002
 [116] Levey AS, Coresh J, Greene T, et al: Using standardized serum creatinine values in the modification 
of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 
145: 247-54, 2006
 [117] Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann 
Intern Med 150: 604-12, 2009
 [118] Zappitelli M, Zhang X, Foster BJ: Estimating glomerular filtration rate in children at serial follow-
up when height is unknown. Clin J Am Soc Nephrol 5: 1763-9, 2010
 [119] Fredriks AM, van Buuren S, Burgmeijer RJ, et al: Continuing positive secular growth change in The 
Netherlands 1955-1997. Pediatr Res 47: 316-23, 2000
 [120] Jung K, Klotzek S, Schulze BD: Refinements of assays for low concentrations of inulin in serum. 
Nephron 54: 360-1, 1990
 [121] Degenaar CP, Frenken LA, von Hooff JP: Enzymatic method for determination of inulin. Clin Chem 
33: 1070-1, 1987
 [122] Pieroni L, Delanaye P, Boutten A, et al: A multicentric evaluation of IDMS-traceable creatinine 
enzymatic assays. Clin Chim Acta 412: 2070-5, 2011
 [123] Pottel H, Vrydags N, Mahieu B, et al: Establishing age/sex related serum creatinine reference 
intervals from hospital laboratory data based on different statistical methods. Clin Chim Acta 
396: 49-55, 2008
 [124] Bossuyt PM, Reitsma JB, Bruns DE, et al: Towards complete and accurate reporting of studies of 
diagnostic accuracy: the STARD initiative. BMJ 326: 41-4, 2003
 [125] Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet 1: 307-10, 1986
 [126] Hogg RJ: Screening for CKD in children: a global controversy. Clin J Am Soc Nephrol 4: 509-15, 
2009
References 165
 [127] Counahan R, Chantler C, Ghazali S, et al: Estimation of glomerular filtration rate from plasma 
creatinine concentration in children. Arch Dis Child 51: 875-8, 1976
 [128] Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glo-
merular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34: 571-90, 1987
 [129] Mattman A, Eintracht S, Mock T, et al: Estimating pediatric glomerular filtration rates in the era of 
chronic kidney disease staging. J Am Soc Nephrol 17: 487-96, 2006
 [130] Agarwal R, Bills JE, Yigazu PM, et al: Assessment of iothalamate plasma clearance: duration of 
study affects quality of GFR. Clin J Am Soc Nephrol 4: 77-85, 2009
 [131] Herget-Rosenthal S, Bokenkamp A, Hofmann W: How to estimate GFR-serum creatinine, serum 
cystatin C or equations? Clin Biochem 40: 153-61, 2007
 [132] Selistre L, De Souza V, Cochat P, et al: GFR estimation in adolescents and young adults. J Am Soc 
Nephrol 23: 989-96, 2012
 [133] Florijn KW, Barendregt JN, Lentjes EG, et al: Glomerular filtration rate measurement by “single-
shot” injection of inulin. Kidney Int 46: 252-9, 1994
 [134] Rehberg PB: Studies on Kidney Function: The Rate of Filtration and Reabsorption in the Human 
Kidney. Biochem J 20: 447-60, 1926
 [135] Grubb A: Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simulta-
neous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an 
internal quality check. Scand J Clin Lab Invest 70: 65-70, 2010
 [136] Bauer JH, Brooks CS, Burch RN: Clinical appraisal of creatinine clearance as a measurement of 
glomerular filtration rate. Am J Kidney Dis 2: 337-46, 1982
 [137] Blackwood WS, Maudgal DP, Pickard RG, et al: Cimetidine in duodenal ulcer. Controlled trial. 
Lancet 2: 174-6, 1976
 [138] Burry HC, Dieppe PA: Apparent reduction of endogenous creatinine clearance by salicylate treat-
ment. Br Med J 2: 16-7, 1976
 [139] van Acker BA, Koomen GC, Koopman MG, et al: Discrepancy between circadian rhythms of inulin 
and creatinine clearance. J Lab Clin Med 120: 400-10, 1992
 [140] Nyman U, Grubb A, Larsson A, et al: The revised Lund-Malmö GFR estimating equation outper-
forms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin 
Chem Lab Med Epub ahead of print, 2013
 [141] Lofberg H, Grubb AO: Quantitation of gamma-trace in human biological fluids: indications for 
production in the central nervous system. Scand J Clin Lab Invest 39: 619-26, 1979
 [142] Kyhse-Andersen J, Schmidt C, Nordin G, et al: Serum cystatin C, determined by a rapid, automated 
particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular 
filtration rate. Clin Chem 40: 1921-6, 1994
 [143] Preiss DJ, Godber IM, Lamb EJ, et al: The influence of a cooked-meat meal on estimated glomeru-
lar filtration rate. Ann Clin Biochem 44: 35-42, 2007
 [144] Filler G, Gharib M, Casier S, et al: Prevention of chronic kidney disease in spina bifida. Int Urol 
Nephrol 44: 817-27, 2012
 [145] Segarra A, de la Torre J, Ramos N, et al: Assessing glomerular filtration rate in hospitalized patients: 
a comparison between CKD-EPI and four cystatin C-based equations. Clin J Am Soc Nephrol 6: 
2411-20, 2011
 [146] Thomassen SA, Johannesen IL, Erlandsen EJ, et al: Serum cystatin C as a marker of the renal func-
tion in patients with spinal cord injury. Spinal Cord 40: 524-8, 2002
 [147] Viollet L, Gailey S, Thornton DJ, et al: Utility of cystatin C to monitor renal function in Duchenne 
muscular dystrophy. Muscle Nerve 40: 438-42, 2009
166 References
 [148] Young F, Ensom MH: Pharmacokinetics of aminoglycosides in patients with chronic spinal cord 
injury. Am J Health Syst Pharm 68: 1607-14, 2011
 [149] Zegers I, Auclair G, Schimmel H, et al: Certification of cystatin C in the human serum reference 
material ERM®-DA471/IFCC, Certified Reference Material ERM®-DA471/IFCC. Luxembourg, Publi-
cations Office of the European Union, 2010, pp 26
 [150] Jacobsson L: A method for the calculation of renal clearance based on a single plasma sample. 
Clin Physiol 3: 297-305, 1983
 [151] Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in 
Japan. Am J Kidney Dis 53: 982-92, 2009
 [152] SBU-Swedish Council on Health Technology Assessment: Methods to Estimate and Measure 
Renal Function (Glomerular Filtration Rate), 2013
 [153] Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be 
known. Arch Intern Med (Chic) 17: 863-73, 1916
 [154] Finney H, Newman DJ, Gruber W, et al: Initial evaluation of cystatin C measurement by particle-
enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 
43: 1016-22, 1997
 [155] Tanaka M, Matsuo K, Enomoto M, et al: A sol particle homogeneous immunoassay for measuring 
serum cystatin C. Clin Biochem 37: 27-35, 2004
 [156] Horio M, Imai E, Yasuda Y, et al: GFR estimation using standardized serum cystatin C in Japan. Am 
J Kidney Dis 61: 197-203, 2013
 [157] Stevens LA, Zhang Y, Schmid CH: Evaluating the performance of equations for estimating glo-
merular filtration rate. J Nephrol 21: 797-807, 2008
 [158] Blirup-Jensen S: Protein standardization III: Method optimization basic principles for quantitative 
determination of human serum proteins on automated instruments based on turbidimetry or 
nephelometry. Clin Chem Lab Med 39: 1098-109, 2001
 [159] Sjostrom P, Tidman M, Jones I: Determination of the production rate and non-renal clearance 
of cystatin C and estimation of the glomerular filtration rate from the serum concentration of 
cystatin C in humans. Scand J Clin Lab Invest 65: 111-24, 2005
 [160] Shlipak MG, Matsushita K, Arnlov J, et al: Cystatin C versus creatinine in determining risk based on 
kidney function. N Engl J Med 369: 932-43, 2013
 [161] Holweger K, Bokemeyer C, Lipp HP: Accurate measurement of individual glomerular filtration rate 
in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 131: 559-67, 2005
 [162] Andersen TB, Eskild-Jensen A, Frokiaer J, et al: Measuring glomerular filtration rate in children; can 
cystatin C replace established methods? A review. Pediatr Nephrol 24: 929-41, 2009
 [163] Nilsson-Ehle P, Grubb A: New markers for the determination of GFR: iohexol clearance and cys-
tatin C serum concentration. Kidney Int Suppl 47: S17-9, 1994
 [164] K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and 
Stratification. Am J Kidney Dis 39: S1-S0000, 2002
 [165] Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin 
Chem 48: 699-707, 2002
 [166] Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glo-
merular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34: 571-90, 1987
 [167] Jung K, Klotzek S, Schulze BD: Refinements of assays for low concentrations of inulin in serum. 
Nephron 54: 360-1, 1990
 [168] Degenaar CP, Frenken LAM, von Hooff JP: Enzymatic method for the determination of inulin. Clin 
Chem 33: 1070-1, 1987
References 167
 [169] Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation 
tool in clinical medicine. Clin Chem 39: 561-77, 1993
 [170] Skinner R, Cole M, Pearson AD, et al: Inaccuracy of glomerular filtration rate estimation from 
height/plasma creatinine ratio. Arch Dis Child 70: 387-90, 1994
 [171] Gronroos MH, Jahnukainen T, Irjala K, et al: Comparison of glomerular function tests in children 
with cancer. Pediatr Nephrol 23: 797-803, 2008
 [172] Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate 
from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study 
Group. Ann Intern Med 130: 461-70, 1999
 [173] Larsson A, Flodin M, Hansson LO, et al: Patient selection has a strong impact on cystatin C and 
Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate. Clin Biochem 
41: 1355-61, 2008
 [174] Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am 
J Kidney Dis 37: 79-83, 2001
 [175] Grubb AO: Cystatin C--properties and use as diagnostic marker. Adv Clin Chem 35: 63-99, 2000
 [176] Kos J, Stabuc B, Cimerman N, et al: Serum cystatin C, a new marker of glomerular filtration rate, is 
increased during malignant progression. Clin Chem 44: 2556-7, 1998
 [177] Kos J, Krasovec M, Cimerman N, et al: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin 
C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6: 505-11, 
2000
 [178] Stabuc B, Vrhovec L, Stabuc-Silih M, et al: Improved prediction of decreased creatinine clearance 
by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46: 193-7, 
2000
 [179] Knight EL, Verhave JC, Spiegelman D, et al: Factors influencing serum cystatin C levels other than 
renal function and the impact on renal function measurement. Kidney Int 65: 1416-21, 2004
 [180] Lankisch P, Wessalowski R, Maisonneuve P, et al: Serum cystatin C is a suitable marker for routine 
monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr 
Blood Cancer 46: 767-72, 2006
 [181] Newman DJ: Cystatin C. Ann Clin Biochem 39: 89-104, 2002
 [182] Thomas F, Seronie-Vivien S, Gladieff L, et al: Cystatin C as a new covariate to predict renal elimina-
tion of drugs: application to carboplatin. Clin Pharmacokinet 44: 1305-16, 2005
 [183] Gatta G, Zigon G, Capocaccia R, et al: Survival of European children and young adults with cancer 
diagnosed 1995-2002. Eur J Cancer 45: 992-1005, 2009
 [184] Bhatia S, Constine LS: Late morbidity after successful treatment of children with cancer. Cancer J 
15: 174-80, 2009
 [185] Geenen MM, Cardous-Ubbink MC, Kremer LC, et al: Medical assessment of adverse health out-
comes in long-term survivors of childhood cancer. JAMA 297: 2705-15, 2007
 [186] Landier W, Bhatia S: Cancer survivorship: a pediatric perspective. Oncologist 13: 1181-92, 2008
 [187] Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of child-
hood cancer. N Engl J Med 355: 1572-82, 2006
 [188] Knijnenburg SL, Jaspers MW, van der Pal HJ, et al: Renal dysfunction and elevated blood pressure 
in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7: 1416-27, 2012
 [189] Oberlin O, Fawaz O, Rey A, et al: Long-term evaluation of Ifosfamide-related nephrotoxicity in 
children. J Clin Oncol 27: 5350-5, 2009
 [190] Skinner R: Nephrotoxicity--what do we know and what don’t we know? J Pediatr Hematol Oncol 
33: 128-34, 2011
168 References
 [191] Cardous-Ubbink MC, Heinen RC, Langeveld NE, et al: Long-term cause-specific mortality among 
five-year survivors of childhood cancer. Pediatr Blood Cancer 42: 563-73, 2004
 [192] Yeh JM, Nekhlyudov L, Goldie SJ, et al: A model-based estimate of cumulative excess mortality in 
survivors of childhood cancer. Ann Intern Med 152: 409-17, W131-8, 2010
 [193] Dutch Childhood Oncology Group: Guideline for long-term follow-up after childhood cancer 
(Richtlijn follow-up na kinderkanker; meer dan 5 jaar na diagnose), 2010
 [194] Jacobsson B, Lignelid H, Bergerheim US: Transthyretin and cystatin C are catabolized in proximal 
tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histo-
pathology 26: 559-64, 1995
 [195] Finney H, Newman DJ, Thakkar H, et al: Reference ranges for plasma cystatin C and creatinine 
measurements in premature infants, neonates, and older children. Arch Dis Child 82: 71-5, 2000
 [196] Egorin MJ, Van Echo DA, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-
diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. 
Cancer Res 44: 5432-8, 1984
 [197] Doz F, Pinkerton R: What is the place of carboplatin in paediatric oncology? Eur J Cancer 30A: 
194-201, 1994
 [198] Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and 
carboplatin. J Clin Oncol 17: 409-22, 1999
 [199] Chatelut E, Boddy AV, Peng B, et al: Population pharamacokinetics of carboplatin in children. Clin 
Pharmacol Ther 59: 436-43, 1996
 [200] Reyno LM, Egorin MJ, Canetta RM, et al: Impact of cyclophosphamide on relationships between 
carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian 
cancer. J Clin Oncol 11: 1156-64, 1993
 [201] Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, et al: Combination therapy with gefitinib, an 
epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients 
with advanced solid tumors. Ann Oncol 15: 831-8, 2004
 [202] Beal S, Sheiner L: NONMEM User’s Guide, in Group NP (ed). San Francisco, University of California, 
1992, pp Part I-VII
 [203] National Kidney Disease Education Program: CKD and Drug Dosing: Information for Providers, 
2010
 [204] Ekhart C, de Jonge ME, Huitema AD, et al: Flat dosing of carboplatin is justified in adult patients 
with normal renal function. Clin Cancer Res 12: 6502-8, 2006
 [205] Dooley MJ, Poole SG, Rischin D, et al: Carboplatin dosing: gender bias and inaccurate estimates of 
glomerular filtration rate. Eur J Cancer 38: 44-51, 2002
 [206] Herrington JD, Tran HT, Riggs MW: Prospective evaluation of carboplatin AUC dosing in patients 
with a BMI>or=27 or cachexia. Cancer Chemother Pharmacol 57: 241-7, 2006
 [207] Blufpand HN, Westland R, van Wijk JAE, et al: Height-independent estimation of GFR in children: 
an alternative for the Schwartz equation. J Pediatr: In press, 2013
 [208] Schmitt A, Gladieff L, Lansiaux A, et al: A universal formula based on cystatin C to perform indi-
vidual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 
15: 3633-9, 2009
 [209] Wurthwein G, Krefeld B, Gerss J, et al: Carboplatin dosing in children: calculation by different 
formulae. Onkologie 34: 16-22, 2011
 [210] Chinnaswamy G, Cole M, Boddy AV, et al: Estimation of renal function and its potential impact on 
carboplatin dosing in children with cancer. Br J Cancer 99: 894-9, 2008
References 169
 [211] Blufpand HN, Hes N, Bokenkamp A, et al: Diversity in renal function monitoring and dose modi-
fications during treatment for childhood cancer: A call for standadization. Pediatr Blood Cancer 
Epub ahead of print, 2013
 [212] Nehus EJ, Laskin BL, Kathman TI, et al: Performance of cystatin C-based equations in a pediatric 
cohort at high risk of kidney injury. Pediatr Nephrol 28: 453-61, 2013
 [213] Murry DJ, Sandlund JT, Stricklin LM, et al: Pharmacokinetics and acute renal effects of continu-
ously infused carboplatin. Clin Pharmacol Ther 54: 374-80, 1993
 [214] Tonda ME, Heideman RL, Petros WP, et al: Carboplatin pharmacokinetics in young children with 
brain tumors. Cancer Chemother Pharmacol 38: 395-400, 1996
 [215] Peng B, Boddy AV, Cole M, et al: Comparison of methods for the estimation of carboplatin phar-
macokinetics in paediatric cancer patients. Eur J Cancer 31A: 1804-10, 1995
 [216] Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morpho-
logical and biological patient characteristics. J Natl Cancer Inst 87: 573-80, 1995
 [217] Lindauer A, Eickhoff C, Kloft C, et al: Population pharmacokinetics of high-dose carboplatin in 
children and adults. Ther Drug Monit 32: 159-68, 2010
 [218] Karlsson MO, Sheiner LB: The importance of modeling interoccasion variability in population 
pharmacokinetic analyses. J Pharmacokinet Biopharm 21: 735-50, 1993
 [219] Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet 
Biopharm 9: 503-12, 1981
 [220] Blufpand HN, Hes N, Bokenkamp A, et al: Diversity in renal function monitoring and dose modi-
fications during treatment for childhood cancer: a call for standardization. Pediatr Blood Cancer 
61: 337-44, 2014
 [221] Ekhart C, Rodenhuis S, Schellens JH, et al: Carboplatin dosing in overweight and obese patients 
with normal renal function, does weight matter? Cancer Chemother Pharmacol 64: 115-22, 2009
 [222] Wright JG, Boddy AV, Highley M, et al: Estimation of glomerular filtration rate in cancer patients. 
Br J Cancer 84: 452-9, 2001
 [223] Jamieson ER, Lippard SJ: Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem 
Rev 99: 2467-98, 1999
 [224] U.S. Department of Health and Human Services, National Institutes of Health, National Cancer 
Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 2010
 [225] Oliver RT, Mead GM, Rustin GJ, et al: Randomized trial of carboplatin versus radiotherapy for stage 
I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 
30982 study (ISRCTN27163214). J Clin Oncol 29: 957-62, 2011
 [226] Marina NM, Rodman J, Shema SJ, et al: Phase I study of escalating targeted doses of carboplatin 
combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 11: 
554-60, 1993
 [227] Horwich A, Dearnaley DP, Nicholls J, et al: Effectiveness of carboplatin, etoposide, and bleomycin 
combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ 
cell tumors. J Clin Oncol 9: 62-9, 1991
 [228] Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med 364: 1844-54, 2011
 [229] Rieselbach RE, Bentzel CJ, Cotlove E, et al: Uric Acid Excretion and Renal Function in the Acute 
Hyperuricemia of Leukemia. Pathogenesis and Therapy of Uric Acid Nephropathy. Am J Med 37: 
872-83, 1964
 [230] Fangusaro J, Gururangan S, Poussaint TY, et al: Bevacizumab (BVZ)-associated toxicities in chil-
dren with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a 
Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 119: 4180-7, 2013
170 References
 [231] Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopa-
thy. N Engl J Med 358: 1129-36, 2008
 [232] Perazella MA, Berns JS, Rosner MH: Cancer and the kidney: the growth of onco-nephrology. Adv 
Chronic Kidney Dis 21: 4-6, 2014
 [233] Salahudeen AK, Bonventre JV: Onconephrology: the latest frontier in the war against kidney 
disease. J Am Soc Nephrol 24: 26-30, 2013
 [234] Larson RA, Stone RM, Mayer RJ, et al: Fifty years of clinical research by the leukemia committee of 
the cancer and leukemia group B. Clin Cancer Res 12: 3556s-63s, 2006
 [235] Children’s Oncology Group: Long-Term Follow-Up Guidelines for Survivors of Childhood, Adoles-
cent and Young Adult Cancers, version 3.0,
 [236] Keevil BG, Kilpatrick ES, Nichols SP, et al: Biological variation of cystatin C: implications for the 
assessment of glomerular filtration rate. Clin Chem 44: 1535-9, 1998
 [237] Bjarnadottir M, Grubb A, Olafsson I: Promoter-mediated, dexamethasone-induced increase in 
cystatin C production by HeLa cells. Scand J Clin Lab Invest 55: 617-23, 1995
 [238] Poge U, Gerhardt T, Bokenkamp A, et al: Time course of low molecular weight proteins in the early 
kidney transplantation period--influence of corticosteroids. Nephrol Dial Transplant 19: 2858-63, 
2004
 [239] Abbink FC, Laarman CA, Braam KI, et al: Beta-trace protein is not superior to cystatin C for the 
estimation of GFR in patients receiving corticosteroids. Clin Biochem 41: 299-305, 2008
 [240] Bokenkamp A, van Wijk JA, Lentze MJ, et al: Effect of corticosteroid therapy on serum cystatin C 
and beta2-microglobulin concentrations. Clin Chem 48: 1123-6, 2002
 [241] Inker LA, Eckfeldt J, Levey AS, et al: Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. 
Am J Kidney Dis 58: 682-4, 2011
 [242] Chew JS, Saleem M, Florkowski CM, et al: Estimating renal function in oncology patients using 
cystatin C-based equations. Clin Oncol (R Coll Radiol) 21: 425-6, 2009
 [243] Finney H, Williams AH, Price CP: Serum cystatin C in patients with myeloma. Clin Chim Acta 309: 
1-6, 2001
 [244] Bardi E, Bobok I, Olah AV, et al: Cystatin C is a suitable marker of glomerular function in children 
with cancer. Pediatr Nephrol 19: 1145-7, 2004
 [245] Mojiminiyi OA, Marouf R, Abdella N, et al: Serum concentration of cystatin C is not affected by 
cellular proliferation in patients with proliferative haematological disorders. Ann Clin Biochem 
39: 308-10, 2002
 [246] Larsson A, Malm J, Grubb A, et al: Calculation of glomerular filtration rate expressed in mL/min 
from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 64: 25-30, 2004
 [247] Shlipak MG, Coresh J, Gansevoort RT: Cystatin C versus creatinine for kidney function-based risk. 
N Engl J Med 369: 2459
 [248] Matsushita K, Mahmoodi BK, Woodward M, et al: Comparison of risk prediction using the CKD-EPI 
equation and the MDRD study equation for estimated glomerular filtration rate. Jama 307: 1941-
51, 2012
 [249] Terpos E, Christoulas D, Kastritis E, et al: The Chronic Kidney Disease Epidemiology Collaboration 
cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in 
newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD 
to CKD-EPI-CysC equations? Eur J Haematol 91: 347-55, 2013
 [250] Halpern SA: American pediatrics: the social dynamic of professionalism, 1880-1980. Berkeley, 
University of California Press, 1988
References 171
 [251] Kearns GL, Abdel-Rahman SM, Alander SW, et al: Developmental pharmacology--drug disposi-
tion, action, and therapy in infants and children. N Engl J Med 349: 1157-67, 2003
 [252] Arant BS, Jr.: Developmental patterns of renal functional maturation compared in the human 
neonate. J Pediatr 92: 705-12, 1978
 [253] Smits C, Swen SJ, Theo Goverts S, et al: Assessment of hearing in very young children receiving 
carboplatin for retinoblastoma. Eur J Cancer 42: 492-500, 2006
 [254] Lambert MP, Shields C, Meadows AT: A retrospective review of hearing in children with retinoblas-
toma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50: 223-6, 2008
 [255] Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al: Analysis of ototoxicity in young children 
receiving carboplatin in the context of conservative management of unilateral or bilateral retino-
blastoma. Pediatr Blood Cancer 52: 637-43, 2009
 [256] Dreyer ZE, Dinndorf PA, Camitta B, et al: Analysis of the role of hematopoietic stem-cell transplan-
tation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrange-
ments: a report from the Children’s Oncology Group. J Clin Oncol 29: 214-22, 2011
 [257] Pinkerton CR, Broadbent V, Horwich A, et al: ‘JEB’--a carboplatin based regimen for malignant 
germ cell tumours in children. Br J Cancer 62: 257-62, 1990
 [258] Mann JR, Raafat F, Robinson K, et al: UKCCSG’s germ cell tumour (GCT) studies: improving out-
come for children with malignant extracranial non-gonadal tumours--carboplatin, etoposide, 
and bleomycin are effective and less toxic than previous regimens. United Kingdom Children’s 
Cancer Study Group. Med Pediatr Oncol 30: 217-27, 1998
 [259] Shepherd ST, Gillen G, Morrison P, et al: Performance of formulae based estimates of glomerular 
filtration rate for carboplatin dosing in stage 1 seminoma. Eur J Cancer 50: 944-52, 2014
 [260] Ghazal-Aswad S, Tilby MJ, Lind M, et al: Pharmacokinetically guided dose escalation of carbo-
platin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA 
adduct levels. Ann Oncol 10: 329-34, 1999
 [261] Veal GJ, Dias C, Price L, et al: Influence of cellular factors and pharmacokinetics on the formation 
of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 7: 
2205-12, 2001
 [262] Schellens JH, Ma J, Planting AS, et al: Relationship between the exposure to cisplatin, DNA-adduct 
formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73: 1569-
75, 1996
 [263] Reed E, Ostchega Y, Steinberg SM, et al: Evaluation of platinum-DNA adduct levels relative to 
known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50: 2256-60, 1990

Curriculum vitae

Curriculum vitae 175
The author of this thesis, Hester Naomi Blufpand, was born on October 24th 1980 in Amsterdam. 
She lived in Paramaribo, Surinam the first years of her life and started primary school there. 
After that she went to school in the village of Alphen aan den Rijn and later Curaçao. In 1998, 
she graduated from secondary school at the Hermann Wesselink College in Amstelveen. After 
graduation, she studied Psychology at the Leiden University and in 2000 she started medical 
school at the same university. While attending medical school she worked as a student assis-
tant at the Cardiothoracic Intensive Care Unit of the Leiden University Medical Center. In 2003 
she interrupted medical school for a year and a half to take place in the board of her Student 
Society “Leidse Studenten Vereniging Minerva”. After finishing medical school in March 2008, 
she worked at the department of pediatrics of the Flevoziekenhuis, Almere and VU University 
Medical Center in Amsterdam, where she developed a special interest in pediatric oncology. 
Hester started her PhD project supervised by prof. dr. G. J.L. Kaspers and dr. A. Bökenkamp, 
which resulted in the thesis you are holding. In 2011 and 2014 she joined the Doctor 2 Doctor 
program in Eldoret, Kenya to train doctors, nurses and medical students at The Moi Teaching 
and Referral Hospital. In 2014 she obtained her master’s degree in Epidemiology and in April 
of that year she started her residency training in pediatrics. Hester lives in Amsterdam with 
Dirk Westdijk and their daughter Olivia. They expect their second child in the spring of 2015. 

List of publications

List of publications 179
this thesis
Blufpand hn, Kaspers GJL, Bökenkamp A. Nierfunctie bij kinderen: meten schatten, nieuwe 
markers of toch creatinine? Tijdschrift voor Kindergeneeskunde. 2014;82(4):126-133.
Blufpand hn, Westland R, van Wijk JAE, Roelandse-Koop EA, Kaspers GJL, Bökenkamp A. 
Height-independent estimation of GFR in children: an alternative to the Schwartz equation. J 
Pediatr. 2013;163(6):1722-1727
Blufpand hn, Hes N, Bökenkamp A, van de Wetering MD, Kaspers GJL. Diversity in renal 
function monitoring and dose modifications during treatment for childhood cancer: a call for 
standardization. Pediatric Blood Cancer. 2014;61(2)337-344.
Blufpand hn, Tromp J, Abbink FCH, Stoffel-Wagner B, Bouman AA, Schouten-van Meeteren 
AYN, van Wijk JAE, Kaspers GJL, Bökenkamp A. Cystatin C more accurately detects mildly im-
paired renal function than creatinine in children receiving treatment for malignancy. Pediatric 
Blood Cancer. 2011;57(2):262-267.
Grubb A, Horio M, Hansson L, Björk J, Nyman U, Flodin M, Larsson A, Bökenkamp A, Yasuda Y, 
Blufpand hn, Lindström V, Zegers I, Althaus H, Blirup-Jensen S, Itoh Y, Sjöström P, Nordin G, 
Christensson A, Klima H, Sunde K, Hjort-Christensen P, Armbruster D and Ferrero C. Genera-
tion of a new cystatin c-based estimating equation for glomerular filtration rate using seven 
assays standardized to the international calibrator. Clinical Chemistry 2014;60(7):974-986.
Blufpand hn, Kaspers GJL, Abbink FCH, Wilhelm AJ, Honeywell RJ, Peters GJ, Stoffel-Wagner, 
B, Buffart LM, Bökenkamp A. Carboplatin dosing in children using estimated glomerular filtra-
tion rate: equation matters. 2014; In revision.
Blufpand hn, Kaspers GJL, Abbink FCH, Wilhelm AJ, Honeywell RJ, Peters GJ, Stoffel-Wagner 
B, Bökenkamp A. A simple formula based on cystatin C for individualized carboplatin dosing 
in children. 2014; Submitted
Blufpand hn, Bökenkamp A, Abbink FCH, Wilhelm AJ, Honeywell RJ, Peters GJ, Kaspers 
GJL. Failure to correct for renal function results in highly imprecise carboplatin exposure in 
children. 2014; Submitted
others
Bijlsma MW, Blufpand hn, Kaspers GJL, Bökenkamp A. Why pediatricians fail to diagnose 
hypertension: a multicenter survey. J Pediatr 2014;164(1)173-177.
Knijnenburg SL, Mulder RL, Schouten-van Meeteren AYN, Bökenkamp A, Blufpand hn, 
Dulmen-den Broeder E, Veening MA, Kremer LCM, Jaspers MWM. Early and late renal adverse 
effects after potentially nephrotoxic treatment for childhood cancer. The Cochrane Database 
of systematic reviews 2013;Oct 8:10

Dankwoord

Dankwoord 183
Het is klaar! Ik heb veel geleerd, ben gefrustreerd geweest, maar heb ook ontzettend veel 
gelachen. Veel mensen ben ik dank verschuldigd en bij deze wil ik een ieder van jullie dan 
ook hartelijk bedanken voor je bijdrage, in welke vorm dan ook, aan de totstandkoming van 
dit boekje. Ontzettend veel dank!
Allereerst wil ik alle kinderen en hun ouders bedanken voor hun deelname aan de Carbo-
platinstudie. Ik heb diep respect voor het feit dat jullie in moeilijke tijden bereid waren deel 
te nemen aan een onderzoek waar jullie zelf niet direct voordeel van hadden. Zonder jullie 
zou dit proefschrift er niet zijn geweest.
Prof.dr. G.J.L. Kaspers, beste Gert-Jan, het is allemaal begonnen met het vertrouwen dat jij 
in me stelde nadat ik een aantal maanden als ANIOS op de Kinderoncologie had gewerkt. Ik 
heb grote bewondering voor de wijze waarop jij je werkzaamheden als clinicus, afdelings-
hoofd, wetenschapper met een flink aantal promovendi en studenten en bestuurder van het 
nog te bouwen Prinses Máxima Centrum voor kinderoncologie combineert. Desondanks was 
jij veelal de eerste van wie ik een reactie op een manuscript kon verwachten. Jouw nuchtere 
kijk op zaken heb ik als heel prettig ervaren. Ik heb het bijzonder gewaardeerd dat je mij zo-
veel ruimte hebt gegeven om mijzelf op verschillende vlakken verder te ontwikkelen tijdens 
mijn promotietraject. De master Epidemiologie, klinische patiëntenzorg, coördinatie van de 
klinische studies en de bezoeken aan Kenia in het kader van het outreach programma, ik heb 
er waanzinnig veel van geleerd en het als een fijne afwisseling van het onderzoek gezien. Ik 
wens je heel veel succes in het Prinses Máxima Centrum in Utrecht en hoop er in de toekomst 
opnieuw jouw collega te mogen zijn.
Dr. A. Bökenkamp, beste Arend, wat heb ik veel van jou geleerd! Je bent een ontzettend 
bevlogen clinicus en wetenschapper met engelengeduld. Je weet te motiveren en en thou-
sias meren, met recht een ‘pediatric role model’ dus. Je had (of maakte) altijd tijd voor mij, hoe 
vol je poli ook was, en dat immer met het enthousiasme en geduld dat jou zo kenmerkt. Van 
het feit dat wij alles van mijn hand samen doornamen, of het nou een abstract, presentatie, 
peer-review, poster of manuscript was, heb ik echt super veel geleerd. De wijze waarop jij mij 
wegwijs hebt gemaakt in de wondere wereld van cystatine C vond ik echt tof. Ik hoop dat wij 
in de toekomst samen onderzoek blijven doen op dit gebied, want cystatine C is naast jouw 
kind inmiddels ook mijn lievelings laag-moleculair eiwit geworden.
Leden van de promotiecommissie, prof.dr. E. Boven, prof.dr. R.A.A. Mahtôt, prof.dr. A.C. Moll, 
dr. D.M. te Loo, dr. M.F Schreuder en prof.dr. P.M. ter Wee, ik wil u hartelijk danken voor het be-
oordelen van het manuscript en uw bereidheid om zitting te nemen in de promotiecommissie. 
Het is mij een waar genoegen de inhoud van mijn proefschrift met u te mogen bediscussiëren.
Beste medeauteurs, Floor Abbink, Anneke Bouman, Laurien Buffart, Nicole Hes, Frits Peters, 
Elianne Roelandse-Koop, Netteke Schouten, Jorien Tromp, Marianne van de Wetering en 
Ans van Wijk, ik ben jullie bijzonder veel dank verschuldigd. Mede dankzij jullie input in de 
verschillende hoofdstukken ligt hier mijn proefschrift. Anders Grubb and co-workers, Richard 
Honeywell and Birgit-Stoffel-Wagner, for you in English, thank you very much for all your 
184 Dankwoord
efforts in our publications. In het bijzonder wil ik Bram Wilhem bedanken. Bram, ontzettend 
veel dank voor de geduldige wijze waarop jij mij wegwijs hebt gemaakt in de wereld van de 
klinische farmacologie.
Lieve PK 4X collega’s, wij hebben het heel vaak gehad over dankwoorden in boekjes en 
ik heb jullie beloofd dat de langste alinea voor jullie zou zijn en daar ga ik me aan houden. 
Zonder de eindeloos durende lunches, publicatie-sushi, zinloze discussies over stompzinnige 
onderwerpen, doornemen van de onderzoekerssite, zeer frequente koffiepauzes en Q-music 
foute uurtjes met jullie had ik het nog geen maand uitgehouden als onderzoeker. Anneke, 
Annemieke, Marleen, Eline D, Ineke, Tamara, Willemijn, Sophie, Bibian, Anne, Hannemieke, Mo-
nique, Eline H,  Sietske, Ilse en Dana veel dank voor jullie aandeel hierin aan de lunchtafel, het 
belangrijkste onderdeel van onze afdeling. Een aantal van jullie wil ik persoonlijk bedanken, te 
beginnen bij de (oud) roommies. Dat wij daar hebben kunnen werken op die kamer is echt een 
wonder aangezien het er nooit langer dan drie minuten stil was, zeker na de komst van Jolice. 
Maar wat heb ik daar wat afgelachen! Suus, gedeelde smart, halve smart. Het eten van cake 
heeft voor mij een bijzondere betekenis gekregen. Gerrit, gek genoeg ging het promoveren na 
je vertrek een stuk beter. Zou dat aan jouw nu.nl updates à 10 minuten hebben gelegen? Jolice, 
topmens en topcollega: bedankt voor je continue gezellige afleiding en al je tripjes naar mijn 
bureau zodat mijn computerproblemen vanzelf verdwenen. Heel fijn dat wij onze ‘uitvaart’ een 
beetje gelijktijdig hebben geregeld, ook al haakte je opeens af voor Chicago. Rik, nefrobuddy, 
het was echt lachen om samen met jou iets te publiceren. OK behalve op het einde dan. Nog 
maar vijf jaar tot elkaar veroordeeld… Steef en Marita, lief duo, wat fijn dat jullie op mijn kamer 
zaten voor de dagelijkse mode update. En wat fijn dat jullie lijst met nevenactiviteiten altijd 
langer was dan die van mij. Super, mega lieve Kim, als ik er drie mocht kiezen… Jammer dat 
het maar zo kort was. Lieve Raphaële, fijn dat ik met jou, een echte kinderdokter én onderzoe-
ker, kon sparren, vanaf mijn bureau tot aan huis. Arend, EpidM buddy en mentor, nooit meer 
I got skills please. Charlotte, rustig maar o zo gevat, zonder jouw super tip voor Word was ik 
nu denk ik nog steeds bezig met mijn manuscript. Annelies, jouw mok heeft mij er doorheen 
gesleept! Je krijgt ’m terug voor jouw laatste loodjes. Leuk dat we in Alkmaar weer collega’s 
zijn. Marc, je hoeft je schoen dus niet op te eten, het is inderdaad allemaal goed gekomen met 
mij. Kat, altijd gezellig aan jouw bureau, dankjewel dat je op mijn studie, mijn andere baby, 
gepast hebt tijdens mijn verlof. Femke en Miret, veel dank voor de samenwerking binnen het 
klinische studie team. Super lieve en attente San jij ook bedankt, vooral voor alle roti, bonbons 
en andere lekkernijen! Ik hoop jullie allemaal in de komende jaren nog vaak te zien.
Beste Floor, Arjenne, Margreet, Dannis en Valerie, kinderoncologen van VUmc, bedankt 
voor alles wat ik op oncologisch gebied van jullie heb geleerd. Ik heb het bijzonder gewaar-
deerd dat jullie hiervoor altijd laagdrempelig bereikbaar waren. Lieve dames van de DBH, 
super veel dank voor de gezelligheid en koffie in dat kippenhok van jullie! Speciale dank ook 
aan mijn AKS maatjes, wat was het gezellig en wat hebben we dat goed gedaan, en aan de 
klinische VUmc en MCA collega’s voor de leuke samenwerking.
Dankwoord 185
Lieve (schoon)familie - lievelingstante, neefje, bruttie, oma - vrienden, oudhuisgenootjes 
en clubbies, zonder de afleiding buiten het onderzoek om was ik wellicht doorgedraaid. Ont-
zettend veel dank voor jullie oprechte interesse in mijn (voor jullie vaak saaie) bezigheden en 
alle gezellige momenten de afgelopen jaren. Er zullen er vast en zeker nog veel meer volgen. 
Aan een ieder die ik vergeten ben, ondanks mijn oprechte spijt is mijn dank en waardering 
niet minder groot! Dat ooit een promotie voltooid zou worden door de auteur van dit boekje 
is lang twijfelachtig geweest. Zonder jullie hulp en steun was dit nooit gelukt.
En dan natuurlijk mijn paranimfen. Lieve B, in het druilerige Westfriesland hebben we 
elkaar leren kennen, het klikte meteen. De afgelopen zes jaar hebben we samen meerdere 
major life-events afgevinkt. Vrijdag 6 juni 2014 was een dag om nooit te vergeten! Tof dat jij 
mij op mijn grote dag wilt bijstaan als paranimf. Lieve bruttie, de rol van paranimf is op jouw 
lijf geschreven. Een ceremoniële dag vol academische tradities en rituelen, eigenlijk dus een 
soort theater. En dan mag je ook nog een rokkostuum aan. Het belangrijkste onderdeel van 
mijn boekje, de voorkant, en veelal het enige dat mensen zich zullen herinneren is van jouw 
hand. Het is prachtig geworden. Fijn dat juist jij mijn paranimf bent.
Lieve, lieve Dirk, één alinea is natuurlijk niet genoeg. Zonder jouw relaxte instelling en 
steun thuis was dit nooit gelukt. Jouw vertrouwen in het feit dat mijn boekje er echt zou 
komen was bewonderenswaardig. Soms ietwat optimistisch want als ik op maandag vertelde 
dat ik aan een nieuw manuscript begonnen was vroeg jij me vrijdag of het al gepubliceerd 
was. Wat hebben wij het goed met onze Olijf! Lieve kleine Olivia, je bent een echte boeken-
wurm, net zoals ik vroeger was. Er kunnen ’s avonds niet genoeg boeken in je bedje liggen. 
Gelukkig voor jou heeft mama nu een absoluut slaapverwekkend exemplaar geschreven om 
aan jouw collectie toe te voegen. Ik heb jullie intens lief! We hebben het fantastisch goed met 
z’n drietjes, zo meteen fijn met z’n viertjes.
De laatste woorden zijn voor jou lieve mam. Zonder jou had hier geen letter op papier 
gestaan. Bedankt voor je onvoorwaardelijke liefde en steun op alle vlakken.
Hester Blufpand
Amsterdam, augustus 2014
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